US20200048372A1 - Biological Products - Google Patents
Biological Products Download PDFInfo
- Publication number
- US20200048372A1 US20200048372A1 US16/508,967 US201916508967A US2020048372A1 US 20200048372 A1 US20200048372 A1 US 20200048372A1 US 201916508967 A US201916508967 A US 201916508967A US 2020048372 A1 US2020048372 A1 US 2020048372A1
- Authority
- US
- United States
- Prior art keywords
- fab
- dab
- antibody
- fabb
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Definitions
- the present invention relates to new dual specificity antibody fusion proteins.
- Such antibodies comprise a first specificity to an antigen of interest, and a second specificity for a second antigen of interest, for example a serum carrier protein for use in extending their in vivo serum half-life.
- a serum carrier protein for use in extending their in vivo serum half-life.
- antibody fragments such as Fv, Fab, Fab′ and F(ab′) 2 fragments and other antibody fragments.
- Fv, Fab, Fab′ and F(ab′) 2 fragments retain the antigen binding activity of whole antibodies and can also exhibit improved tissue penetration and pharmacokinetic properties in comparison to whole immunoglobulin molecules.
- antibody fragments are proving to be versatile therapeutic agents, as seen by the recent success of products such as ReoPro® and Lucentis®.
- Antibodies with dual specificity i.e. which bind to two different antigens have been previously described (for reviews, see Segal et al., 1999, Curr. Opin. Immunol. 11:558-562; Plückthun & Pack, 1997, Immunotechnology, 3:83-105; Fischer and Leger, 2007, Pathobiology, 74, 3-14). Dual specificity antibodies are also described in WO02/02773, US2007065440, US2006257406, US2006106203 and US2006280734.
- Previous approaches to making hetero-bispecific antibody-based molecules have generally employed chemical cross-linking or protein engineering techniques. Chemical cross-linking suffers from poor yields of hetero- and homo-dimer formation and the requirement for their subsequent chromatographic separation.
- Protein engineering approaches have either been highly elaborate (e.g. knobs-into-holes engineering; Ridgway et al., 1996, Protein Eng. 9(7):617-621) or have used molecules with inappropriate stability characteristics (e.g. diabodies, scFv).
- bispecific antibodies can also suffer from steric hindrance problems such that both antigens cannot bind simultaneously to each antibody arm.
- Single variable domain antibodies also known as single domain antibodies or dAbs, correspond to the variable regions of either the heavy (VH) or light (VL) chain of an antibody.
- Murine single-domain antibodies were described by Ward et al., 1989, Nature, 341, 544-546. Human and ‘camelised’ human single domain antibodies have also been described (Holt et al., 2003 , Trends in Biotechnology, 21, 484-490). Single domain antibodies have also been obtained from the camelids (camels and llamas) and cartilaginous fish (wobbegong and nurse sharks).
- VhH high affinity single V-like domains
- V-NAR high affinity single V-like domains
- Fc-equivalent constant domain framework an integral and crucial component of their immune system
- Single domain antibody-enzyme fusions have been described in EP0368684.
- Single domain-effector group fusions have also been described in WO2004/058820 which comprise a single variable domain.
- Dual variable domain immunoglobulins have been described in WO2007/024715.
- Dual specific ligands comprising two single domain antibodies with differing specificities have been described in EP1517921.
- thyroxine-binding protein thyroxine-binding protein
- transthyretin ⁇ 1-acid glycoprotein
- transferrin fibrinogen and albumin
- Serum carrier proteins circulate within the body with half-lives measured in days, for example, 5 days for thyroxine-binding protein or 2 days for transthyretin (Bartalena & Robbins, 1993, Clinics in Lab. Med. 13:583-598), or 65 hours in the second phase of turnover of iodinated ⁇ 1-acid glycoprotein (Bree et al., 1986, Clin. Pharmacokin. 11:336-342).
- the present invention provides improved dual specificity antibody fusion proteins which can be produced recombinantly and are capable of binding two antigens simultaneously, in particular two distinct/different antigens.
- the present invention provides dual specificity antibody fusion proteins which comprise an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprise a single domain antibody (dAb) with specificity for a second antigen of interest, in particular where the first antigen and second antigen are different entities.
- an immunoglobulin moiety for example a Fab or Fab′ fragment
- dAb single domain antibody
- Multivalent as employed herein is intended to refer to an entity that has two or more binding sites, for example two or three binding sites such as two binding sites. Each binding site may bind the same epitope or different epitopes on the same antigen, or may bind different (distinct) antigens.
- the present invention also provides dual specificity antibody fusion proteins which comprise an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprise at least one single domain antibody with specificity for a second antigen of interest.
- an immunoglobulin moiety for example a Fab or Fab′ fragment
- a dual specificity antibody fusion of the invention will be capable of selectively binding to two antigens of interest.
- the first and second antigen are the same antigen.
- an antigen of interest bound by the Fab or Fab′ fragment may be a cell-associated protein, for example a cell surface protein on cells such as bacterial cells, yeast cells, T-cells, endothelial cells or tumour cells, or it may be a soluble protein.
- Antigens of interest may also be any medically relevant protein such as those proteins upregulated during disease or infection, for example receptors and/or their corresponding ligands.
- cell surface proteins include adhesion molecules, for example integrins such as ⁇ 1 integrins e.g.
- VLA-4 E-selectin, P selectin or L-selectin
- Soluble antigens include interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16 or IL-17, viral antigens for example respiratory syncytial virus or cytomegalovirus antigens, immunoglobulins, such as IgE, interferons such as interferon ⁇ , interferon ⁇ or interferon ⁇ , tumour necrosis factor- ⁇ , tumor necrosis factor- ⁇ , colony stimulating factors such as G-CSF or GM-CSF, and platelet derived growth factors such as PDGF- ⁇ , and PDGF- ⁇ and where appropriate receptors thereof.
- Other antigens include bacterial cell surface antigens, bacterial toxins, viruses such as influenza, EBV, HepA, B and C, bioterrorism agents, radionuclides and heavy metals, and snake and spider venoms and toxins.
- the antibody fusion protein of the invention may be used to functionally alter the activity of the antigen of interest.
- the antibody fusion protein may neutralize, antagonize or agonise the activity of said antigen, directly or indirectly.
- a second antigen of interest bound by the single domain antibody or antibodies in the dual specificity antibody fusion proteins of the invention may be a cell-associated protein, for example a cell surface protein on cells such as bacterial cells, yeast cells, T-cells, endothelial cells or tumour cells, or it may be a soluble protein.
- Antigens of interest may also be any medically relevant protein such as those proteins upregulated during disease or infection, for example receptors and/or their corresponding ligands.
- Particular examples of cell surface proteins include adhesion molecules, for example integrins such as ⁇ 1 integrins e.g.
- VLA-4 E-selectin, P selectin or L-selectin
- Soluble antigens include interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16 or IL-17, viral antigens for example respiratory syncytial virus or cytomegalovirus antigens, immunoglobulins, such as IgE, interferons such as interferon ⁇ , interferon ⁇ or interferon ⁇ , tumour necrosis factor- ⁇ , tumor necrosis factor- ⁇ , colony stimulating factors such as G-CSF or GM-CSF, and platelet derived growth factors such as PDGF- ⁇ , and PDGF- ⁇ and where appropriate receptors thereof.
- Other antigens include bacterial cell surface antigens, bacterial toxins, viruses such as influenza, EBV, HepA, B and C, bioterrorism agents, radionuclides and heavy metals, and snake and spider venoms and toxins.
- antigens which may be bound by the single domain antibody or antibodies include serum carrier proteins, polypeptides which enable cell-mediated effector function recruitment and nuclide chelator proteins.
- the present invention provides dual specificity antibody fusion proteins which comprise an immunoglobulin moiety with a first specificity for an antigen of interest, and further comprise a single domain antibody with specificity for a second protein, the latter providing the ability to recruit effector functions, such as complement pathway activation and/or effector cell recruitment.
- fusion proteins of the present invention may be used to chelate radionuclides by virtue of a single domain antibody which binds to a nuclide chelator protein. Such fusion proteins are of use in imaging or radionuclide targeting approaches to therapy.
- an isolated dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one dAb which has specificity for a recruitment polypeptide, said dAb providing the ability to recruit cell-mediated effector function(s), directly or indirectly, by binding to said recruitment polypeptide.
- the recruitment of effector function may be direct in that effector function is associated with a cell, said cell bearing a recruitment molecule on its surface. Indirect recruitment may occur when binding of a dAb to a recruitment molecule causes release of, for example, a factor which in turn may directly or indirectly recruit effector function, or may be via activation of a signalling pathway. Examples include TNF ⁇ , IL2, IL6, IL8, IL17, IFN ⁇ , histamine, C1q, opsonin and other members of the classical and alternative complement activation cascades, such as C2, C4, C3-convertase, and C5 to C9.
- a recruitment polypeptide includes a Fc ⁇ R such as Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII, a complement pathway protein such as, but without limitation, C1q and C3, a CD marker protein (Cluster of Differentiation marker) such as, but without limitation, CD68, CD115, CD16, CD80, CD83, CD86, CD56, CD64, CD3, CD4, CD8, CD28, CD45, CD19, CD20 and CD22.
- a CD marker protein Cluster of Differentiation marker
- CD marker proteins include CD1, CD1d, CD2, CD5, CD8, CD9, CD10, CD11, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD40, CD43, CD44, CD45, CD46, CD49, CD49a, CD49b, CD49c, CD49d, CD52, CD53, CD54, CD55, CD56, CD58, CD59, CD61, CD62, D62E, CD62L, CD62P, CD63, CD64, CD66e, CD68, CD70, CD71, CD72, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD88, CD89, CD90, CD94, CD95, CD
- the second protein for which the dAb has specificity is a complement pathway protein, with C1q being particularly preferred.
- the second protein for which the dAb has specificity is a CD marker protein, with CD68, CD80, CD86, CD64, CD3, CD4, CD8 CD45, CD16 and CD35 being particularly preferred.
- an isolated dual specificity antibody fusion protein comprising an antibody fragment with specificity for an antigen of interest, said fragment being fused to at least one dAb which has specificity for a CD molecule selected from the group consisting of CD68, CD80, CD86, CD64, CD3, CD4, CD8 CD45, CD16 and CD35.
- the single domain antibody or antibodies provide an extended half-life to the immunoglobulin moiety with the first specificity.
- a dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1, said single domain antibody providing an extended half-life to the antibody fragment with specificity for said antigen of interest by binding to said serum carrier protein, circulating immunoglobulin molecule or CD35/CR1.
- an isolated dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1, said single domain antibody providing an extended half-life to the antibody fragment with specificity for said antigen of interest by binding to said serum carrier protein, circulating immunoglobulin molecule or CD35/CR1.
- serum carrier proteins include thyroxine-binding protein, transthyretin, ⁇ 1-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any thereof.
- a ‘circulating immunoglobulin molecule’ includes IgG1, IgG2, IgG3, IgG4, sIgA, IgM and IgD, or a fragment of any thereof.
- CD35/CR1 is a protein present on red blood cells which have a half life of 36 days (normal range of 28 to 47 days; Lanaro et al., 1971, Cancer, 28(3):658-661).
- the second protein for which the dAb has specificity is a serum carrier protein, with a human serum carrier protein being particularly preferred.
- the serum carrier protein is human serum albumin.
- a dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for human serum albumin.
- the present invention provides an isolated dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for human serum albumin.
- the antibody fragment with specificity for an antigen of interest is a Fab fragment. In another embodiment, the antibody fragment with specificity for an antigen of interest is a Fab′ fragment.
- the antibody fusion proteins of the invention are translation fusion proteins, i.e. genetic fusions, the sequence of each of which is encoded by an expression vector.
- the antibody fusion protein components have been fused using chemical means, i.e. by chemical conjugation or chemical cross-linking. Such chemical means are known in the art.
- the antibody fragments are Fab′ fragments which possess a native or a modified hinge region.
- the antibody fragment for use in preparing a dual specificity antibody fusion protein of the invention is a Fab′ fragment
- said fragment is generally extended at the C-terminus of the heavy chain by one or more amino acids.
- an antibody fusion of the invention can comprise a Fab′ fragment translation fused (or chemically fused) to a dAb, directly or via a linker.
- suitable antibody Fab′ fragments include those described in WO2005003170 and WO2005003171.
- an antibody fusion of the invention can comprise a Fab fragment translation fused (or chemically fused) to a linker sequence which in turn is translation fused (or chemically fused) to a dAb.
- the Fab fragment is a Fab fragment which terminates at the interchain cysteines, as described in WO2005/003169.
- the antibody Fab or Fab′ fragments of use in the present invention can be from any species but are preferably derived from a monoclonal antibody, a human antibody, or are humanised fragments.
- An antibody fragment for use in the present invention can be derived from any class (e.g. IgG, IgE, IgM, IgD or IgA) or subclass of immunoglobulin molecule and may be obtained from any species including for example mouse, rat, shark, rabbit, pig, hamster, camel, llama, goat or human.
- the antibody Fab or Fab′ fragment is a monoclonal, fully human, humanized or chimeric antibody fragment. In one embodiment the antibody Fab or Fab′ fragments are fully human or humanised.
- Monoclonal antibodies may be prepared by any method known in the art such as the hybridoma technique (Kohler & Milstein, Nature, 1975, 256, 495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today, 1983, 4, 72) and the EBV-hybridoma technique (Cole et al., “Monoclonal Antibodies and Cancer Therapy”, pp. 77-96, Alan R. Liss, Inc., 1985).
- Antibodies for use in the invention may also be generated using single lymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNAs generated from single lymphocytes selected for the production of specific antibodies by, for example, the methods described by Babcook, J. et al., Proc. Natl. Acad. Sci. USA, 1996, 93(15), 7843-7848, WO 92/02551, WO2004/051268 and WO2004/106377.
- Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule (see, for example, U.S. Pat. No. 5,585,089).
- CDRs complementarity determining regions
- the antibodies for use in the present invention can also be generated using various phage display methods known in the art and include those disclosed by Brinkman et al., J. Immunol. Methods, 1995, 182, 41-50; Ames et al., J. Immunol. Methods, 1995, 184, 177-186; Kettleborough et al. Eur. J.
- transgenic mice or other organisms, including other mammals, may be used to generate humanized antibodies.
- Fully human antibodies are those antibodies in which the variable regions and the constant regions (where present) of both the heavy and the light chains are all of human origin, or substantially identical to sequences of human origin, not necessarily from the same antibody.
- Examples of fully human antibodies may include antibodies produced for example by the phage display methods described above and antibodies produced by mice in which the murine immunoglobulin variable and/or constant region genes have been replaced by their human counterparts eg. as described in general terms in EP0546073 B1, U.S. Pat. Nos. 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, EP 0438474 B1 and EP0463151 B1.
- the antibody Fab or Fab′ fragment starting material for use in the present invention may be obtained from any whole antibody, especially a whole monoclonal antibody, using any suitable enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin.
- the antibody starting material may be prepared by the use of recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions. Standard molecular biology techniques may be used to modify, add or delete amino acids or domains as desired. Any alterations to the variable or constant regions are still encompassed by the terms ‘variable’ and ‘constant’ regions as used herein.
- the antibody fragment starting material may be obtained from any species including for example mouse, rat, rabbit, hamster, camel, llama, goat or human. Parts of the antibody fragment may be obtained from more than one species, for example the antibody fragments may be chimeric. In one example, the constant regions are from one species and the variable regions from another. The antibody fragment starting material may also be modified. In another example, the variable region of the antibody fragment has been created using recombinant DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies.
- variable region domains containing at least one CDR and, optionally, one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody.
- the methods for creating and manufacturing these antibody fragments are well known in the art (see for example, Boss et al., U.S. Pat. No. 4,816,397; Cabilly et al., U.S. Pat. No. 6,331,415; Shrader et al., WO 92/02551; Ward et al., 1989, Nature, 341, 544; Orlandi et al., 1989, Proc. Natl. Acad. Sci.
- each single domain antibody fused to the Fab or Fab′ fragment may linked directly or via a linker.
- linker regions for linking a dAb to a Fab or Fab′ include, but are not limited to, flexible linker sequences and rigid linker sequences.
- Flexible linker sequences include those disclosed in Huston et al., 1988, PNAS 85:5879-5883; Wright & Deonarain, Mol. Immunol., 2007, 44(11):2860-2869; Alfthan et al., Prot. Eng., 1995, 8(7):725-731; Luo et al., J. Biochem., 1995, 118(4):825-831; Tang et al., 1996, J. Biol. Chem. 271(26):15682-15686; and Turner et al., 1997, JIMM 205, 42-54, (see Table 1 for representative examples).
- S) is optional in sequence 3 and 45 to 48.
- rigid linkers examples include the peptide sequences GAPAPAAPAPA (SEQ ID NO:34), PPPP (SEQ ID NO:35) and PPP.
- the peptide linker is an albumin binding peptide.
- albumin binding peptides are provided in WO 2007/106120 and include:
- an antibody hinge sequence or part thereof is used as a linker, eg. the upper hinge sequence.
- antibody Fab′ fragments for use in the present invention possess a native or a modified hinge region.
- Such hinge regions are used as a natural linker to the dAb moiety.
- the native hinge region is the hinge region normally associated with the C H 1 domain of the antibody molecule.
- a modified hinge region is any hinge that differs in length and/or composition from the native hinge region.
- Such hinges can include hinge regions from any other species, such as human, mouse, rat, rabbit, hamster, camel, llama or goat hinge regions.
- Other modified hinge regions may comprise a complete hinge region derived from an antibody of a different class or subclass from that of the C H 1 domain.
- a C H 1 domain of class ⁇ 1 may be attached to a hinge region of class ⁇ 4.
- the modified hinge region may comprise part of a natural hinge or a repeating unit in which each unit in the repeat is derived from a natural hinge region.
- the natural hinge region may be altered by converting one or more cysteine or other residues into neutral residues, such as alanine, or by converting suitably placed residues into cysteine residues. By such means the number of cysteine residues in the hinge region may be increased or decreased.
- the hinge cysteine(s) from the light chain interchain cysteine can affect properties of the hinge such as flexibility e.g. glycines may be incorporated into the hinge to increase rotational flexibility or prolines may be incorporated to reduce flexibility.
- glycines may be incorporated into the hinge to increase rotational flexibility or prolines may be incorporated to reduce flexibility.
- combinations of charged or hydrophobic residues may be incorporated into the hinge to confer multimerisation properties, see for example, Richter et al., 2001, Prot. Eng. 14(10):775-783 for use of charged or ionic tails, e.g., acidic tails as linkers and Kostelny et al., 1992, J. Immunol. 5(1):1547-1553 for leucine zipper sequences.
- Other modified hinge regions may be entirely synthetic and may be designed to possess desired properties such as length, composition and flexibility.
- Hinge linker sequences SEQ ID NO: SEQUENCE 36 DKTHTCAA 37 DKTHTCPPCPA 38 DKTHTCPPCPATCPPCPA 39 DKTHTCPPCPATCPPCPATCPPCPA 40 DKTHTCPPCPAGKPTLYNSLVMSDTAGTCY 41 DKTHTCPPCPAGKPTHVNVSVVMAEVDGTCY 42 DKTHTCCVECPPCPA 43 DKTHTCPRCPEPKSCDTPPPCPRCPA 44 DKTHTCPSCPA
- Single variable domains also known as single domain antibodies or dAbs for use in the present invention can be generated using methods known in the art and include those disclosed in WO2005118642, Ward et al., 1989, Nature, 341, 544-546 and Holt et al., 2003 , Trends in Biotechnology, 21, 484-490.
- a single domain antibody for use in present invention is a heavy chain variable domain (VH) or a light chain domain (VL). Each light chain domain may be either of the kappa or lambda subgroup. Methods for isolating VH and VL domains have been described in the art, see for example EP0368684 and Ward et al., supra. Such domains may be derived from any suitable species or antibody starting material.
- the single domain antibody may be derived from a rodent, a human or other species.
- the single domain antibody is humanised.
- the single domain antibody is derived from a phage display library, using the methods described in for example, WO2005/118642, Jespers et al., 2004 , Nature Biotechnology, 22, 1161-1165 and Holt et al., 2003 , Trends in Biotechnology, 21, 484-490.
- Preferably such single domain antibodies are fully human but may also be derived from other species.
- the single variable domain is chimeric in that the framework is human or substantially human in origin and the CDR(s) is/are of non-human origin. It will be appreciated that the sequence of the single domain antibody once isolated may be modified to improve the characteristics of the single domain antibody, for example solubility, as described in Holt et al., supra.
- Substantially human as employed herein is intended to refer that the human character of the original material is retained, which may be relevant to immunogenicity.
- Substantially human material would include wherein one amino acid in the framework sequence is added deleted or replaced by another amino acid.
- the dAb is a human sequence obtained from scFv phage-display or from a transgenic HumouseTM or VelocimouseTM or a humanised rodent.
- the dAb is obtained from a human or humanised rodent, a camelid or a shark. Such a dAb will preferably be humanised.
- the single domain antibody is a VHH domain based on camelid immunoglobulins as described in EP0656946.
- a camel or a llama is immunised with an antigen of interest and blood collected when the titre is appropriate.
- the gene encoding the dAb may be cloned by single cell PCR, or the B cell(s) encoding the dAb may be immortalised by EBV transformation, or by fusion to an immortal cell line.
- the present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody, directly or via a linker, which has specificity for a second antigen of interest.
- the antibody fragment eg. Fab or Fab′ fragment is fused at the N-terminus of the heavy or the light chain variable region to a dAb directly or via a linker.
- the antibody Fab or Fab′ fragment is fused at the C-terminus of the heavy or light chain to a dAb directly or via a linker.
- the heavy and light chains of the antibody Fab or Fab′ fragment are each fused at the C-terminus to a dAb directly or via a linker.
- the linkage can be a chemical conjugation but is most preferably a translation fusion, i.e. a genetic fusion where the sequence of each is encoded in sequence by an expression vector.
- the N-terminus of the single domain antibody will be fused to the C-terminus of the heavy or light chain of the Fab or Fab′ fragment, directly or via a linker, and where the single domain antibody is fused to the N-terminus of the Fab or Fab′ it will be fused via its C-terminus, optionally via a linker.
- the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to a single domain antibody at the N-terminus of the heavy or light chain which has specificity for a second antigen of interest.
- the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to a single domain antibody at the C-terminus of the heavy or light chain which has specificity for a second antigen of interest.
- the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody at the C-terminus of the heavy or light chain which has specificity for a second antigen of interest.
- the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to two single domain antibodies wherein each single domain antibody is fused in linear sequence to each other, optionally via a linker and the resulting single domain antibody fusion is fused to the C-terminus of the light chain or the heavy chain of the Fab or Fab′ fragment.
- the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to two single domain antibodies wherein one single domain antibody is fused to the C-terminus of the light chain of the Fab or Fab′ fragment and the other single domain antibody is fused to the C-terminus of the heavy chain of the Fab or Fab′ fragment, said single domain antibodies having specificity for a second antigen of interest.
- the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus
- the two single domain antibodies are identical i.e. have the same binding specificity for the same antigen. In one example, they bind the same epitope on the same antigen.
- the single domain antibodies may both be the same VH dAb, the same VHH dAb or the same VL dAb.
- the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus
- the two single domain antibodies are a complementary VH/VL pair which bind the antigen co-operatively i.e. they are a complementary VH/VL pair which have the same binding specificity. Typically they will be a VH/VL pair derived from the same antibody.
- the dual specificity antibody fusion protein of the present invention comprises two single domain antibodies which are a complementary VH/VL pair
- the VH single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VL single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda).
- the dual specificity antibody fusion protein of the present invention comprises two single domain antibodies which are a complementary VH/VL pair
- the VL single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VH single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda).
- the dual specificity antibody fusion protein of the present invention comprises two single domain antibodies which are linked by one or more disulfide bonds
- two single domain antibodies which are a complementary VH/VL pair linked by one ore more (such as 1 or 2) disulfide bonds such as the VH single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VL single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda).
- the VL single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VH single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda).
- the disulfide bond is thought to provide additional stabilisation to the construct, which may be advantageous.
- the disulfide bond between the heavy and light chain such as between the CH domain and CL or CK domain is not present, for example because one or more cysteines which form the bond are replaced. Said one or more cysteines may be replaced with, for example serine.
- an interchain disulfide bond between the heavy and light chain between the CH domain and CL or CK domain is present.
- a F(ab) 2 fragment comprising one, two, three or four single domain antibodys, for example a two separate VH/VL pairs which may be directed to the same or different antigens.
- the single domain antibody or antibodies bind to a second antigen, different from that bound by the Fab or Fab′ fragment component.
- the dAbs for use in the present invention exhibit specificity for a complement pathway protein, a CD marker protein or an Fc ⁇ R.
- the dAb is preferably specific for a CD molecule.
- the dAb exhibits specificity for a CD molecule selected from the group consisting of CD68, CD80, CD86, CD64, CD3, CD4, CD8 CD45, CD16 and CD35.
- the dAbs for use in the present invention exhibit specificity for a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1, the serum carrier protein preferably being a human serum carrier protein such as thyroxine-binding protein, transthyretin, ⁇ 1-acid glycoprotein, transferrin, fibrinogen or serum albumin.
- the dAb exhibits specificity for human serum albumin.
- a rabbit, mouse, rat, camel or a llama is immunised with a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1 (e.g. human serum albumin) and blood collected when the titre is appropriate.
- the gene encoding the dAb may be cloned by single cell PCR, or the B cell(s) encoding the dAb may be immortalised by EBV transformation, or by fusion to an immortal cell line.
- the single domain antibody may be obtained by phage display as described herein above.
- the single domain antibody or antibodies bind human serum albumin. In one embodiment the single domain antibody or antibodies bind human serum albumin, murine serum albumin and rat serum albumin.
- the single domain antibody which binds serum albumin is a dAb provided in WO2005/118642 (see for example FIGS. 1 c and 1 d ) or a VHH provided in WO2004/041862 or a humanised nanobody described in, for example table III of WO2006/122787.
- a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH single domain antibody which comprises at least one of a CDR having the sequence given in FIG. 5 ( e ) SEQ ID NO:56 or FIG. 5 ( k ) SEQ ID NO:62 for CDR-H1, a CDR having the sequence given in FIG. 5( f ) SEQ ID NO:57 or FIG. 5 (1) SEQ ID NO:63 for CDR-H2 and a CDR having the sequence given in FIG. 5 ( g ) SEQ ID NO:58 or FIG. 5 ( m ) SEQ ID NO:64 for CDR-H3.
- a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH antibody, wherein at least two of CDR-H1, CDR-H2 and CDR-H3 of the VH domain are selected from the following: the sequence given in SEQ ID NO:56 or SEQ ID NO:62 for CDR-H1, the sequence given in SEQ ID NO:57 or SEQ ID NO:63 for CDR-H2 and the sequence given in SEQ ID NO:58 or SEQ ID NO:64 for CDR-H3.
- the single domain antibody may comprise a VH domain wherein CDR-H1 has the sequence given in SEQ ID NO:56 and CDR-H2 has the sequence given in SEQ ID NO:57.
- the single domain antibody may comprise a VH domain wherein CDR-H1 has the sequence given in SEQ ID NO:56 and CDR-H3 has the sequence given in SEQ ID NO:58.
- CDR-H1 has the sequence given in SEQ ID NO:56
- CDR-H3 has the sequence given in SEQ ID NO:58.
- a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH single domain antibody, wherein the VH domain comprises the sequence given in SEQ ID NO:56 for CDR-H1, the sequence given in SEQ ID NO:57 for CDR-H2 and the sequence given in SEQ ID NO:58 for CDR-H3.
- a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH single domain antibody, wherein the VH domain comprises the sequence given in SEQ ID NO:62 for CDR-H1, the sequence given in SEQ ID NO:63 for CDR-H2 and the sequence given in SEQ ID NO:64 for CDR-H3.
- a single domain antibody which binds human serum albumin for use in the present invention is a humanised heavy chain VH single domain antibody, dAbH1, having the sequence given in FIG. 5 ( a ) (SEQ ID NO:52).
- dAbH1 humanised heavy chain VH single domain antibody
- FIG. 6 An example of a suitable CH1-dAbH1 fusion comprising a G 4 S linker is given in FIG. 6 (SEQ ID NO:68).
- the single domain antibody which binds human serum albumin for use in the present invention is a humanised heavy chain VH single domain antibody, dAbH2, having the sequence given in FIG. 5 ( c ) (SEQ ID NO:54).
- dAbH2 humanised heavy chain VH single domain antibody
- FIG. 6 An example of a suitable CH1-dAbH2 fusion comprising a G 4 S linker is given in FIG. 6 (SEQ ID NO:69).
- the Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues.
- the actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure.
- CDR complementarity determining region
- the correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat numbered sequence.
- CDR-H1 comprises residues 26 to 35, as described by a combination of the Kabat numbering system and Chothia's topological loop definition.
- the CDRs of the light chain variable domain are located at residues 24-34 (CDR-L1), residues 50-56 (CDR-L2) and residues 89-97 (CDR-L3) according to the Kabat numbering system.
- a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL single domain antibody which comprises at least one of a CDR having the sequence given in FIG. 5 ( h ) SEQ ID NO:59 or FIG. 5 ( n ) SEQ ID NO:65 for CDR-L1, a CDR having the sequence given in FIG. 5( i ) SEQ ID NO:60 or FIG. 5 ( o ) SEQ ID NO:66 for CDR-L2 and a CDR having the sequence given in FIG. 5 ( j ) SEQ ID NO:61 or FIG. 5 ( p ) SEQ ID NO:67 for CDR-L3.
- a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL antibody, wherein at least two of CDR-L1, CDR-L2 and CDR-L3 of the VL domain are selected from the following: the sequence given in SEQ ID NO:59 or SEQ ID NO:65 for CDR-L1, the sequence given in SEQ ID NO:60 or SEQ ID NO:66 for CDR-L2 and the sequence given in SEQ ID NO:61 or SEQ ID NO:67 for CDR-L3.
- the domain antibody may comprise a VL domain wherein CDR-L1 has the sequence given in SEQ ID NO:59 and CDR-L2 has the sequence given in SEQ ID NO:60.
- the domain antibody may comprise a VL domain wherein CDR-L1 has the sequence given in SEQ ID NO:59 and CDR-L3 has the sequence given in SEQ ID NO:61.
- CDR-L1 has the sequence given in SEQ ID NO:59
- CDR-L3 has the sequence given in SEQ ID NO:61.
- a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL domain antibody, wherein the VL domain comprises the sequence given in SEQ ID NO:59 for CDR-L1, the sequence given in SEQ ID NO:60 for CDR-L2 and the sequence given in SEQ ID NO:61 for CDR-L3.
- a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL domain antibody, wherein the VL domain comprises the sequence given in SEQ ID NO:65 for CDR-L1, the sequence given in SEQ ID NO:66 for CDR-L2 and the sequence given in SEQ ID NO:67 for CDR-L3.
- a single domain antibody which binds human serum albumin for use in the present invention is a humanised light chain VL single domain antibody, dAbL1, having the sequence given in FIG. 5 ( b ) (SEQ ID NO:53).
- dAbL1 humanised light chain VL single domain antibody
- FIG. 6 An example of a suitable CH1-dAbL1 fusion and a Ck1-dAbL1 fusion both comprising a G 4 S linker is given in FIG. 6 (SEQ ID NO:70 and SEQ ID NO:72).
- a single domain antibody which binds human serum albumin for use in the present invention is a humanised light chain VL single domain antibody, dAbL2, having the sequence given in FIG. 5 ( d ) (SEQ ID NO:55).
- dAbL2 humanised light chain VL single domain antibody
- An example of a suitable CH1-dAbL2 fusion and a Ck1-dAbL2 fusion both comprising a G 4 S linker is given in FIG. 6 (SEQ ID NO:71 and SEQ ID NO:73).
- the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus and the two single domain antibodies are a complementary VH/VL pair which bind the antigen co-operatively as described herein above
- the VH dAb is dAbH1 (SEQ ID NO:52) and the VL dAb is dAbL1 (SEQ ID NO:53).
- the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus the two single domain antibodies are a complementary VH/VL pair which bind the antigen co-operatively as described herein above, the VH dAb is dAbH2 (SEQ ID NO:54) and the VL dAb is dAbL2 (SEQ ID NO:55).
- the present invention provides albumin binding antibodies or fragments thereof containing one or more of the CDRs provided herein above and in FIG. 5 ( e - p ), in particular comprising a CDRH1 with the sequence shown in SEQ ID NO. 56, a CDRH2 with the sequence shown in SEQ ID NO. 57, a CDRH3 with the sequence shown in SEQ ID NO. 58, a CDRL1 with the sequence shown in SEQ ID NO. 59, a CDRL2 with the sequence shown in SEQ ID NO. 60, and/or a CDRL3 with the sequence shown in SEQ ID NO. 61.
- the albumin binding antibodies or fragments comprise a CDRH1 with the sequence shown in SEQ ID NO.
- CDRH2 with the sequence shown in SEQ ID NO. 63
- CDRH3 with the sequence shown in SEQ ID NO. 64
- CDRL1 with the sequence shown in SEQ ID NO. 65
- CDRL2 with the sequence shown in SEQ ID NO. 66
- CDRL3 with the sequence shown in SEQ ID NO. 67.
- Said CDRs may be incorporated into any suitable antibody framework and into any suitable antibody format.
- Such antibodies include whole antibodies and functionally active fragments or derivatives thereof which may be, but are not limited to, monoclonal, humanised, fully human or chimeric antibodies.
- albumin binding antibodies may comprise a complete antibody molecule having full length heavy and light chains or a fragment thereof and may be, but are not limited to Fab, modified Fab, Fab′, F(ab′) 2 , Fv, single domain antibodies, scFv, bi, tri or tetra-valent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies and epitope-binding fragments of any of the above (see for example Holliger and Hudson, 2005, Nature Biotech. 23(9):1126-1136; Adair and Lawson, 2005, Drug Design Reviews—Online 2(3), 209-217).
- Multi-valent antibodies may comprise multiple specificities or may be monospecific (see for example WO 92/22853 and WO05/113605). It will be appreciated that this aspect of the invention also extends to variants of these albumin binding antibodies.
- albumin binding antibodies in particular single domain antibodies may be conjugated to any other antibody or protein or other molecule, as desired or used in any other suitable context.
- the single domain antibodies dAbH1, dAbL1, dAbH2, dAbL2 as described above and shown in FIG. 5 ( a - d ) may be incorporated into any suitable antibody format or used as single domain antibodies in any suitable context, such as a fusion or conjugate.
- antibodies of this aspect of the invention comprise the sequence given in FIG. 5( e ) for CDR-H1, the sequence given in FIG. 5( f ) for CDR-H2 and the sequence given in FIG. 5( g ) for CDR-H3.
- antibodies of this aspect of the invention comprise the sequence given in FIG. 5( k ) for CDR-H1, the sequence given in FIG. 5( l ) for CDR-H2 and the sequence given in FIG. 5( m ) for CDR-H3.
- antibodies of this aspect of the invention comprise the sequence given in FIG. 5( h ) for CDR-L1, the sequence given in FIG. 5( i ) for CDR-L2 and the sequence given in FIG. 5( j ) for CDR-L3.
- antibodies of this aspect of the invention comprise the sequence given in FIG. 5( n ) for CDR-L1, the sequence given in FIG. 5( o ) for CDR-L2 and the sequence given in FIG. 5( p ) for CDR-L3.
- each of the sequences from the sequence listing herein may be located in the position corresponding to the natural position or a non-natural position.
- Natural position will be for the relevant sequence in the listing labelled CDRH1 position H1, for the relevant sequence in the listing labelled CDRH2 position H2, for the relevant sequence in the listing labelled CDRH3 position H3, for the relevant sequence in the listing labelled CDRL1 position L1, for the relevant sequence in the listing labelled CDRL2 position L2, and for the relevant sequence in the listing labelled CDRL3 position L3.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 88 to 93.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 94 to 99.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 100 to 105.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 106 to 111.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 112 to 117.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 118 to 123.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 124 to 129.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 130 to 135.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 136 to 141.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 142 to 147.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 148 to 153.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 154 to 159.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 160 to 165.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 166 to 171.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 172 to 177.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 178 to 183.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 184 to 189.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 190 to 195.
- the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 196 to 201.
- the antibody fusion protein of the disclosure comprises Sequence ID No: 202.
- the antibody fusion protein of the disclosure comprises Sequence ID No: 203.
- the antibody fusion protein of the disclosure comprises Sequence ID Nos: 202 and 203.
- the antibody fusion protein of the disclosure comprises Sequence ID No: 204.
- the antibody fusion protein of the disclosure comprises Sequence ID No: 205.
- the antibody fusion protein of the disclosure comprises Sequence ID Nos: 204 and 205.
- the antibody fusion protein of the disclosure comprises Sequence ID No: 206.
- the antibody fusion protein of the disclosure comprises Sequence ID No: 207.
- the antibody fusion protein of the disclosure comprises Sequence ID No: 206 and 207.
- the binding affinity of the single domain antibody for albumin will be sufficient to extend the half-life of the Fab or Fab′ in vivo. It has been reported that an affinity for albumin of less than or equal to 2.5 ⁇ M affinity will extend half-life in vivo (Nguyen, A. et al (2006) Protein Engineering, Design & Selection, 19(7), 291-297).
- the single domain antibody molecules of the present invention preferably have a binding affinity suited to their purpose and the antigen to which they bind.
- the single domain antibodies have a high binding affinity, for example picomolar.
- the single domain antibodies have a binding affinity for antigen which is nanomolar or micromolar. Affinity may be measured using any suitable method known in the art, including BIAcore as described in the Examples herein using natural or recombinant antigen.
- the single domain antibody molecules of the present invention which bind albumin have a binding affinity of about 2 ⁇ M or better. In one embodiment the single domain antibody molecule of the present invention has a binding affinity of about 1 ⁇ M or better. In one embodiment the single domain antibody molecule of the present invention has a binding affinity of about 500 nM or better. In one embodiment the single domain antibody molecule of the present invention has a binding affinity of about 200 nM or better. In one embodiment the domain antibody molecule of the present invention has a binding affinity of about 1 nM or better. It will be appreciated that the affinity of single domain antibodies provided by the present invention and known in the art may be altered using any suitable method known in the art.
- the present invention therefore also relates to variants of the domain antibody molecules of the present invention, which have an improved affinity for albumin.
- variants can be obtained by a number of affinity maturation protocols including mutating the CDRs (Yang et al., J. Mol. Biol., 254, 392-403, 1995), chain shuffling (Marks et al., Bio/Technology, 10, 779-783, 1992), use of mutator strains of E. coli (Low et al., J. Mol. Biol., 250, 359-368, 1996), DNA shuffling (Patten et al., Curr. Opin.
- the single domain antibody or antibodies of the dual specificity fusion protein may be provided as monomers, dimmers or trimers, as required.
- the desired product may be obtained by adjusting the downstream processing steps the material is subjected to.
- the processed material is provided as a substantially homogenous monomer.
- the processed material is provided a substantially homogenous dimer.
- the processed material is provided as a substantially homogenous trimer.
- the present invention also provides an isolated DNA sequence encoding a dual specificity antibody fusion protein of the present invention.
- the DNA sequences of the present invention may comprise synthetic DNA, for instance produced by chemical processing, cDNA, genomic DNA or any combination thereof.
- DNA sequences which encode the dual specificity antibody fusion protein of the present invention can be obtained by methods well known to those skilled in the art. For example, DNA sequences coding for part or all of the antibody fragments, linkers and/or dAbs may be synthesised as desired from the determined DNA sequences or on the basis of the corresponding amino acid sequences.
- Standard techniques of molecular biology may be used to prepare DNA sequences coding for the dual specificity antibody fusion protein of the present invention. Desired DNA sequences may be synthesised completely or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as appropriate.
- PCR polymerase chain reaction
- the present invention further relates to a cloning or expression vector comprising one or more DNA sequences of the present invention. Accordingly, provided is a cloning or expression vector comprising one or more DNA sequences encoding a dual specificity antibody fusion protein of the present invention.
- the cloning or expression vector comprises a single DNA sequence encoding the entire dual specificity antibody fusion protein.
- the cloning or expression vector comprises DNA encoded transcription units in sequence such that a translation fusion protein is produced.
- a fusion protein of the invention can have the dAb at the N-terminus or the C-terminus and thus, the dAb DNA encoded transcription unit will be first or last, respectively, within the DNA sequence encoding the translation fusion.
- a translation fusion may comprise an N-terminal dAb and a C-terminal Fab or Fab′.
- a translation fusion may comprise an N-terminal Fab or Fab′ and a C-terminal dAb.
- Suitable mammalian host cells include NS0, CHO, myeloma or hybridoma cells. Accordingly in one embodiment the fusion protein of the present invention is expressed in E. coli . In another embodiment the fusion protein of the present invention is expressed in mammalian cells.
- the present invention also provides a process for the production of a dual specificity antibody fusion protein comprising culturing a host cell comprising a vector of the present invention under conditions suitable for the expression of protein from the DNA sequence encoding said dual specificity antibody fusion protein.
- the invention further provides methods for isolating the dual specificity antibody fusion protein.
- a dual specificity antibody fusion protein of the present invention may be purified, where necessary, using any suitable method known in the art.
- chromatographic techniques such as ion exchange, size exclusion, protein G or hydrophobic interaction chromatography may be used.
- the size of a dual specificity antibody fusion protein may be confirmed by conventional methods known in the art such as size exclusion chromatography and non-reducing SDS-PAGE. Such techniques can be used, for example to confirm that the protein has not dimerised and/or does not have a portion missing, e.g. the dAb portion. If dimers are detected and a homogenous monomeric product is required then the monomeric dual specificity antibody fusion protein may be purified away from the dimeric species using conventional chromatography techniques as described above.
- Dual specificity antibody fusion proteins of the invention are useful in the treatment of diseases or disorders including inflammatory diseases and disorders, immune disease and disorders, fibrotic disorders and cancers.
- inflammatory disease or “disorder” and “immune disease or disorder” includes rheumatoid arthritis, psoriatic arthritis, still's disease, Muckle Wells disease, psoriasis, Crohn's disease, ulcerative colitis, SLE (Systemic Lupus Erythematosus), asthma, allergic rhinitis, atopic dermatitis, multiple sclerosis, vasculitis, Type I diabetes mellitus, transplantation and graft-versus-host disease.
- fibrotic disorder includes idiopathic pulmonary fibrosis (IPF), systemic sclerosis (or scleroderma), kidney fibrosis, diabetic nephropathy, IgA nephropathy, hypertension, end-stage renal disease, peritoneal fibrosis (continuous ambulatory peritoneal dialysis), liver cirrhosis, age-related macular degeneration (ARMD), retinopathy, cardiac reactive fibrosis, scarring, keloids, burns, skin ulcers, angioplasty, coronary bypass surgery, arthroplasty and cataract surgery.
- IPF idiopathic pulmonary fibrosis
- systemic sclerosis or scleroderma
- kidney fibrosis diabetic nephropathy
- IgA nephropathy IgA nephropathy
- hypertension end-stage renal disease
- peritoneal fibrosis continuous ambulatory peritoneal dialysis
- liver cirrhosis liver cirrhos
- cancer includes a malignant new growth that arises from epithelium, found in skin or, more commonly, the lining of body organs, for example: breast, ovary, prostate, lung, kidney, pancreas, stomach, bladder or bowel. Cancers tend to infiltrate into adjacent tissue and spread (metastasise) to distant organs, for example: to bone, liver, lung or the brain.
- a pharmaceutical composition which comprises an antibody fusion of the invention in association with one or more pharmaceutically acceptable carriers, excipients or diluents. Also provided is the use of an antibody fusion protein of the invention for the manufacture of a medicament for the treatment of a disease or disorder. Most preferably, the disease or disorder is an inflammatory disease or disorder.
- compositions according to the invention may take a form suitable for oral, buccal, parenteral, subcutaneous, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.
- the single domain antibody or antibodies of the antibody fusion protein bind to albumin
- the formulation may further comprise albumin, for example human serum albumin, in particular recombinant albumin such as recombinant human serum albumin. Suitable amounts may be in the range of less than 2% w/w of the total formulation, in particular less than 1, 0.5, or 0.1% w/w. This may assist in stabilizing the antibody component in the formulation.
- the pharmaceutical composition may be lyophilized for reconstitution later, with an aqueous solvent.
- a unit dose container such as a vial, comprising a lyophilized “antibody” according to the invention.
- the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate).
- binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose
- fillers e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate
- lubricants e.g. magnesium stearate, talc or silica
- disintegrants e.g. potato starch or sodium glycollate
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles or preservatives.
- the preparations may also contain buffer salts, flavouring agents, colouring agents or sweetening agents, as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the bispecific antibodies of the invention may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion.
- Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials.
- the compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
- the bispecific antibodies of the invention may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.
- the compounds according to the present invention may be conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- a suitable propellant e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack or dispensing device may be accompanied by instructions for administration.
- the compounds according to the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water.
- the compounds according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.
- the formulation is provided as a formulation for topical administrations including inhalation.
- Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases.
- Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable excipient.
- These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another.
- monosaccharides e.g. glucose or arabinose
- disaccharides e.g. lactose, saccharose, maltose
- oligo- and polysaccharides e.g. dextranes
- polyalcohols e.g. sorbitol, mannitol, xylitol
- salts e.g. sodium chloride, calcium carbonate
- Particles for deposition in the lung require a particle size less than 10 microns, such as 1-9 microns for example from 0.1 to 5 ⁇ m, in particular from 1 to 5 ⁇ m.
- the particle size of the active ingredient (such as the antibody or fragment) is of primary importance.
- propellent gases which can be used to prepare the inhalable aerosols are known in the art.
- Suitable propellent gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
- hydrocarbons such as n-propane, n-butane or isobutane
- halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
- the abovementioned propellent gases may be used on their own or in mixtures thereof.
- Particularly suitable propellent gases are halogenated alkane derivatives selected from among TG 11, TG 12, TG 134a and TG227.
- halogenated alkane derivatives selected from among TG 11, TG 12, TG 134a and TG227.
- TG134a 1,1,1,2-tetrafluoroethane
- TG227 1,1,2,3,3,3-heptafluoropropane
- mixtures thereof are particularly suitable.
- the propellent-gas-containing inhalable aerosols may also contain other ingredients such as cosolvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
- the propellant-gas-containing inhalable aerosols according to the invention may contain up to 5% by weight of active substance. Aerosols according to the invention contain, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1% by weight of active ingredient.
- topical administrations to the lung may also be by administration of a liquid solution or suspension formulation, for example employing a device such as a nebulizer, for example, a nebulizer connected to a compressor (e.g., the Pari LC-Jet Plus® nebulizer connected to a Pari Master® compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.).
- a nebulizer for example, a nebulizer connected to a compressor (e.g., the Pari LC-Jet Plus® nebulizer connected to a Pari Master® compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.).
- the antibody formats of the invention can be delivered dispersed in a solvent, e.g., in the form of a solution or a suspension. It can be suspended in an appropriate physiological solution, e.g., saline or other pharmacologically acceptable solvent or a buffered solution.
- Buffered solutions known in the art may contain 0.05 mg to 0.15 mg disodium edetate, 8.0 mg to 9.0 mg NaCl, 0.15 mg to 0.25 mg polysorbate, 0.25 mg to 0.30 mg anhydrous citric acid, and 0.45 mg to 0.55 mg sodium citrate per 1 ml of water so as to achieve a pH of about 4.0 to 5.0.
- a suspension can employ, for example, lyophilised antibody.
- the therapeutic suspensions or solution formulations can also contain one or more excipients.
- Excipients are well known in the art and include buffers (e.g., citrate buffer, phosphate buffer, acetate buffer and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. Solutions or suspensions can be encapsulated in liposomes or biodegradable microspheres.
- the formulation will generally be provided in a substantially sterile form employing sterile manufacture processes.
- This may include production and sterilization by filtration of the buffered solvent/solution used for the for the formulation, aseptic suspension of the antibody in the sterile buffered solvent solution, and dispensing of the formulation into sterile receptacles by methods familiar to those of ordinary skill in the art.
- Nebulizable formulation according to the present disclosure may be provided, for example, as single dose units (e.g., sealed plastic containers or vials) packed in foil envelopes. Each vial contains a unit dose in a volume, e.g., 2 ml, of solvent/solution buffer.
- the antibodies formats of the present disclosure are thought to be suitable for delivery via nebulisation.
- the compounds according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH-adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
- a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
- compounds may be formulated in an ointment such as petrolatum.
- the compounds according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component.
- suitable non-irritating excipient include, for example, cocoa butter, beeswax and polyethylene glycols.
- daily dosages may range from around 10 ng/kg to 1000 mg/kg, typically from 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and from around 0.05 mg to around 1000 mg, e.g. from around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.
- Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.
- FIG. 1 Diagrammatic representation of Fab-dAbs where the dAb is at the C-terminus
- FIG. 2A Diagrammatic representation of Fab-didAbs
- FIG. 2B Diagrammatic representation of Fab-didAbs with additional disulfide stabilisation between the dAbs.
- FIG. 3 SDS PAGE analysis of FabA-dAbL3 (CK-SG 4 SE) (1) and FabA-dAbL3 (CK-G[APAPA] 2 ) (2).
- FIG. 4 Western blot analysis of FabA-dAbL3 (CK-SG 4 SE) (1) and FabA-dAbL3 (CK-G[APAPA] 2 ) (2).
- FIG. 4 a SDS PAGE of FabB-didAbs
- FIG. 5 Sequences of domain antibodies dAbH1, dAbH2, dAbL1 and dAbL2 and the CDRs derived from each of those antibodies.
- FIG. 6 FabB-dAb constructs comprising FabB heavy or light chain variable domain fused to a domain antibody.
- FIG. 7 Fab′A heavy and light chain sequences and FabA heavy chain sequence.
- FIGS. 8 a , 8 b & 8c Murinised Fab-didAb amino acid sequences.
- FIG. 8 a shows the amino acid sequence of CDRs in various murine dAbs.
- FIG. 8 b shows the amino acid sequence of mFabD-mdidAb:
- FIG. 8 c shows the amino acid sequence of mFabD-mdidAb:
- FIG. 9 shows SDS PAGE of FabB-didAbs
- FIG. 10 shows a diagrammatic representation of a Thermofluor thermal stability assay.
- FIG. 11 shows a plot of HAS-FITC signal/HAS-FITC mixes bound to activated mouse T cells.
- FIG. 12 shows a plot of an aggregation stability assay.
- FIG. 13 shows in vivo concentration profiles over time after subcutaneous and intravenous dosing
- FIGS. 14A , B and C show certain CD4+ cell and CD8+ cell readouts
- FIG. 15 shows SDS-PAGE analysis of FabB-645Fv
- FIG. 16 shows size exclusion analysis of FabB-645Fv
- FIG. 17 shows thermograms of FabB-645Fv with various linker lengths.
- FIG. 18 shows SDS-PAGE analysis of certain FabB constructs
- FIG. 19 shows size exclusion analysis of various FabB-645Fv constructs
- FIGS. 20 to 24 show sequences for certain formats.
- Fab A, Fab B, Fab C and Fab D components may be provided below in different formats.
- An in-frame DNA encoded transcription unit encoding a dAb with specificity for human serum albumin was produced using recombinant DNA technology.
- an in-frame DNA encoded transcription unit encoding a dAb with specificity for a recruitment protein can be produced using recombinant DNA technology.
- DNA was synthesised encoding a human kappa light chain constant region (with the Km3 allotype of the kappa constant region), a peptide linker and a dAb and cloned as a SacI-PvuII restriction fragment into the UCB-Celltech in-house expression vector pTTOD(Fab) (a derivative of pTTO-1, described in Popplewell et al., Methods Mol. Biol. 2005; 308: 17-30) which contains DNA encoding the human gamma-1 CH1 constant region.
- pTTOD(Fab) a derivative of pTTO-1, described in Popplewell et al., Methods Mol. Biol. 2005; 308: 17-30
- DNA was synthesised encoding a human CH1 fragment (of the ⁇ 1 isotype) followed by a linker encoding sequence and a dAb. This was subcloned as an ApaI-EcoRI restriction fragment into the UCB-Celltech in-house expression vector pTTOD(Fab) (a derivative of pTTO-1, described in Popplewell et al., above) which contains DNA encoding the human gamma-1 CH1 constant region.
- pTTOD(Fab) a derivative of pTTO-1, described in Popplewell et al., above
- the antibody chain to which the dAb is fused is denoted either as CK or LC for the cKappa light chain and as CH1 or HC for the heavy chain constant domain, CH1.
- Fab-dAb fusion proteins were constructed by fusing dAbL3 or dAbH4 to the C-terminus of the constant region of either the light or heavy chain of FabA.
- a flexible (SGGGGSE (SEQ ID NO:1)) or a rigid (G(APAPA) 2 (SEQ ID NO: 34)) linker was used to link the dAb to the cKappa region (SEQ ID NO:75) whereas the linker DKTHTS (SEQ ID NO:2) was used to link the dAb to the CHI region (SEQ ID NO:76).
- the DNA sequence coding for the constant region-dAb fusion was manufactured synthetically as fragments to enable sub-cloning into the FabA sequence of the in-house pTTOD vector.
- Light chain-dAb fusions were constructed by sub-cloning the SacI-ApaI fragment of the synthesized genes, encoding a C-terminal cKappa fused to either dAbL3 or dAbH4 via either a (SGGGGSE (SEQ ID NO:1)) or a rigid (G(APAPA) 2 (SEQ ID NO: 34)) linker, into the corresponding sites of a plasmid capable of expressing FabA.
- SGGGGSE SEQ ID NO:1
- G(APAPA) 2 SEQ ID NO: 34
- Heavy chain-dAb fusions were constructed by sub-cloning the ApaI-EcoRI fragment of the synthesised genes, encoding a C-terminal CHI fused to either dAbL3 or dAbH4 via a DKTHTS linker, into the corresponding sites of a plasmid capable of expressing FabA.
- Fab′ A is derived from an IL-1 beta binding antibody, the heavy and light chain sequences of which are provided in SEQ ID NOs: 74 and 75 respectively as shown in FIG. 7 .
- the hinge of the heavy chain was altered to DKTHTS even where no dAb is attached to the heavy chain (SEQ ID NO:76).
- FabA comprises the same light chain sequence (SEQ ID NO:75) and a truncated heavy chain sequence which terminates at the interchain cysteine (SEQ ID NO:77).
- dAbL3 and dAbH4 are light and heavy chain domain antibodies respectively which bind human serum albumin.
- FabA-didAb with dAbL3 or dAbH4 on both light and heavy chains were constructed by sub-cloning the ApaI-EcoRI fragment coding for CH1-dAb fusions into the existing Fab-dAb plasmids where the dAb is fused to the light chain via the flexible linker.
- FabB-dAbs FabB-dAbH1 (CH1-G 4 S ⁇ 2), FabB-dAbH2 (CH1-G 4 S ⁇ 2), FabB-dAbL1 (CH1-G 4 S ⁇ 2), FabB-dAbL2 (CH1-G 4 S ⁇ 2) were all assembled by PCR then cloned into a mammalian expression vector under the control of the HCMV-MIE promoter and SV40E polyA sequence. These were paired with a similar vector containing the FabB light chain for expression in mammalian cells (see below).
- FabB is derived from an antibody which bids a cell surface co-stimulatory molecule.
- dAbH1, dAbH2, dAbL1 and dAbL2 were obtained as described in Example 3.
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 2 ⁇ g heavy chain plasmid+2 ⁇ g light chain plasmid was incubated with 10 ⁇ l 293fectin+340 ⁇ l Optimem media for 20 mins at RT. The mixture was then added to 5 ⁇ 10 6 HEK293 cells in suspension and incubated for 4 days with shaking at 37° C.
- Binding affinities and kinetic parameters for the interactions of Fab-dAb constructs were determined by surface plasmon resonance (SPR) conducted on a Biacore T100 using CM5 sensor chips and HBS-EP (10 mM HEPES (pH7.4), 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20) running buffer.
- Fab-dAb samples were captured to the sensor chip surface using either a human F(ab′) 2 -specific goat Fab (Jackson ImmunoResearch, 109-006-097) or an in-house generated anti human CH1 monoclonal antibody. Covalent immobilisation of the capture antibody was achieved by standard amine coupling chemistry.
- Each assay cycle consisted of firstly capturing the Fab-dAb using a 1 min injection, before an association phase consisting of a 3 min injection of antigen, after which dissociation was monitored for 5 min. After each cycle, the capture surface was regenerated with 2 ⁇ 1 min injections of 40 mM HCl followed by 30 s of 5 mM NaOH. The flow rates used were 10 ⁇ l/min for capture, 30 ⁇ l/min for association and dissociation phases, and 10 ⁇ l/min for regeneration.
- a titration of antigen for human serum albumin typically 62.5 nM-2 ⁇ M, for IL-1 ⁇ 1.25-40 nM was performed, a blank flow-cell was used for reference subtraction and buffer-blank injections were included to subtract instrument noise and drift.
- E. coli pellets containing the Fab-dAbs within the periplasm were re-suspended in original culture volume with 100 mM Tris/HCl, 10 mM EDTA pH 7.4. These suspensions were then incubated at 4° C. for 16 hours at 250 rpm. The re-suspended pellets were centrifuged at 10000 ⁇ g for 1 hour at 4° C. The supernatants were removed and 0.45 ⁇ m filtered.
- the Fab-dAbs were captured from the filtered supernatant by Protein-G chromatography. Briefly the supernatants were applied, with a 20 minute residence time, to a Gammabind Plus Sepharose (GE Healthcare) column equilibrated in 20 mM phosphate, 150 mM NaCl pH7.1. The column was washed with 20 mM phosphate, 150 mM NaCl pH7.1 and the bound material eluted with 0.1M glycine/HCl pH2.8. The elution peak was collected and pH adjusted to ⁇ pH5 with 1M sodium acetate. The pH adjusted elutions were concentrated and diafiltered into 50 mM sodium acetate pH4.5 using a 10 k MWCO membrane.
- GE Healthcare Gammabind Plus Sepharose
- the Fab-dAbs were further purified by cation exchange chromatography at pH4.5 with a NaCl elution gradient. Briefly the diafiltered Protein-G eluates were applied to a Source15S (GE Healthcare) column equilibrated in 50 mM sodium acetate pH4.5. The column was washed with 50 mM sodium acetate pH4.5 and the bound material eluted with a 20 column volume linear gradient from 0 to 1M NaCl in 50 mM sodium acetate pH4.5. Third column volume fractions were collected through out the gradient. The fractions were analysed by A280 and SDS-PAGE and relevant fractions pooled.
- the Fab-dAbs were further purified by gel filtration. Briefly the FabA-dAbL3 (CK-SG 4 SE) pooled ion exchange elution fractions were applied to a Superdex200 (GE Healthcare) column equilibrated in 50 mM sodium acetate, 125 mM NaCl pH 5.0 and eluted with an isocratic gradient of 50 mM sodium acetate, 125 mM NaCl pH 5.0. 1/120 column volume fractions were collected through out the gradient. The fractions were analysed by A280 and SDS-PAGE and relevant fractions pooled.
- the pooled ion exchange elution fractions were concentrated and diafiltered into 50 mM sodium acetate, 125 mM NaCl pH 5.0 using a 10 k MWCO membrane.
- Samples were diluted with water where required and then to 10 ⁇ l was added 10 ⁇ L 2 ⁇ sample running buffer. For non-reduced samples, 2 ⁇ L of 100 mM NEM was added at this point, for reduced samples 2 ⁇ L of 10 ⁇ reducing agent was added. The sample were vortexed, incubated at 85° C. for 5 mins, cooled and centrifuged at 12500 rpm for 30 secs. The prepared samples were loaded on to a 4-20% acrylamine Tris/Glycine SDS gel and run for 100 mins at 125V. The gels were either transferred onto PVDF membranes for Western blotting or stained with Coomassie Blue protein stain.
- HRP-rabbit anti-human kappa light chains 1/5000 dilution in blocking buffer for 1 hr.
- mouse anti-human heavy chain 1/7000 dilution in blocking buffer for 1 hr.
- HRP-goat anti-mouse 1/2000 dilution in blocking buffer for 1 hr.
- the yields of Fab-dAb were measured using a sandwich ELISA. Briefly, the Fab-dAb was captured with an anti-CH1 antibody then revealed with an anti-kappa-HRP.
- the light chain grafted sequences were sub-cloned into the rabbit light chain expression vector pVRbcK which contains the DNA encoding the rabbit C-Kappa constant region.
- the heavy chain grafted sequences were sub-cloned into the rabbit heavy chain expression vector pVRbHFab, which contains the DNA encoding the rabbit Fab′ heavy chain constant region. Plasmids were co-transfected into CHO cells and the antibodies produced screened for albumin binding and affinity (Table 1). Transfections of CHO cells were performed using the LipofectamineTM 2000 procedure according to manufacturer's instructions (InVitrogen, catalogue No. 11668).
- Humanised VL and VH regions were designed using human V-region acceptor frameworks and donor residues in the framework regions.
- One grafted VL region (L1 (SEQ ID NO:53) and L2 (SEQ ID NO:55)) and one VH region (H1 (SEQ ID NO:52) and H2 (SEQ ID NO:54)) were designed for each of antibodies 1 and 2 respectively and genes were built by oligonucleotide assembly and PCR mutagenesis.
- the grafted domain antibodies and their CDRs are shown in FIG. 5 .
- FabB-dAb constructs were produced as described in the methods and the supernatants from the transfected HEK293 cells containing the FabB-dAbs were tested directly in BIAcore.
- FabB-dAb constructs were assessed to assess the interaction of HSA with FabB-dAb constructs. These consisted of either dAbL1, dAbH2 or dAbL3 fused to the C-terminus of CH1 of FabB (See FIG. 6 ).
- FabB-didAb constructs were produced as described in the methods and the supernatants from the transfected HEK293 cells containing the didAbs tested directly in BIAcore.
- Plasmids for expression of the Fab-dAbs, Fab′A-dAbL3 (CK-SG 4 SE) Fab′A-dAbL3 (CK-G[APAPA] 2 ) in E. coli were constructed as described in the methods.
- the Fab-dAbs were expressed into the periplasm of the E. coli and purified to homogeneity as described in the methods.
- the purity of the Fab-dAbs were assessed by high temperature reverse phase HPLC, SDS-PAGE and Western blotting.
- the Fab-dAbs were also assessed for antigen binding by Biacore.
- Fab-dAb samples were prepared under non-reduced and reduced conditions and run on a gel as described in the methods. The gel was Coomassie stained. The banding profile of both Fab-dAb samples, Fab′A-dAbL3 (CK-SG 4 SE) and Fab′A-dAbL3 (CK-G[APAPA] 2 ), corresponds well to the profile observed by high temperature reverse phase HPLC ( FIG. 3 ).
- Fab-dAb samples were subjected to non-reduced SDS-PAGE followed by western blot analysis with anti-light chain and anti-heavy chain antibodies as described in the methods. This confirmed that the dAb was on the light chain of the Fab and that the heavy chain was unmodified in both samples ( FIG. 4 ). It also demonstrates that all bands detected by coomassie stained, non-reduced SDS PAGE are Fab-dAb related products.
- each construct to bind simultaneously to both human serum albumin and the IL-1 ⁇ antigen was assessed by capturing each construct to the sensor chip surface, before performing either separate 3 min injections of 5 ⁇ M human serum albumin or 100 nM IL-1 ⁇ , or a mixed solution of both 5 ⁇ M human serum albumin and 100 nM IL-1 ⁇ .
- the response seen for the combined HSA/IL-1 ⁇ solution was almost identical to the sum of the responses of the independent injections, see table 7. This shows that the Fab-dAbs are capable of simultaneous binding to both IL-1 ⁇ and human serum albumin, and that binding of either IL-1 ⁇ or human serum albumin does not inhibit the interaction of the other.
- the original FabA bound only to IL-1 ⁇ , with negligible binding to human serum albumin.
- the table above shows the binding response (RU) seen for each construct after separate injections of HSA or IL-1 ⁇ , or injection of premixed HSA and IL-1 ⁇ . In each case the final concentration was 5 ⁇ M for HSA and 100 nM for IL-1 ⁇ . The sum of the individual HSA and IL-1 ⁇ responses is shown in parentheses.
- FabA-dAbs and FabA-didAb fusions terminating with a C-terminal histidine tag were expressed in Escherichia coli . After periplasmic extraction, dAb fusion proteins were purified via the C-terminal His6 tag. Fab expression was analysed by Western blotting of a non-reduced gel with anti-CH1 and anti-cKappa antibodies. FabA-dAb and FabA-didAb were expressed as full-length proteins and were shown to react to both antibody detection reagents.
- Binding assays were performed on a variety of constructs in which dAbL3 or dAbH4 fused to either the light or heavy chain of the FabA (see Table 8 for details of the constructs and summary of the binding data). Although constructs carrying only dAbH4, on either the light or heavy chain, were seen to bind HSA with comparatively poor affinity ( ⁇ 9 ⁇ M and 3 ⁇ M respectively), higher affinity binding was observed for constructs carrying dAbL3, either as a single fusion (on either light or heavy chain) or partnered with a second dAb (dAbL3 or dAbH4) on the opposing chain.
- CHO-XE cells Prior to transfection CHO-XE cells were washed in Earls Balanced Salts Solution (EBSS), pelleted and resuspended in EBSS at 2 ⁇ 10 8 cells/ml. Heavy and light chain plasmids were added to the cells at a total concentration of 400 ug. Optimised electrical parameters for 800 ⁇ l cells/DNA mix on the in-house electroporator were used for transfection. Transfected cells were directly transferred to 1 L CD-CHO media supplied with glutamax, HT and antimycotic antibiotic solution. Cells were incubated, shaking at 37° C. for 24 hours and then shifted to 32° C. Sodium Butyrate 3 mM was added on day 4. Supernatants were harvested on day 14 by centrifugation at 1500 ⁇ g to remove cells. Expression levels were determined by ELISA.
- EBSS Earls Balanced Salts Solution
- the mammalian supernatants containing ⁇ 55 ⁇ g/ml of FabB-didAb as assessed by ELISA were concentrated from 1.8 L to 200 ml using a Minisette concentrator fitted with a 10 kDa molecular weight cut off polyethersulphone (PES) membrane.
- PES polyethersulphone
- the concentrated supernatants were applied to a Gammabind Plus Sepharose (GE Healthcare) column equilibrated in 20 mM phosphate, 150 mM NaCl pH7.1.
- the column was washed with 20 mM phosphate, 150 mM NaCl pH7.1 and the bound material eluted with 0.1M glycine/HCl pH2.7.
- the elution peak was collected and pH adjusted to ⁇ pH7 with 2M Tris/HCl pH8.8.
- the pH adjusted elutions were concentrated to 1 mg/ml and diafiltered into 20 mM phosphate, 150 mM NaCl pH7.1 using a 10 kD molecular weight cut off PES membrane.
- Samples were diluted with water where required and then to 26 ⁇ l was added 10 ⁇ L 4 ⁇ LDS sample running buffer. For non-reduced samples, 4 ⁇ L of 100 mM NEM was added and for reduced samples 4 ⁇ L of 10 ⁇ reducing agent was added. The samples were vortexed, incubated at 85° C. for 5 mins, cooled and centrifuged at 12500 rpm for 30 secs. The prepared samples were loaded on to a 4-20% acrylamine Tris/Glycine SDS gel and run for 110 mins at 125V. The gels were stained with Coomassie Blue protein stain.
- the yields of Fab-didAb were measured using a sandwich ELISA. Briefly, the Fab-didAb was captured with an anti-CH1 antibody then revealed with an anti-kappa-HRP.
- FabB and FabB-didAb samples were prepared under non-reduced and reduced conditions and separated on a gel and stained as described in the methods. See FIG. 9 .
- Samples (1 ⁇ l of sample at ⁇ 1 mg/ml, 8 ⁇ l of PBS and 1 ⁇ l of 30 ⁇ stock of Sypro orange fluorescent dye) were run in quadruplicate in 384 well plates. The plate is heated from 20-99° C. using a 7900HT fast real-time PCR system and the fluorescence (excitation at 490 nm, emission at 530 nm) measured. The results are shown in Table D and FIG. 10 .
- Binding affinities for the interactions of Fab-Fv constructs with HSA were determined as described in the methods except that the running buffers at pH5.0, 5.5, 6.0 and 7.0 were created by mixing 40 mM citric acid, 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20 and 80 mM disodium hydrogen phosphate, 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20 to give the desired pH.
- the affinity of FabB-645Fv (G 4 S ⁇ 2) for HSA is unaffected by pH from 7.4 (standard assay pH) to 5.0.
- the affinity of FabB-648Fv (G 4 S ⁇ 2) for HSA is affected by pH and there is approximately a 10 fold loss in affinity between pH7.4 and pH5.0.
- mice were dosed for each construct and route of administration.
- Serial blood samples (30 ⁇ L) were collected from the tail vein at the following time points: 1, 4, 8, 24, 48, 72, 102 and 168 hours following subcutaneous administration and 30 minutes, 1, 8, 24, 48, 72, 96 and 168 hours following intravenous administration.
- the collected blood was dispensed into a Sarstedt microvette CB300Z with clot activator for serum separation, and left at room temperature for at least 20 minutes.
- the microvette was then centrifuged at 20° C. at 10,000 rpm for 5 minutes. Serum was removed and stored frozen prior to analysis. The concentration of FabB-645Fv (G 4 S ⁇ 2) or FabB-648Fv (G 4 S ⁇ 2) in serum samples was assessed by ELISA. Briefly Nunc Maxisorb Immunomodule Plates were coated with hOX40-Fc in PBS and blocked with 1% BSA in PBS. Serum samples and standards were diluted in 1% BSA in PBS and applied to the plate for 1 hour. The plate was washed with PBS and the revealing antibody of goat anti-human kappa HRP conjugate applied in 1% BSA in PBS for 1 hour. The plate was washed and then developed with TMB substrate followed by stopping with 2.5M sulphuric acid. The absorbance at 630 nm wash measured and the concentrations determined from the standard curve.
- Both FabB-645Fv (G 4 S ⁇ 2) and FabB-648Fv (G 4 S ⁇ 2) have extended half-life in plasma, FIG. 13 .
- the half-lives for FabB-645Fv (G 4 S ⁇ 2) are 71 h sc and 62 h iv and for FabB-648Fv (G 4 S ⁇ 2) are 25 h sc and 30 h iv.
- CB17 SCID mice were dosed with a loading dose subcutaneously on day ⁇ 2 of 2.475 mg/kg FabB-645Fv or FabB-648Fv or FabB-PEG40 k or PBS. On every subsequent day up to and including day 10 they were dosed with a maintenance dose subcutaneously of 0.75 mg/kg FabB-645Fv or FabB-648Fv or FabB-PEG40 k or PBS. Each dosing group consisted of 9-10 mice. On day ⁇ 1 all the mice were treated with 0.87 mg/mouse of rat anti-murine TM- ⁇ 1 antibody to abrogate natural killer cell activity.
- mice On day 0 all the mice received an inter peritoneal injection of 8 ⁇ 10 6 human peripheral blood mononuclear cells. On day 14 the mice are sacrificed and the blood, spleen and a peritoneal lavage were taken. The samples were analysed by FACS for CD4 + and CD8 + T cells. The data sets were analysed by one way Anova with Dunnett's post test comparison. All the test constructs FabB-645Fv, FabB-648Fv and FabB-PEG40 k were equally efficacious in all the compartments tested, i.e. blood peritoneum and spleen. FIGS. 14A , B and C.
- Point mutations were introduced into selected residues in the CDRs of the heavy chain of the 645Fv portion of FabB-645dsFv (S3 ⁇ G 4 S) by mutagenic PCR.
- I50A is a replacement of Ile 50 with Ala.
- the various mutations are given in Table 11 below.
- the affinity of the Fab-645Fv mutants for human albumin was assessed by BIAcore as described in the methods. All the mutations had either unchanged or reduced affinity for human albumin.
- the FabB-645Fv's with either a SGGGGS, SGGGGSGGGGS, SGGGGSGGGGSGGGGS, SGGGGSGGGGSGGGGSGGGGS or SGGGGSGGGGSGGGGSGGGGSGGGGS linker between the C-termini of the Fab and the N-termini of the Fv were assembled by PCR then cloned into a mammalian expression vectors under the control of the HCMV-MIE promoter and SV40E polyA sequence.
- the relevant heavy and light chain plasmids were paired for expression in mammalian cells.
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 24 ⁇ g heavy chain plasmid+24 ⁇ g light chain plasmid was incubated with 120 ⁇ l 293fectin+4080 ⁇ l Optimem media for 20 mins at RT. The mixture was then added to 60 ⁇ 10 6 HEK293 cells in 60 mL suspension and incubated for 4 days with shaking at 37° C. All the constructs were equally well expressed.
- the mammalian expression suspensions were clarified by centrifugation and the supernatants were concentrated to ⁇ 1.8 mL using 10 kDa molecular weight cut off centrifugation concentrators.
- the concentrated supernatants were centrifuged at 16000 ⁇ g for 10 min to remove any precipitate and then 1.5 mL was loaded onto 1 ml HiTrap Protein-G columns (GE Healthcare) at 1 ml/min.
- the columns were washed with 20 mM phosphate, 40 mM NaCl pH7.4 and bound material eluted with 0.1M glycine/HCl pH2.7.
- the elution peak (2 mL) was collected and pH adjusted to ⁇ pH5 with 250 ⁇ L of 1M sodium acetate.
- the pH adjusted elutions were diafiltered into 20 mM phosphate, 150 mM NaCl pH7.1 using 10 kDa molecular weight cut off centrifugation concentrators and concentrated to ⁇ 250 ⁇ L. All the constructs had similar purification profiles and the final concentrations were 0.5-1.1 mg/ml.
- the affinities of the purified FabB-645Fv (1-5 ⁇ G 4 S) constructs for human and mouse albumin were determined as described in the Methods.
- the different linker lengths of the Fv of 1 to 5 ⁇ Gly4Ser between the C-termini of the Fab and the N-termini of the Fv had no affect on the affinity of the 645Fv for either human or mouse albumin.
- FabB-645Fv (1-5 ⁇ G 4 S) samples were prepared under non-reduced and reduced conditions and separated on a gel and stained as described in the methods. See FIG. 15 .
- FabB-645Fv (1-5 ⁇ G 4 S) samples were analysed for size on a Superdex200 10/300GL Tricorn column (GE Healthcare) developed with an isocratic gradient of 20 mM phosphate 150 mM NaCl pH7.4 at 1 ml/min.
- a linker length between the C-termini of the Fab and the N-termini of the Fv of either 1 ⁇ G 4 S or 2 ⁇ G 4 S reduces the amount of monomer FabB-645Fv whilst increasing the amount of dimer and higher multimers.
- the amount of monomer is least for the 1 ⁇ G 4 S linker length.
- a linker length between the C-termini of the Fab and the N-termini of the Fv of either 3 ⁇ G 4 S, 4 ⁇ G 4 S or 5 ⁇ G 4 S increased the amount of monomer FabB-645Fv whilst decreasing the amount of dimer and higher multimers with the levels being similar for all three linker lengths.
- FIG. 16 A linker length between the C-termini of the Fab and the N-termini of the Fv of either 1 ⁇ G 4 S or 2 ⁇ G 4 S reduces the amount of monomer FabB-645Fv whilst increasing the amount of dimer and higher multimers.
- the amount of monomer is least for the 1 ⁇ G 4
- Samples (1 ⁇ l of sample at ⁇ 1 mg/ml, 8 ⁇ l of PBS and 1 ⁇ l of 30 ⁇ stock of Sypro orange fluorescent dye) were run in quadruplicate in 384 well plates. The plate is heated from 20-99° C. using a 7900HT fast real-time PCR system and the fluorescence (excitation at 490 nm, emission at 530 nm) measured. The results are shown in Table 14 and FIG. 17 .
- Point mutations were introduced into the FabB-645Fv (2 ⁇ G 4 S) and FabB-648Fv (2 ⁇ G 4 S) DNA sequences at selected residues in the framework region of both the heavy chain and the light chain of the Fv by mutagenic PCR.
- the mutations introduced to create an interchain disulphide bond between the heavy and light chains of the Fv were heavy chain G44C and light chain G100C.
- the natural interchain disulphide between the heavy chain and light chain of the Fab was removed by mutagenic PCR by changing the cysteines to serines.
- dsFv Fvs that contain an interchain disulphide bond
- FabA Fvs that lack an interchain disulphide bond
- the DNA for all these constructs was then cloned into a mammalian expression vectors under the control of the HCMV-MIE promoter and SV40E polyA sequence.
- the relevant heavy and light chain plasmids were paired for expression in mammalian cells.
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 24 ⁇ g heavy chain plasmid+24 ⁇ g light chain plasmid was incubated with 120 ⁇ l 293fectin+4080 ⁇ l Optimem media for 20 mins at RT. The mixture was then added to 60 ⁇ 10 6 HEK293 cells in 60 mL suspension and incubated for 4 days with shaking at 37° C. All the constructs were equally well expressed.
- the mammalian expression suspensions were clarified by centrifugation and the supernatants were concentrated to ⁇ 1.8 mL using 10 kDa molecular weight cut off centrifugation concentrators.
- the concentrated supernatants were centrifuged at 16000 ⁇ g for 10 min to remove any precipitate and then 1.5 mL was loaded onto 1 ml HiTrap Protein-G columns (GE Healthcare) at 1 ml/min.
- the columns were washed with 20 mM phosphate, 40 mM NaCl pH7.4 and bound material eluted with 0.1M glycine/HCl pH2.7.
- the elution peak (2 mL) was collected and pH adjusted to ⁇ pH5 with 250 ⁇ L of 1M sodium acetate.
- the pH adjusted elutions were diafiltered into 20 mM phosphate, 150 mM NaCl pH7.1 using 10 kDa molecular weight cut off centrifugation concentrators and concentrated to ⁇ 250 ⁇ L. All the constructs had similar purification profiles and the final concentrations were 0.5-0.8 mg/ml.
- affinities of the purified FabB-645dsFv (2 ⁇ G 4 S), FabB-648dsFv (2 ⁇ G 4 S) Fab ⁇ B-645dsFv (2 ⁇ G 4 S), Fab ⁇ B-648dsFv (2 ⁇ G 4 S) constructs for human and mouse albumin were determined as described in the Methods.
- the disulphide stabilisation of the Fv had no affect or slightly increased the affinity of the Fv for both human or mouse albumin.
- FabB-645dsFv (2 ⁇ G 4 S), FabB-648dsFv (2 ⁇ G 4 S) Fab ⁇ B-645dsFv (2 ⁇ G 4 S), Fab ⁇ B-648dsFv (2 ⁇ G 4 S) samples were analysed for size on a Superdex200 10/300GL Tricorn column (GE Healthcare) developed with an isocratic gradient of 20 mM phosphate 150 mM NaCl pH7.4 at 1 ml/min.
- Samples (1 ⁇ l of sample at ⁇ 1 mg/ml, 8 ⁇ l of PBS and 1 ⁇ l of 30 ⁇ stock of Sypro orange fluorescent dye) were run in quadruplicate in 384 well plates. The plate is heated from 20-99° C. using a 7900HT fast real-time PCR system and the fluorescence (excitation at 490 nm, emission at 530 nm) measured.
- Binding affinities and kinetic parameters for the interactions of Fab-dAb and Fab-didAb constructs were determined by surface plasmon resonance (SPR) conducted on a Biacore T100 using CM5 sensor chips and HBS-EP (10 mM HEPES (pH7.4), 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20) running buffer.
- Human Fab samples were captured to the sensor chip surface using either a human F(ab′) 2 -specific goat Fab (Jackson ImmunoResearch, 109-006-097) or an in-house generated anti human CH1 monoclonal antibody.
- Murine Fab samples were captured using a murine F(ab′)2-specific goat Fab (Jackson ImmunoResearch, 115-006-072). Covalent immobilisation of the capture antibody was achieved by standard amine coupling chemistry.
- Each assay cycle consisted of firstly capturing the Fab-dAb or Fab-didAb construct using a 1 min injection, before an association phase consisting of a 3 min injection of antigen, after which dissociation was monitored for 5 min. After each cycle, the capture surface was regenerated with 2 ⁇ 1 min injections of 40 mM HCl followed by 30 s of 5 mM NaOH. The flow rates used were 10 ⁇ l/min for capture, 30 ⁇ l/min for association and dissociation phases, and 10 ⁇ l/min for regeneration.
- a titration of antigen for human or mouse serum albumin typically 62.5 nM-2 ⁇ M, for IL-1 ⁇ 1.25-40 nM, for cell surface receptor D 20-1.25 nM was performed, a blank flow-cell was used for reference subtraction and buffer-blank injections were included to subtract instrument noise and drift.
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 2 ⁇ g heavy chain plasmid+2 ⁇ g light chain plasmid was incubated with 10 ⁇ l 293 fectin+340 ⁇ l Optimem media for 20 mins at RT. The mixture was then added to 5 ⁇ 10 6 HEK293 cells in suspension and incubated for 6 days with shaking at 37° C.
- the yields of mFab-mdidAb were measured using a sandwich ELISA. Briefly, the mFab-mdidAb was captured with an anti-CH1 antibody then revealed with an anti-kappa-HRP.
- the potential for the FabB-didAb, -dAbL1(CK-G4S ⁇ 2) & -dAbH1(CH1-G4S ⁇ 2) and FabB-didAb, -dAbL2(CK-G4S ⁇ 2) & -dAbH2(CH1-G4S ⁇ 2) constructs to bind simultaneously to both human or mouse serum albumin and human OX40 was assessed by capturing each Fab-didAb construct to the sensor chip surface, before performing either separate 3 min injections of 2 ⁇ M albumin (human or mouse) or 50 nM human OX40, or a mixed solution of both 2 ⁇ M albumin and 50 nM OX40. HSA binding was seen for both Fab-didAb constructs.
- the table above shows the binding response (RU) seen for each construct after separate injections of HSA or MSA or hOX40-Fc, or injection of premixed albumin and hOX40-Fc. In each case the final concentration was 2 ⁇ M albumin HSA and 50 nM hOX40-Fc. The sum of the individual albumin and hOX40-Fc responses is shown in parentheses.
- mFabD-mdidAb The potential for mFabD-mdidAb, -mdAbL1(CK-G 4 S ⁇ 2) & mdAbH1(CH1-G 4 S ⁇ 2) and mFabD-mdidAb, -mdAbL2(CK-G 4 S ⁇ 2) & mdAbH2(CH1-G 4 S ⁇ 2) to bind simultaneously to both human or mouse serum albumin and murine cell surface receptor D was assessed by capturing each mFab-mdidAb construct to the sensor chip surface, before performing either separate 3 min injections of 2 ⁇ M albumin (human or mouse) or 20 nM murine cell surface receptor D, or a mixed solution of both 2 ⁇ M albumin and 20 nM cell surface receptor D.
- the table above shows the binding response (RU) seen for each construct after separate injections of HSA or MSA or murine cell surface receptor D-Fc, or injection of premixed albumin and murine cell surface receptor D-Fc. In each case the final concentration was 2 ⁇ M albumin HSA and 20 nM murine cell surface receptor D-Fc. The sum of the individual albumin and murine cell surface receptor D-Fc responses is shown in parentheses.
- mFabD-mdidAb -mdAbL1(CK-G 4 S ⁇ 2) & mdAbH1 (CH1-G 4 S ⁇ 2) or mFabD-mdidAb, -mdAbL2(CK-G 4 S ⁇ 2) & mdAbH2(CH1-G 4 S ⁇ 2) with serum albumin and murine cell surface receptor D expressed on the cell surface.
- Both mFabD-mdidAbs were capable of binding FITC labelled HSA and cell surface receptor X expressed on the cell surface of activated murine T-cells simultaneously ( FIG. 11 ).
- mFabD was capable of binding cell surface receptor X expressed on the cell surface of activated murine T-cells, data not shown, but did not bind FITC labelled HSA.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 13/121,055, filed Mar. 25, 2011, which is a U.S. National Phase application under 35 U.S.C. § 371 of PCT/GB2009/002310, filed Sep. 25, 2009, which claims priority from and the benefit of United Kingdom Application No.: 0817704.0, filed on Sep. 26, 2008 and United Kingdom Application No.: 0905314.1, filed on Mar. 26, 2009, the specifications of which are hereby incorporated by reference in their entireties.
- The present invention relates to new dual specificity antibody fusion proteins. Such antibodies comprise a first specificity to an antigen of interest, and a second specificity for a second antigen of interest, for example a serum carrier protein for use in extending their in vivo serum half-life. Methods for the production of such molecules and pharmaceutical compositions comprising them are also provided.
- The high specificity and affinity of antibodies makes them ideal diagnostic and therapeutic agents, particularly for modulating protein:protein interactions. Advances in the field of recombinant antibody technology have resulted in the production of antibody fragments, such as Fv, Fab, Fab′ and F(ab′)2 fragments and other antibody fragments. These smaller molecules retain the antigen binding activity of whole antibodies and can also exhibit improved tissue penetration and pharmacokinetic properties in comparison to whole immunoglobulin molecules. Indeed, antibody fragments are proving to be versatile therapeutic agents, as seen by the recent success of products such as ReoPro® and Lucentis®. Whilst such fragments appear to exhibit a number of advantages over whole immunoglobulins, they also suffer from an increased rate of clearance from serum since they lack the Fc domain that imparts a long lifetime in vivo (Medasan et al., 1997, J. Immunol. 158:2211-2217).
- Antibodies with dual specificity, i.e. which bind to two different antigens have been previously described (for reviews, see Segal et al., 1999, Curr. Opin. Immunol. 11:558-562; Plückthun & Pack, 1997, Immunotechnology, 3:83-105; Fischer and Leger, 2007, Pathobiology, 74, 3-14). Dual specificity antibodies are also described in WO02/02773, US2007065440, US2006257406, US2006106203 and US2006280734. Previous approaches to making hetero-bispecific antibody-based molecules have generally employed chemical cross-linking or protein engineering techniques. Chemical cross-linking suffers from poor yields of hetero- and homo-dimer formation and the requirement for their subsequent chromatographic separation. Protein engineering approaches have either been highly elaborate (e.g. knobs-into-holes engineering; Ridgway et al., 1996, Protein Eng. 9(7):617-621) or have used molecules with inappropriate stability characteristics (e.g. diabodies, scFv). In some cases bispecific antibodies can also suffer from steric hindrance problems such that both antigens cannot bind simultaneously to each antibody arm.
- Single variable domain antibodies also known as single domain antibodies or dAbs, correspond to the variable regions of either the heavy (VH) or light (VL) chain of an antibody. Murine single-domain antibodies were described by Ward et al., 1989, Nature, 341, 544-546. Human and ‘camelised’ human single domain antibodies have also been described (Holt et al., 2003, Trends in Biotechnology, 21, 484-490). Single domain antibodies have also been obtained from the camelids (camels and llamas) and cartilaginous fish (wobbegong and nurse sharks). These organisms have evolved high affinity single V-like domains (called VhH in camelids and V-NAR in sharks), mounted on an Fc-equivalent constant domain framework as an integral and crucial component of their immune system (see Holliger & Hudson, for a review; 2005, Nature Biotechnology, 23(9):1126-1136).
- Single domain antibody-enzyme fusions have been described in EP0368684. Single domain-effector group fusions have also been described in WO2004/058820 which comprise a single variable domain. Dual variable domain immunoglobulins have been described in WO2007/024715. Dual specific ligands comprising two single domain antibodies with differing specificities have been described in EP1517921.
- Means to improve the half-life of antibody fragments, such as Fv, Fab, Fab′, F(ab′)2 and other antibody fragments, are known. One approach has been to conjugate the fragment to polymer molecules. Thus, the short circulating half-life of Fab′, F(ab′)2 fragments in animals has been improved by conjugation to polyethylene glycol (PEG; see, for example, WO98/25791, WO99/64460 and WO98/37200). Another approach has been to modify the antibody fragment by conjugation to an agent that interacts with the FcRn receptor (see, for example, WO97/34631). Yet another approach to extend half-life has been to use polypeptides that bind serum albumin (see, for example, Smith et al., 2001, Bioconjugate Chem. 12:750-756; EP0486525; U.S. Pat. No. 6,267,964; WO04/001064; WO02/076489; and WO01/45746). However, there still remains a need to produce antigen-binding immunoglobulin proteins that have a long in vivo half-life, as an alternative to those that have a long half life because they interact with the FcRn receptor, without being chemically modified by conjugation to PEG, or being conjugated to human serum albumin.
- A variety of proteins exist in plasma and include thyroxine-binding protein, transthyretin, α1-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any thereof. Serum carrier proteins circulate within the body with half-lives measured in days, for example, 5 days for thyroxine-binding protein or 2 days for transthyretin (Bartalena & Robbins, 1993, Clinics in Lab. Med. 13:583-598), or 65 hours in the second phase of turnover of iodinated α1-acid glycoprotein (Bree et al., 1986, Clin. Pharmacokin. 11:336-342). Data from Gitlin et al. (1964, J. Clin. Invest. 10:1938-1951) suggest that in pregnant women, the half-life of α1-acid glycoprotein is 3.8 days, 12 days for transferrin and 2.5 days for fibrinogen. Serum albumin is an abundant protein in both vascular and extravascular compartments with a half-life in man of about 19 days (Peters, 1985, Adv Protein Chem. 37:161-245). This is similar to the half-life of IgG1, which is about 21 days (Waldeman & Strober, 1969, Progr. Allergy, 13:1-110).
- The present invention provides improved dual specificity antibody fusion proteins which can be produced recombinantly and are capable of binding two antigens simultaneously, in particular two distinct/different antigens.
- Thus, the present invention provides dual specificity antibody fusion proteins which comprise an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprise a single domain antibody (dAb) with specificity for a second antigen of interest, in particular where the first antigen and second antigen are different entities.
- Multivalent as employed herein is intended to refer to an entity that has two or more binding sites, for example two or three binding sites such as two binding sites. Each binding site may bind the same epitope or different epitopes on the same antigen, or may bind different (distinct) antigens.
- The present invention also provides dual specificity antibody fusion proteins which comprise an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprise at least one single domain antibody with specificity for a second antigen of interest.
- A dual specificity antibody fusion of the invention will be capable of selectively binding to two antigens of interest.
- In one embodiment the first and second antigen are the same antigen.
- In one embodiment, an antigen of interest bound by the Fab or Fab′ fragment may be a cell-associated protein, for example a cell surface protein on cells such as bacterial cells, yeast cells, T-cells, endothelial cells or tumour cells, or it may be a soluble protein. Antigens of interest may also be any medically relevant protein such as those proteins upregulated during disease or infection, for example receptors and/or their corresponding ligands. Particular examples of cell surface proteins include adhesion molecules, for example integrins such as β1 integrins e.g. VLA-4, E-selectin, P selectin or L-selectin, CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CDW52, CD69, CD134 (OX40), ICOS, BCMP7, CD137, CD27L, CDCP1, DPCR1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, nectin-like2, NKCC1, PTK7, RAIG1, TCAM1, SC6, BCMP101, BCMP84, BCMP11, DTD, carcinoembryonic antigen (CEA), human milk fat globulin (HMFG1 and 2), MHC Class I and MI-IC Class II antigens, and VEGF, and where appropriate, receptors thereof.
- Soluble antigens include interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16 or IL-17, viral antigens for example respiratory syncytial virus or cytomegalovirus antigens, immunoglobulins, such as IgE, interferons such as interferon α, interferon β or interferon γ, tumour necrosis factor-α, tumor necrosis factor-β, colony stimulating factors such as G-CSF or GM-CSF, and platelet derived growth factors such as PDGF-α, and PDGF-β and where appropriate receptors thereof. Other antigens include bacterial cell surface antigens, bacterial toxins, viruses such as influenza, EBV, HepA, B and C, bioterrorism agents, radionuclides and heavy metals, and snake and spider venoms and toxins.
- In one embodiment, the antibody fusion protein of the invention may be used to functionally alter the activity of the antigen of interest. For example, the antibody fusion protein may neutralize, antagonize or agonise the activity of said antigen, directly or indirectly.
- In one embodiment, a second antigen of interest bound by the single domain antibody or antibodies in the dual specificity antibody fusion proteins of the invention may be a cell-associated protein, for example a cell surface protein on cells such as bacterial cells, yeast cells, T-cells, endothelial cells or tumour cells, or it may be a soluble protein. Antigens of interest may also be any medically relevant protein such as those proteins upregulated during disease or infection, for example receptors and/or their corresponding ligands. Particular examples of cell surface proteins include adhesion molecules, for example integrins such as β1 integrins e.g. VLA-4, E-selectin, P selectin or L-selectin, CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CDW52, CD69, CD134 (OX40), ICOS, BCMP7, CD137, CD27L, CDCP1, DPCR1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, nectin-like2, NKCC1, PTK7, RAIG1, TCAM1, SC6, BCMP101, BCMP84, BCMP11, DTD, carcinoembryonic antigen (CEA), human milk fat globulin (HMFG1 and 2), MHC Class I and MHC Class II antigens, and VEGF, and where appropriate, receptors thereof.
- Soluble antigens include interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16 or IL-17, viral antigens for example respiratory syncytial virus or cytomegalovirus antigens, immunoglobulins, such as IgE, interferons such as interferon α, interferon β or interferon γ, tumour necrosis factor-α, tumor necrosis factor-β, colony stimulating factors such as G-CSF or GM-CSF, and platelet derived growth factors such as PDGF-α, and PDGF-β and where appropriate receptors thereof. Other antigens include bacterial cell surface antigens, bacterial toxins, viruses such as influenza, EBV, HepA, B and C, bioterrorism agents, radionuclides and heavy metals, and snake and spider venoms and toxins.
- Other antigens which may be bound by the single domain antibody or antibodies include serum carrier proteins, polypeptides which enable cell-mediated effector function recruitment and nuclide chelator proteins.
- Thus, in one example the present invention provides dual specificity antibody fusion proteins which comprise an immunoglobulin moiety with a first specificity for an antigen of interest, and further comprise a single domain antibody with specificity for a second protein, the latter providing the ability to recruit effector functions, such as complement pathway activation and/or effector cell recruitment. Further, fusion proteins of the present invention may be used to chelate radionuclides by virtue of a single domain antibody which binds to a nuclide chelator protein. Such fusion proteins are of use in imaging or radionuclide targeting approaches to therapy.
- Accordingly, in one example there is provided an isolated dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one dAb which has specificity for a recruitment polypeptide, said dAb providing the ability to recruit cell-mediated effector function(s), directly or indirectly, by binding to said recruitment polypeptide.
- The recruitment of effector function may be direct in that effector function is associated with a cell, said cell bearing a recruitment molecule on its surface. Indirect recruitment may occur when binding of a dAb to a recruitment molecule causes release of, for example, a factor which in turn may directly or indirectly recruit effector function, or may be via activation of a signalling pathway. Examples include TNFα, IL2, IL6, IL8, IL17, IFNγ, histamine, C1q, opsonin and other members of the classical and alternative complement activation cascades, such as C2, C4, C3-convertase, and C5 to C9.
- As used herein, ‘a recruitment polypeptide’ includes a FcγR such as FcγRI, FcγRII and FcγRIII, a complement pathway protein such as, but without limitation, C1q and C3, a CD marker protein (Cluster of Differentiation marker) such as, but without limitation, CD68, CD115, CD16, CD80, CD83, CD86, CD56, CD64, CD3, CD4, CD8, CD28, CD45, CD19, CD20 and CD22. Further recruitment polypeptides which are CD marker proteins include CD1, CD1d, CD2, CD5, CD8, CD9, CD10, CD11, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD40, CD43, CD44, CD45, CD46, CD49, CD49a, CD49b, CD49c, CD49d, CD52, CD53, CD54, CD55, CD56, CD58, CD59, CD61, CD62, D62E, CD62L, CD62P, CD63, CD64, CD66e, CD68, CD70, CD71, CD72, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD88, CD89, CD90, CD94, CD95, CD98, CD106, CD114, CD116, CD117, CD118, CD120, CD122, CD130, CD131, CD132, CD133, CD134, CD135, CD137, CD138, CD141, CD142, CD143, CD146, CD147, CD151, CD152, CD153, CD154, CD155, CD162, CD164, CD169, CD184, CD206, CD209, CD257, CD278, CD281, CD282, CD283 and CD304, or a fragment of any thereof which retains the ability to recruit cell-mediated effector function either directly or indirectly. A recruitment polypeptide also includes immunoglobulin molecules such as IgG1, IgG2, IgG3, IgG4, IgE and IgA which possess effector function.
- In one embodiment, the second protein for which the dAb has specificity is a complement pathway protein, with C1q being particularly preferred.
- In a preferred embodiment, the second protein for which the dAb has specificity is a CD marker protein, with CD68, CD80, CD86, CD64, CD3, CD4, CD8 CD45, CD16 and CD35 being particularly preferred.
- Accordingly also provided is an isolated dual specificity antibody fusion protein comprising an antibody fragment with specificity for an antigen of interest, said fragment being fused to at least one dAb which has specificity for a CD molecule selected from the group consisting of CD68, CD80, CD86, CD64, CD3, CD4, CD8 CD45, CD16 and CD35.
- In one embodiment the single domain antibody or antibodies provide an extended half-life to the immunoglobulin moiety with the first specificity.
- Accordingly, in one embodiment there is provided a dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1, said single domain antibody providing an extended half-life to the antibody fragment with specificity for said antigen of interest by binding to said serum carrier protein, circulating immunoglobulin molecule or CD35/CR1.
- In one embodiment there is provided an isolated dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1, said single domain antibody providing an extended half-life to the antibody fragment with specificity for said antigen of interest by binding to said serum carrier protein, circulating immunoglobulin molecule or CD35/CR1.
- As used herein, ‘serum carrier proteins’ include thyroxine-binding protein, transthyretin, α1-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any thereof.
- As used herein, a ‘circulating immunoglobulin molecule’ includes IgG1, IgG2, IgG3, IgG4, sIgA, IgM and IgD, or a fragment of any thereof.
- CD35/CR1 is a protein present on red blood cells which have a half life of 36 days (normal range of 28 to 47 days; Lanaro et al., 1971, Cancer, 28(3):658-661).
- In a preferred embodiment, the second protein for which the dAb has specificity is a serum carrier protein, with a human serum carrier protein being particularly preferred. In a most preferred embodiment, the serum carrier protein is human serum albumin.
- Accordingly provided is a dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for human serum albumin.
- In one embodiment the present invention provides an isolated dual specificity antibody fusion protein comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for human serum albumin.
- In one embodiment, the antibody fragment with specificity for an antigen of interest is a Fab fragment. In another embodiment, the antibody fragment with specificity for an antigen of interest is a Fab′ fragment.
- Thus, in one most preferred embodiment, the antibody fusion proteins of the invention are translation fusion proteins, i.e. genetic fusions, the sequence of each of which is encoded by an expression vector. Alternatively, the antibody fusion protein components have been fused using chemical means, i.e. by chemical conjugation or chemical cross-linking. Such chemical means are known in the art.
- In one example, the antibody fragments are Fab′ fragments which possess a native or a modified hinge region. Where the antibody fragment for use in preparing a dual specificity antibody fusion protein of the invention is a Fab′ fragment, said fragment is generally extended at the C-terminus of the heavy chain by one or more amino acids. Thus, an antibody fusion of the invention can comprise a Fab′ fragment translation fused (or chemically fused) to a dAb, directly or via a linker. Further, examples of suitable antibody Fab′ fragments include those described in WO2005003170 and WO2005003171.
- In another example, the antibody fragments are Fab fragments. Thus, an antibody fusion of the invention can comprise a Fab fragment translation fused (or chemically fused) to a linker sequence which in turn is translation fused (or chemically fused) to a dAb. Preferably, the Fab fragment is a Fab fragment which terminates at the interchain cysteines, as described in WO2005/003169.
- The antibody Fab or Fab′ fragments of use in the present invention can be from any species but are preferably derived from a monoclonal antibody, a human antibody, or are humanised fragments. An antibody fragment for use in the present invention can be derived from any class (e.g. IgG, IgE, IgM, IgD or IgA) or subclass of immunoglobulin molecule and may be obtained from any species including for example mouse, rat, shark, rabbit, pig, hamster, camel, llama, goat or human.
- In one embodiment, the antibody Fab or Fab′ fragment is a monoclonal, fully human, humanized or chimeric antibody fragment. In one embodiment the antibody Fab or Fab′ fragments are fully human or humanised.
- Monoclonal antibodies may be prepared by any method known in the art such as the hybridoma technique (Kohler & Milstein, Nature, 1975, 256, 495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today, 1983, 4, 72) and the EBV-hybridoma technique (Cole et al., “Monoclonal Antibodies and Cancer Therapy”, pp. 77-96, Alan R. Liss, Inc., 1985).
- Antibodies for use in the invention may also be generated using single lymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNAs generated from single lymphocytes selected for the production of specific antibodies by, for example, the methods described by Babcook, J. et al., Proc. Natl. Acad. Sci. USA, 1996, 93(15), 7843-7848, WO 92/02551, WO2004/051268 and WO2004/106377.
- Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule (see, for example, U.S. Pat. No. 5,585,089).
- The antibodies for use in the present invention can also be generated using various phage display methods known in the art and include those disclosed by Brinkman et al., J. Immunol. Methods, 1995, 182, 41-50; Ames et al., J. Immunol. Methods, 1995, 184, 177-186; Kettleborough et al. Eur. J. Immunol., 1994, 24, 952-958; Persic et al., Gene, 1997 187, 9-18; and Burton et al., Advances in Immunology, 1994, 57, 191-280; WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; and WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743; and 5,969,108. Also, transgenic mice, or other organisms, including other mammals, may be used to generate humanized antibodies.
- Fully human antibodies are those antibodies in which the variable regions and the constant regions (where present) of both the heavy and the light chains are all of human origin, or substantially identical to sequences of human origin, not necessarily from the same antibody. Examples of fully human antibodies may include antibodies produced for example by the phage display methods described above and antibodies produced by mice in which the murine immunoglobulin variable and/or constant region genes have been replaced by their human counterparts eg. as described in general terms in EP0546073 B1, U.S. Pat. Nos. 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, EP 0438474 B1 and EP0463151 B1.
- The antibody Fab or Fab′ fragment starting material for use in the present invention may be obtained from any whole antibody, especially a whole monoclonal antibody, using any suitable enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin. Alternatively, or in addition the antibody starting material may be prepared by the use of recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions. Standard molecular biology techniques may be used to modify, add or delete amino acids or domains as desired. Any alterations to the variable or constant regions are still encompassed by the terms ‘variable’ and ‘constant’ regions as used herein.
- The antibody fragment starting material may be obtained from any species including for example mouse, rat, rabbit, hamster, camel, llama, goat or human. Parts of the antibody fragment may be obtained from more than one species, for example the antibody fragments may be chimeric. In one example, the constant regions are from one species and the variable regions from another. The antibody fragment starting material may also be modified. In another example, the variable region of the antibody fragment has been created using recombinant DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and, optionally, one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody. The methods for creating and manufacturing these antibody fragments are well known in the art (see for example, Boss et al., U.S. Pat. No. 4,816,397; Cabilly et al., U.S. Pat. No. 6,331,415; Shrader et al., WO 92/02551; Ward et al., 1989, Nature, 341, 544; Orlandi et al., 1989, Proc. Natl. Acad. Sci. USA, 86, 3833; Riechmann et al., 1988, Nature, 322, 323; Bird et al, 1988, Science, 242, 423; Queen et al., U.S. Pat. No. 5,585,089; Adair, WO91/09967; Mountain and Adair, 1992, Biotechnol. Genet. Eng. Rev, 10, 1-142; Verma et al., 1998, Journal of Immunological Methods, 216, 165-181).
- In the present invention each single domain antibody fused to the Fab or Fab′ fragment may linked directly or via a linker.
- Linked directly are employed herein is intended to refer to the fact that the “last” amino acid of the Fab or Fab′ is joined by a peptide bond to the “first” amino acid of the single domain antibody (or indeed vice versa)
- Examples of suitable linker regions for linking a dAb to a Fab or Fab′ include, but are not limited to, flexible linker sequences and rigid linker sequences. Flexible linker sequences include those disclosed in Huston et al., 1988, PNAS 85:5879-5883; Wright & Deonarain, Mol. Immunol., 2007, 44(11):2860-2869; Alfthan et al., Prot. Eng., 1995, 8(7):725-731; Luo et al., J. Biochem., 1995, 118(4):825-831; Tang et al., 1996, J. Biol. Chem. 271(26):15682-15686; and Turner et al., 1997, JIMM 205, 42-54, (see Table 1 for representative examples).
-
TABLE 1 Flexible linker sequences SEQ ID NO: SEQUENCE 1 SGGGGSE 2 DKTHTS 3 (S)GGGGS 45 (S)GGGGSGGGGS 46 (S)GGGGSGGGGSGGGGS 47 (S)GGGGSGGGGSGGGGSGGGGS 48 (S) GGGGSGGGGSGGGGSGGGGSGGGGS 4 AAAGSG- GASAS 5 AAAGSG-XGGGS-GASAS 49 AAAGSG-XGGGSXGGGS- GASAS 50 AAAGSG-XGGGSXGGGSXGGGS-GASAS 51 AAAGSG-XGGGSXGGGSXGGGSXGGGS- GASAS 6 AAAGSG-XS-GASAS 7 PGGNRGTTTTRRPATTTGSSPGPTQSHY 8 ATTTGSSPGPT 9 ATTTGS — GS 10 EPSGPISTINSPPSKESHKSP 11 GTVAAPSVFIFPPSD 12 GGGGIAPSMVGGGGS 13 GGGGKVEGAGGGGGS 14 GGGGSMKSHDGGGGS 15 GGGGNLITIVGGGGS 16 GGGGVVPSLPGGGGS 17 GGEKSIPGGGGS 18 RPLSYRPPFPFGFPSVRP 19 YPRSIYIRRRHPSPSLTT 20 TPSHLSHILPSFGLPTFN 21 RPVSPFTFPRLSNSWLPA 22 SPAAHFPRSEPRPGPIRT 23 APGPSAPSHRSLPSRAFG 24 PRNSIHFLHPLLVAPLGA 25 MPSLSGVLQVRYLSPPDL 26 SPQYPSPLTLTLPPHPSL 27 NPSLNPPSYLHRAPSRIS 28 LPWRTSLLPSLPLRRRP 29 PPLFAKGPVGLLSRSFPP 30 VPPAPVVSLRSAHARPPY 31 LRPTPPRVRSYTCCPTP- 37 PNVAHVLPLLTVPVVDNLR 33 CNPLLPLCARSPAVRTFP - S) is optional in
sequence 3 and 45 to 48. - Examples of rigid linkers include the peptide sequences GAPAPAAPAPA (SEQ ID NO:34), PPPP (SEQ ID NO:35) and PPP.
- In one embodiment the peptide linker is an albumin binding peptide. Examples of albumin binding peptides are provided in WO 2007/106120 and include:
-
TABLE 2 SEQ ID NO: SEQUENCE 208 DLCLRDWGCLW 209 DICLPRWGCLW 210 MEDICLPRWGCLWGD 211 QRLMEDICLPRWGCLWEDDE 212 QGLIGDICLPRWGCLWGRSV 213 QGLIGDICLPRWGCLWGRSVK 214 EDICLPRWGCLWEDD 215 RLMEDICLPRWGCLWEDD 216 MEDICLPRWGCLWEDD 217 MEDICLPRWGCLWED 218 RLMEDICLARWGCLWEDD 219 EVRSFCTRWPAEKSCKPLRG 220 RAPESFVCYWETICFERSEQ 221 EMCYFPGICWM - In one embodiment, an antibody hinge sequence or part thereof is used as a linker, eg. the upper hinge sequence. Typically, antibody Fab′ fragments for use in the present invention possess a native or a modified hinge region. Such hinge regions are used as a natural linker to the dAb moiety. The native hinge region is the hinge region normally associated with the
C H1 domain of the antibody molecule. A modified hinge region is any hinge that differs in length and/or composition from the native hinge region. Such hinges can include hinge regions from any other species, such as human, mouse, rat, rabbit, hamster, camel, llama or goat hinge regions. Other modified hinge regions may comprise a complete hinge region derived from an antibody of a different class or subclass from that of theC H1 domain. Thus, for instance, aC H1 domain of class γ1 may be attached to a hinge region of class γ4. Alternatively, the modified hinge region may comprise part of a natural hinge or a repeating unit in which each unit in the repeat is derived from a natural hinge region. In a further alternative, the natural hinge region may be altered by converting one or more cysteine or other residues into neutral residues, such as alanine, or by converting suitably placed residues into cysteine residues. By such means the number of cysteine residues in the hinge region may be increased or decreased. In addition other characteristics of the hinge can be controlled, such as the distance of the hinge cysteine(s) from the light chain interchain cysteine, the distance between the cysteines of the hinge and the composition of other amino acids in the hinge that may affect properties of the hinge such as flexibility e.g. glycines may be incorporated into the hinge to increase rotational flexibility or prolines may be incorporated to reduce flexibility. Alternatively combinations of charged or hydrophobic residues may be incorporated into the hinge to confer multimerisation properties, see for example, Richter et al., 2001, Prot. Eng. 14(10):775-783 for use of charged or ionic tails, e.g., acidic tails as linkers and Kostelny et al., 1992, J. Immunol. 5(1):1547-1553 for leucine zipper sequences. Other modified hinge regions may be entirely synthetic and may be designed to possess desired properties such as length, composition and flexibility. - A number of modified hinge regions have already been described for example, in U.S. Pat. Nos. 5,677,425, 6,642,356, WO9915549, WO2005003170, WO2005003169, WO2005003170, WO9825971 and WO2005003171 and these are incorporated herein by reference. Such hinges generally follow on from the CH1 region, but may also be incorporated onto the end of constant region of a light chain kappa or lambda fragment; see Table 3 for examples.
-
TABLE 3 Hinge linker sequences SEQ ID NO: SEQUENCE 36 DKTHTCAA 37 DKTHTCPPCPA 38 DKTHTCPPCPATCPPCPA 39 DKTHTCPPCPATCPPCPATCPPCPA 40 DKTHTCPPCPAGKPTLYNSLVMSDTAGTCY 41 DKTHTCPPCPAGKPTHVNVSVVMAEVDGTCY 42 DKTHTCCVECPPCPA 43 DKTHTCPRCPEPKSCDTPPPCPRCPA 44 DKTHTCPSCPA - Single variable domains also known as single domain antibodies or dAbs for use in the present invention can be generated using methods known in the art and include those disclosed in WO2005118642, Ward et al., 1989, Nature, 341, 544-546 and Holt et al., 2003, Trends in Biotechnology, 21, 484-490. In one embodiment a single domain antibody for use in present invention is a heavy chain variable domain (VH) or a light chain domain (VL). Each light chain domain may be either of the kappa or lambda subgroup. Methods for isolating VH and VL domains have been described in the art, see for example EP0368684 and Ward et al., supra. Such domains may be derived from any suitable species or antibody starting material. In one embodiment the single domain antibody may be derived from a rodent, a human or other species. In one embodiment the single domain antibody is humanised.
- In one embodiment the single domain antibody is derived from a phage display library, using the methods described in for example, WO2005/118642, Jespers et al., 2004, Nature Biotechnology, 22, 1161-1165 and Holt et al., 2003, Trends in Biotechnology, 21, 484-490. Preferably such single domain antibodies are fully human but may also be derived from other species. In one embodiment the single variable domain is chimeric in that the framework is human or substantially human in origin and the CDR(s) is/are of non-human origin. It will be appreciated that the sequence of the single domain antibody once isolated may be modified to improve the characteristics of the single domain antibody, for example solubility, as described in Holt et al., supra.
- Substantially human as employed herein is intended to refer that the human character of the original material is retained, which may be relevant to immunogenicity. Substantially human material would include wherein one amino acid in the framework sequence is added deleted or replaced by another amino acid.
- In one embodiment the dAb is a human sequence obtained from scFv phage-display or from a transgenic Humouse™ or Velocimouse™ or a humanised rodent.
- In one embodiment, the dAb is obtained from a human or humanised rodent, a camelid or a shark. Such a dAb will preferably be humanised. In one example the single domain antibody is a VHH domain based on camelid immunoglobulins as described in EP0656946. In one example, a camel or a llama is immunised with an antigen of interest and blood collected when the titre is appropriate. The gene encoding the dAb may be cloned by single cell PCR, or the B cell(s) encoding the dAb may be immortalised by EBV transformation, or by fusion to an immortal cell line.
- As described herein above, the present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody, directly or via a linker, which has specificity for a second antigen of interest.
- Accordingly, in one embodiment, the antibody fragment, eg. Fab or Fab′ fragment is fused at the N-terminus of the heavy or the light chain variable region to a dAb directly or via a linker. Alternatively, the antibody Fab or Fab′ fragment is fused at the C-terminus of the heavy or light chain to a dAb directly or via a linker. In another embodiment the heavy and light chains of the antibody Fab or Fab′ fragment are each fused at the C-terminus to a dAb directly or via a linker. The linkage can be a chemical conjugation but is most preferably a translation fusion, i.e. a genetic fusion where the sequence of each is encoded in sequence by an expression vector.
- Typically the N-terminus of the single domain antibody will be fused to the C-terminus of the heavy or light chain of the Fab or Fab′ fragment, directly or via a linker, and where the single domain antibody is fused to the N-terminus of the Fab or Fab′ it will be fused via its C-terminus, optionally via a linker.
- In one embodiment the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to a single domain antibody at the N-terminus of the heavy or light chain which has specificity for a second antigen of interest.
- In one embodiment the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to a single domain antibody at the C-terminus of the heavy or light chain which has specificity for a second antigen of interest.
- In one embodiment the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody at the C-terminus of the heavy or light chain which has specificity for a second antigen of interest.
- In one embodiment the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to two single domain antibodies wherein each single domain antibody is fused in linear sequence to each other, optionally via a linker and the resulting single domain antibody fusion is fused to the C-terminus of the light chain or the heavy chain of the Fab or Fab′ fragment.
- In one embodiment the present invention provides a dual specificity antibody fusion protein comprising or consisting of an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to two single domain antibodies wherein one single domain antibody is fused to the C-terminus of the light chain of the Fab or Fab′ fragment and the other single domain antibody is fused to the C-terminus of the heavy chain of the Fab or Fab′ fragment, said single domain antibodies having specificity for a second antigen of interest.
- In one embodiment where the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus the two single domain antibodies are identical i.e. have the same binding specificity for the same antigen. In one example, they bind the same epitope on the same antigen. For example the single domain antibodies may both be the same VH dAb, the same VHH dAb or the same VL dAb.
- Preferably where the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus the two single domain antibodies are a complementary VH/VL pair which bind the antigen co-operatively i.e. they are a complementary VH/VL pair which have the same binding specificity. Typically they will be a VH/VL pair derived from the same antibody.
- In one embodiment, where the dual specificity antibody fusion protein of the present invention comprises two single domain antibodies which are a complementary VH/VL pair, the VH single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VL single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda). In one embodiment, where the dual specificity antibody fusion protein of the present invention comprises two single domain antibodies which are a complementary VH/VL pair, the VL single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VH single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda).
- In one embodiment, where the dual specificity antibody fusion protein of the present invention comprises two single domain antibodies which are linked by one or more disulfide bonds for example two single domain antibodies which are a complementary VH/VL pair linked by one ore more (such as 1 or 2) disulfide bonds, such as the VH single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VL single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda). Alternatively the VL single domain antibody is fused to the C-terminus of the heavy chain constant region (CH1) and the VH single domain antibody is fused to the C-terminus of the light chain constant region (C kappa or C lambda).
- The disulfide bond is thought to provide additional stabilisation to the construct, which may be advantageous.
- In one or more embodiments the disulfide bond between the heavy and light chain such as between the CH domain and CL or CK domain is not present, for example because one or more cysteines which form the bond are replaced. Said one or more cysteines may be replaced with, for example serine.
- In one or more embodiments an interchain disulfide bond between the heavy and light chain between the CH domain and CL or CK domain is present.
- In one embodiment there is provided a F(ab)2 fragment comprising one, two, three or four single domain antibodys, for example a two separate VH/VL pairs which may be directed to the same or different antigens.
- In dual specificity fusion proteins of the present invention the single domain antibody or antibodies bind to a second antigen, different from that bound by the Fab or Fab′ fragment component.
- In one example the dAbs for use in the present invention exhibit specificity for a complement pathway protein, a CD marker protein or an FcγR. In this case the dAb is preferably specific for a CD molecule. Most preferably, the dAb exhibits specificity for a CD molecule selected from the group consisting of CD68, CD80, CD86, CD64, CD3, CD4, CD8 CD45, CD16 and CD35.
- In a preferred example the dAbs for use in the present invention exhibit specificity for a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1, the serum carrier protein preferably being a human serum carrier protein such as thyroxine-binding protein, transthyretin, α1-acid glycoprotein, transferrin, fibrinogen or serum albumin. Most preferably, the dAb exhibits specificity for human serum albumin. Thus, in one example, a rabbit, mouse, rat, camel or a llama is immunised with a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1 (e.g. human serum albumin) and blood collected when the titre is appropriate. The gene encoding the dAb may be cloned by single cell PCR, or the B cell(s) encoding the dAb may be immortalised by EBV transformation, or by fusion to an immortal cell line. Alternatively the single domain antibody may be obtained by phage display as described herein above.
- In one embodiment the single domain antibody or antibodies bind human serum albumin. In one embodiment the single domain antibody or antibodies bind human serum albumin, murine serum albumin and rat serum albumin.
- In one embodiment the single domain antibody which binds serum albumin is a dAb provided in WO2005/118642 (see for example
FIGS. 1c and 1d ) or a VHH provided in WO2004/041862 or a humanised nanobody described in, for example table III of WO2006/122787. - In one embodiment a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH single domain antibody which comprises at least one of a CDR having the sequence given in
FIG. 5 (e) SEQ ID NO:56 orFIG. 5 (k) SEQ ID NO:62 for CDR-H1, a CDR having the sequence given inFIG. 5(f) SEQ ID NO:57 orFIG. 5 (1) SEQ ID NO:63 for CDR-H2 and a CDR having the sequence given inFIG. 5 (g) SEQ ID NO:58 orFIG. 5 (m) SEQ ID NO:64 for CDR-H3. - In another embodiment a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH antibody, wherein at least two of CDR-H1, CDR-H2 and CDR-H3 of the VH domain are selected from the following: the sequence given in SEQ ID NO:56 or SEQ ID NO:62 for CDR-H1, the sequence given in SEQ ID NO:57 or SEQ ID NO:63 for CDR-H2 and the sequence given in SEQ ID NO:58 or SEQ ID NO:64 for CDR-H3. For example, the single domain antibody may comprise a VH domain wherein CDR-H1 has the sequence given in SEQ ID NO:56 and CDR-H2 has the sequence given in SEQ ID NO:57. Alternatively, the single domain antibody may comprise a VH domain wherein CDR-H1 has the sequence given in SEQ ID NO:56 and CDR-H3 has the sequence given in SEQ ID NO:58. For the avoidance of doubt, it is understood that all permutations are included.
- In another embodiment a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH single domain antibody, wherein the VH domain comprises the sequence given in SEQ ID NO:56 for CDR-H1, the sequence given in SEQ ID NO:57 for CDR-H2 and the sequence given in SEQ ID NO:58 for CDR-H3.
- In another embodiment a single domain antibody which binds human serum albumin for use in the present invention is a heavy chain VH single domain antibody, wherein the VH domain comprises the sequence given in SEQ ID NO:62 for CDR-H1, the sequence given in SEQ ID NO:63 for CDR-H2 and the sequence given in SEQ ID NO:64 for CDR-H3.
- In one embodiment a single domain antibody which binds human serum albumin for use in the present invention is a humanised heavy chain VH single domain antibody, dAbH1, having the sequence given in
FIG. 5 (a) (SEQ ID NO:52). An example of a suitable CH1-dAbH1 fusion comprising a G4S linker is given inFIG. 6 (SEQ ID NO:68). - In one embodiment the single domain antibody which binds human serum albumin for use in the present invention is a humanised heavy chain VH single domain antibody, dAbH2, having the sequence given in
FIG. 5 (c) (SEQ ID NO:54). An example of a suitable CH1-dAbH2 fusion comprising a G4S linker is given inFIG. 6 (SEQ ID NO:69). - The residues in antibody variable domains are conventionally numbered according to a system devised by Kabat et al. This system is set forth in Kabat et al., 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (hereafter “Kabat et al. (supra)”). This numbering system is used in the present specification except where otherwise indicated.
- The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues. The actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure. The correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat numbered sequence.
- The CDRs of the heavy chain variable domain are located at residues 31-35 (CDR-H1), residues 50-65 (CDR-H2) and residues 95-102 (CDR-H3) according to the Kabat numbering system. However, according to Chothia (Chothia, C. and Lesk, A. M. J. Mol. Biol., 196, 901-917 (1987)), the loop equivalent to CDR-H1 extends from residue 26 to residue 32. Thus ‘CDR-H1’, as used herein, comprises residues 26 to 35, as described by a combination of the Kabat numbering system and Chothia's topological loop definition.
- The CDRs of the light chain variable domain are located at residues 24-34 (CDR-L1), residues 50-56 (CDR-L2) and residues 89-97 (CDR-L3) according to the Kabat numbering system.
- In one embodiment a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL single domain antibody which comprises at least one of a CDR having the sequence given in
FIG. 5 (h) SEQ ID NO:59 orFIG. 5 (n) SEQ ID NO:65 for CDR-L1, a CDR having the sequence given inFIG. 5(i) SEQ ID NO:60 orFIG. 5 (o) SEQ ID NO:66 for CDR-L2 and a CDR having the sequence given inFIG. 5 (j) SEQ ID NO:61 orFIG. 5 (p) SEQ ID NO:67 for CDR-L3. - In another embodiment a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL antibody, wherein at least two of CDR-L1, CDR-L2 and CDR-L3 of the VL domain are selected from the following: the sequence given in SEQ ID NO:59 or SEQ ID NO:65 for CDR-L1, the sequence given in SEQ ID NO:60 or SEQ ID NO:66 for CDR-L2 and the sequence given in SEQ ID NO:61 or SEQ ID NO:67 for CDR-L3. For example, the domain antibody may comprise a VL domain wherein CDR-L1 has the sequence given in SEQ ID NO:59 and CDR-L2 has the sequence given in SEQ ID NO:60. Alternatively, the domain antibody may comprise a VL domain wherein CDR-L1 has the sequence given in SEQ ID NO:59 and CDR-L3 has the sequence given in SEQ ID NO:61. For the avoidance of doubt, it is understood that all permutations are included.
- In another embodiment a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL domain antibody, wherein the VL domain comprises the sequence given in SEQ ID NO:59 for CDR-L1, the sequence given in SEQ ID NO:60 for CDR-L2 and the sequence given in SEQ ID NO:61 for CDR-L3.
- In another embodiment a single domain antibody which binds human serum albumin for use in the present invention is a light chain VL domain antibody, wherein the VL domain comprises the sequence given in SEQ ID NO:65 for CDR-L1, the sequence given in SEQ ID NO:66 for CDR-L2 and the sequence given in SEQ ID NO:67 for CDR-L3.
- In one embodiment a single domain antibody which binds human serum albumin for use in the present invention is a humanised light chain VL single domain antibody, dAbL1, having the sequence given in
FIG. 5 (b) (SEQ ID NO:53). An example of a suitable CH1-dAbL1 fusion and a Ck1-dAbL1 fusion both comprising a G4S linker is given inFIG. 6 (SEQ ID NO:70 and SEQ ID NO:72). - In one embodiment a single domain antibody which binds human serum albumin for use in the present invention is a humanised light chain VL single domain antibody, dAbL2, having the sequence given in
FIG. 5 (d) (SEQ ID NO:55). An example of a suitable CH1-dAbL2 fusion and a Ck1-dAbL2 fusion both comprising a G4S linker is given inFIG. 6 (SEQ ID NO:71 and SEQ ID NO:73). - In one embodiment where the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus and the two single domain antibodies are a complementary VH/VL pair which bind the antigen co-operatively as described herein above, the VH dAb is dAbH1 (SEQ ID NO:52) and the VL dAb is dAbL1 (SEQ ID NO:53).
- In one embodiment where the heavy and light chains of the Fab or Fab′ fragment each comprise a single domain antibody at the C-terminus the two single domain antibodies are a complementary VH/VL pair which bind the antigen co-operatively as described herein above, the VH dAb is dAbH2 (SEQ ID NO:54) and the VL dAb is dAbL2 (SEQ ID NO:55).
- In another aspect, the present invention provides albumin binding antibodies or fragments thereof containing one or more of the CDRs provided herein above and in
FIG. 5 (e-p), in particular comprising a CDRH1 with the sequence shown in SEQ ID NO. 56, a CDRH2 with the sequence shown in SEQ ID NO. 57, a CDRH3 with the sequence shown in SEQ ID NO. 58, a CDRL1 with the sequence shown in SEQ ID NO. 59, a CDRL2 with the sequence shown in SEQ ID NO. 60, and/or a CDRL3 with the sequence shown in SEQ ID NO. 61. In one embodiment the albumin binding antibodies or fragments comprise a CDRH1 with the sequence shown in SEQ ID NO. 62, a CDRH2 with the sequence shown in SEQ ID NO. 63, a CDRH3 with the sequence shown in SEQ ID NO. 64, a CDRL1 with the sequence shown in SEQ ID NO. 65, a CDRL2 with the sequence shown in SEQ ID NO. 66, and/or a CDRL3 with the sequence shown in SEQ ID NO. 67. Said CDRs may be incorporated into any suitable antibody framework and into any suitable antibody format. Such antibodies include whole antibodies and functionally active fragments or derivatives thereof which may be, but are not limited to, monoclonal, humanised, fully human or chimeric antibodies. Accordingly, such albumin binding antibodies may comprise a complete antibody molecule having full length heavy and light chains or a fragment thereof and may be, but are not limited to Fab, modified Fab, Fab′, F(ab′)2, Fv, single domain antibodies, scFv, bi, tri or tetra-valent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies and epitope-binding fragments of any of the above (see for example Holliger and Hudson, 2005, Nature Biotech. 23(9):1126-1136; Adair and Lawson, 2005, Drug Design Reviews—Online 2(3), 209-217). The methods for creating and manufacturing these antibody fragments are well known in the art (see for example Verma et al., 1998, Journal of Immunological Methods, 216, 165-181). Multi-valent antibodies may comprise multiple specificities or may be monospecific (see for example WO 92/22853 and WO05/113605). It will be appreciated that this aspect of the invention also extends to variants of these albumin binding antibodies. - It will be appreciated that such albumin binding antibodies, in particular single domain antibodies may be conjugated to any other antibody or protein or other molecule, as desired or used in any other suitable context. In one example the single domain antibodies dAbH1, dAbL1, dAbH2, dAbL2 as described above and shown in
FIG. 5 (a-d) may be incorporated into any suitable antibody format or used as single domain antibodies in any suitable context, such as a fusion or conjugate. - In one embodiment antibodies of this aspect of the invention comprise the sequence given in
FIG. 5(e) for CDR-H1, the sequence given inFIG. 5(f) for CDR-H2 and the sequence given inFIG. 5(g) for CDR-H3. - In one embodiment antibodies of this aspect of the invention comprise the sequence given in
FIG. 5(k) for CDR-H1, the sequence given inFIG. 5(l) for CDR-H2 and the sequence given inFIG. 5(m) for CDR-H3. - In one embodiment antibodies of this aspect of the invention comprise the sequence given in
FIG. 5(h) for CDR-L1, the sequence given inFIG. 5(i) for CDR-L2 and the sequence given inFIG. 5(j) for CDR-L3. - In one embodiment antibodies of this aspect of the invention comprise the sequence given in
FIG. 5(n) for CDR-L1, the sequence given inFIG. 5(o) for CDR-L2 and the sequence given inFIG. 5(p) for CDR-L3. - In the antibody formats below each of the sequences from the sequence listing herein may be located in the position corresponding to the natural position or a non-natural position. Natural position will be for the relevant sequence in the listing labelled CDRH1 position H1, for the relevant sequence in the listing labelled CDRH2 position H2, for the relevant sequence in the listing labelled CDRH3 position H3, for the relevant sequence in the listing labelled CDRL1 position L1, for the relevant sequence in the listing labelled CDRL2 position L2, and for the relevant sequence in the listing labelled CDRL3 position L3. Combinations thereof are also envisaged such as H1 and H2, H1 and H3, H1 and L1, H1 and L2, H1 and L3, H2 and L1, H2 and L2, H2 and L3, H2 and H3, H3 and L1, H3 and L2, H3 and L3, H1 and H2 and H3, H1 and H2 and L1, H1 and H2 and L2, H1 and H2 and L3, H2 and H3 and L1, H2 and H3 and L2, H2 and H3 and L3, H3 and L1 and L2, H3 and L1 and L3, 1-13 and L2 and L3, L1 and L2 and L3, H1 and H2 and H3 and L1, H1 and H2 and H3 and L2, H1 and H2 and 1-13 and L3, H2 and H3 and L1 and L2, H2 and H3 and L1 and L3, and H2 and H3 and L2 and L3, H3 and L1 and L2 and L3, H1 and H2 and H3 and L1 and L2, H1 and H2 and H3 and L2 and L3, H1 and H2 and 1-13 and L1 and L3, L1 and L2 and L3 and H1 and H2, L1 and L2 and L3 and H1 and H3, L1 and L2 and L3 and H2 and H3, H1 and H2 and H3 and L1 and L2 and L3.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 88 to 93.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 94 to 99.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 100 to 105.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 106 to 111.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 112 to 117.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 118 to 123.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 124 to 129.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 130 to 135.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 136 to 141.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 142 to 147.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 148 to 153.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 154 to 159.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 160 to 165.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 166 to 171.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 172 to 177.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 178 to 183.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 184 to 189.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 190 to 195.
- In one embodiment the antibody fusion protein of the disclosure comprises a sequence, for example 1, 2, 3, 4, 5 or 6 sequence(s) selected from Sequence ID NO: 196 to 201.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID No: 202.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID No: 203.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID Nos: 202 and 203.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID No: 204.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID No: 205.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID Nos: 204 and 205.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID No: 206.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID No: 207.
- In one embodiment the antibody fusion protein of the disclosure comprises Sequence ID No: 206 and 207.
- Where the single domain antibody or antibodies of the dual specificity fusion protein of the present invention bind to albumin the binding affinity of the single domain antibody for albumin will be sufficient to extend the half-life of the Fab or Fab′ in vivo. It has been reported that an affinity for albumin of less than or equal to 2.5 μM affinity will extend half-life in vivo (Nguyen, A. et al (2006) Protein Engineering, Design & Selection, 19(7), 291-297). The single domain antibody molecules of the present invention preferably have a binding affinity suited to their purpose and the antigen to which they bind. In one example the single domain antibodies have a high binding affinity, for example picomolar. In one example the single domain antibodies have a binding affinity for antigen which is nanomolar or micromolar. Affinity may be measured using any suitable method known in the art, including BIAcore as described in the Examples herein using natural or recombinant antigen.
- Preferably the single domain antibody molecules of the present invention which bind albumin have a binding affinity of about 2 μM or better. In one embodiment the single domain antibody molecule of the present invention has a binding affinity of about 1 μM or better. In one embodiment the single domain antibody molecule of the present invention has a binding affinity of about 500 nM or better. In one embodiment the single domain antibody molecule of the present invention has a binding affinity of about 200 nM or better. In one embodiment the domain antibody molecule of the present invention has a binding affinity of about 1 nM or better. It will be appreciated that the affinity of single domain antibodies provided by the present invention and known in the art may be altered using any suitable method known in the art. The present invention therefore also relates to variants of the domain antibody molecules of the present invention, which have an improved affinity for albumin. Such variants can be obtained by a number of affinity maturation protocols including mutating the CDRs (Yang et al., J. Mol. Biol., 254, 392-403, 1995), chain shuffling (Marks et al., Bio/Technology, 10, 779-783, 1992), use of mutator strains of E. coli (Low et al., J. Mol. Biol., 250, 359-368, 1996), DNA shuffling (Patten et al., Curr. Opin. Biotechnol., 8, 724-733, 1997), phage display (Thompson et al., J. Mol. Biol., 256, 77-88, 1996) and sexual PCR (Crameri et al., Nature, 391, 288-291, 1998). Vaughan et al. (supra) discusses these methods of affinity maturation.
- The single domain antibody or antibodies of the dual specificity fusion protein may be provided as monomers, dimmers or trimers, as required. The desired product may be obtained by adjusting the downstream processing steps the material is subjected to. In one embodiment the processed material is provided as a substantially homogenous monomer. In one embodiment the processed material is provided a substantially homogenous dimer. In one embodiment the processed material is provided as a substantially homogenous trimer.
- The present invention also provides an isolated DNA sequence encoding a dual specificity antibody fusion protein of the present invention. The DNA sequences of the present invention may comprise synthetic DNA, for instance produced by chemical processing, cDNA, genomic DNA or any combination thereof.
- DNA sequences which encode the dual specificity antibody fusion protein of the present invention can be obtained by methods well known to those skilled in the art. For example, DNA sequences coding for part or all of the antibody fragments, linkers and/or dAbs may be synthesised as desired from the determined DNA sequences or on the basis of the corresponding amino acid sequences.
- Standard techniques of molecular biology may be used to prepare DNA sequences coding for the dual specificity antibody fusion protein of the present invention. Desired DNA sequences may be synthesised completely or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as appropriate.
- The present invention further relates to a cloning or expression vector comprising one or more DNA sequences of the present invention. Accordingly, provided is a cloning or expression vector comprising one or more DNA sequences encoding a dual specificity antibody fusion protein of the present invention. In one preferred embodiment, the cloning or expression vector comprises a single DNA sequence encoding the entire dual specificity antibody fusion protein. Thus, the cloning or expression vector comprises DNA encoded transcription units in sequence such that a translation fusion protein is produced.
- Indeed, it will be understood by those skilled in the art that a fusion protein of the invention can have the dAb at the N-terminus or the C-terminus and thus, the dAb DNA encoded transcription unit will be first or last, respectively, within the DNA sequence encoding the translation fusion. Thus, a translation fusion may comprise an N-terminal dAb and a C-terminal Fab or Fab′. Further, a translation fusion may comprise an N-terminal Fab or Fab′ and a C-terminal dAb.
-
-
646Pv CDRH1 (SEQ ID NO: 222) GIDLSNYAIN CDRH2 (SEQ ID NO: 223) IIWASGTTFYATWAKG CDRH3 (SEQ ID NO: 90) TVPGYSTAPYFDL CDRL1 (SEQ ID NO: 91) QSSPSVWSDFLS CDRL2 (SEQ ID NO: 92) GASTLAS CDRL3 (SEQ ID NO: 93) GGGYSSISD TT 647Fv CDRH1 (SEQ ID NO: 94) GFTLSNNYWMC CDRH2 (SEQ ID NO: 95) CIYTGDGDTAYTSWAKG CDRH3 (SEQ ID NO: 96) SGGSYYDYVFIL CDRL1 (SEQ ID NO: 97) QASQSLGNRLA CDRL2 (SEQ ID NO: 98) RASTLAS CDRL3 (SEQ ID NO: 99) QCTYIGSKMGA 648Fv is the same as a didAb of dAbH2, dAbL2 649Fy CDRH1 (SEQ ID NO: 100) GFSFSGNYWIC CDRH2 (SEQ ID NO: 101) CIFTADGDTAYTSWAKG CDRH3 (SEQ ID NO: 102) SGGSAFDYVFIL CDRL1 (SEQ ID NO: 103) QASQSIGNRLG CDRL2 (SEQ ID NO: 104) RASTLES CDRL3 (SEQ ID NO: 105) QCTYIGKLMGA 645HeavyI50AFv CDRH1 (SEQ ID NO: 106) GIDLSNYAIN CDRH2 (SEQ ID NO: 107) AIWASGTTFYATWAKG CDRH3 (SEQ ID NO: 108) TVPGYSTAPYFDL CDRL1 (SEQ ID NO: 109) QSSPSVWSNFLS CDRL2 (SEQ ID NO: 110) EASKLTS CDRL3 (SEQ ID NO: 111) GGGYSSISDTT
used. Suitable mammalian host cells include NS0, CHO, myeloma or hybridoma cells. Accordingly in one embodiment the fusion protein of the present invention is expressed in E. coli. In another embodiment the fusion protein of the present invention is expressed in mammalian cells. - The present invention also provides a process for the production of a dual specificity antibody fusion protein comprising culturing a host cell comprising a vector of the present invention under conditions suitable for the expression of protein from the DNA sequence encoding said dual specificity antibody fusion protein. The invention further provides methods for isolating the dual specificity antibody fusion protein.
- On production, a dual specificity antibody fusion protein of the present invention may be purified, where necessary, using any suitable method known in the art. For example, but without limitation, chromatographic techniques such as ion exchange, size exclusion, protein G or hydrophobic interaction chromatography may be used.
- The size of a dual specificity antibody fusion protein may be confirmed by conventional methods known in the art such as size exclusion chromatography and non-reducing SDS-PAGE. Such techniques can be used, for example to confirm that the protein has not dimerised and/or does not have a portion missing, e.g. the dAb portion. If dimers are detected and a homogenous monomeric product is required then the monomeric dual specificity antibody fusion protein may be purified away from the dimeric species using conventional chromatography techniques as described above.
- Dual specificity antibody fusion proteins of the invention are useful in the treatment of diseases or disorders including inflammatory diseases and disorders, immune disease and disorders, fibrotic disorders and cancers.
- The term “inflammatory disease” or “disorder” and “immune disease or disorder” includes rheumatoid arthritis, psoriatic arthritis, still's disease, Muckle Wells disease, psoriasis, Crohn's disease, ulcerative colitis, SLE (Systemic Lupus Erythematosus), asthma, allergic rhinitis, atopic dermatitis, multiple sclerosis, vasculitis, Type I diabetes mellitus, transplantation and graft-versus-host disease.
- The term “fibrotic disorder” includes idiopathic pulmonary fibrosis (IPF), systemic sclerosis (or scleroderma), kidney fibrosis, diabetic nephropathy, IgA nephropathy, hypertension, end-stage renal disease, peritoneal fibrosis (continuous ambulatory peritoneal dialysis), liver cirrhosis, age-related macular degeneration (ARMD), retinopathy, cardiac reactive fibrosis, scarring, keloids, burns, skin ulcers, angioplasty, coronary bypass surgery, arthroplasty and cataract surgery.
- The term “cancer” includes a malignant new growth that arises from epithelium, found in skin or, more commonly, the lining of body organs, for example: breast, ovary, prostate, lung, kidney, pancreas, stomach, bladder or bowel. Cancers tend to infiltrate into adjacent tissue and spread (metastasise) to distant organs, for example: to bone, liver, lung or the brain.
- Thus, according to a further aspect of the invention, there is provided a pharmaceutical composition which comprises an antibody fusion of the invention in association with one or more pharmaceutically acceptable carriers, excipients or diluents. Also provided is the use of an antibody fusion protein of the invention for the manufacture of a medicament for the treatment of a disease or disorder. Most preferably, the disease or disorder is an inflammatory disease or disorder.
- Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, subcutaneous, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.
- Where appropriate, for example if the single domain antibody or antibodies of the antibody fusion protein bind to albumin, it may be desirable to pre-formulate the dual specificity fusion protein with human or recombinant serum albumin, using any suitable method known in the art.
- Where the pharmaceutical formulation is a liquid, for example a solution or suspension then the formulation may further comprise albumin, for example human serum albumin, in particular recombinant albumin such as recombinant human serum albumin. Suitable amounts may be in the range of less than 2% w/w of the total formulation, in particular less than 1, 0.5, or 0.1% w/w. This may assist in stabilizing the antibody component in the formulation. The pharmaceutical composition may be lyophilized for reconstitution later, with an aqueous solvent.
- In one embodiment there is provided a unit dose container, such as a vial, comprising a lyophilized “antibody” according to the invention.
- For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles or preservatives. The preparations may also contain buffer salts, flavouring agents, colouring agents or sweetening agents, as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
- The bispecific antibodies of the invention may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
- In addition to the formulations described above, the bispecific antibodies of the invention may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.
- For nasal administration or administration by inhalation, the compounds according to the present invention may be conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.
- For topical administration the compounds according to the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water. Alternatively, the compounds according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, sorbitan monostearate,
polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water. - In one embodiment the formulation is provided as a formulation for topical administrations including inhalation.
- Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases. Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable excipient.
- These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another. Mono- or disaccharides are suitably used, the use of lactose or glucose, particularly but not exclusively in the form of their hydrates.
- Particles for deposition in the lung require a particle size less than 10 microns, such as 1-9 microns for example from 0.1 to 5 μm, in particular from 1 to 5 μm. The particle size of the active ingredient (such as the antibody or fragment) is of primary importance.
- The propellent gases which can be used to prepare the inhalable aerosols are known in the art. Suitable propellent gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The abovementioned propellent gases may be used on their own or in mixtures thereof.
- Particularly suitable propellent gases are halogenated alkane derivatives selected from among TG 11,
TG 12, TG 134a and TG227. Of the abovementioned halogenated hydrocarbons, TG134a (1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof are particularly suitable. - The propellent-gas-containing inhalable aerosols may also contain other ingredients such as cosolvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
- The propellant-gas-containing inhalable aerosols according to the invention may contain up to 5% by weight of active substance. Aerosols according to the invention contain, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1% by weight of active ingredient.
- Alternatively topical administrations to the lung may also be by administration of a liquid solution or suspension formulation, for example employing a device such as a nebulizer, for example, a nebulizer connected to a compressor (e.g., the Pari LC-Jet Plus® nebulizer connected to a Pari Master® compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.).
- The antibody formats of the invention can be delivered dispersed in a solvent, e.g., in the form of a solution or a suspension. It can be suspended in an appropriate physiological solution, e.g., saline or other pharmacologically acceptable solvent or a buffered solution. Buffered solutions known in the art may contain 0.05 mg to 0.15 mg disodium edetate, 8.0 mg to 9.0 mg NaCl, 0.15 mg to 0.25 mg polysorbate, 0.25 mg to 0.30 mg anhydrous citric acid, and 0.45 mg to 0.55 mg sodium citrate per 1 ml of water so as to achieve a pH of about 4.0 to 5.0. A suspension can employ, for example, lyophilised antibody.
- The therapeutic suspensions or solution formulations can also contain one or more excipients. Excipients are well known in the art and include buffers (e.g., citrate buffer, phosphate buffer, acetate buffer and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. Solutions or suspensions can be encapsulated in liposomes or biodegradable microspheres. The formulation will generally be provided in a substantially sterile form employing sterile manufacture processes.
- This may include production and sterilization by filtration of the buffered solvent/solution used for the for the formulation, aseptic suspension of the antibody in the sterile buffered solvent solution, and dispensing of the formulation into sterile receptacles by methods familiar to those of ordinary skill in the art.
- Nebulizable formulation according to the present disclosure may be provided, for example, as single dose units (e.g., sealed plastic containers or vials) packed in foil envelopes. Each vial contains a unit dose in a volume, e.g., 2 ml, of solvent/solution buffer.
- The antibodies formats of the present disclosure are thought to be suitable for delivery via nebulisation.
- For ophthalmic administration the compounds according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH-adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate. Alternatively, for ophthalmic administration compounds may be formulated in an ointment such as petrolatum.
- For rectal administration the compounds according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component. Such materials include, for example, cocoa butter, beeswax and polyethylene glycols.
- The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen and the condition of the patient to be treated. In general, however, daily dosages may range from around 10 ng/kg to 1000 mg/kg, typically from 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and from around 0.05 mg to around 1000 mg, e.g. from around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.
- Preferred features of each embodiment of the invention are as for each of the other embodiments mutatis mutandis. All publications, including but not limited to patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
- Comprising in the context of the present specification is intended to meaning including.
- Where technically appropriate embodiments of the invention may be combined.
- Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.
- The invention will now be described with reference to the following examples, which are merely illustrative and should not in any way be construed as limiting the scope of the present invention.
-
FIG. 1 : Diagrammatic representation of Fab-dAbs where the dAb is at the C-terminus -
FIG. 2A : Diagrammatic representation of Fab-didAbs -
FIG. 2B : Diagrammatic representation of Fab-didAbs with additional disulfide stabilisation between the dAbs. -
FIG. 3 : SDS PAGE analysis of FabA-dAbL3 (CK-SG4SE) (1) and FabA-dAbL3 (CK-G[APAPA]2) (2). -
FIG. 4 : Western blot analysis of FabA-dAbL3 (CK-SG4SE) (1) and FabA-dAbL3 (CK-G[APAPA]2) (2). -
FIG. 4a : SDS PAGE of FabB-didAbs -
- Lane M=See Blue markers
-
Lanes 1 & 2=IgG control -
Lane 3=FabB -
Lane 4=FabB-didAb, -dAbL1 (CK-G4S×2) & dAbH1 (CH1-G4S×2) -
Lane 5=FabB-didAb, -dAbL2 (CK-G4S×2) & dAbH2 (CH1-G4S×2)
-
FIG. 5 : Sequences of domain antibodies dAbH1, dAbH2, dAbL1 and dAbL2 and the CDRs derived from each of those antibodies. -
FIG. 6 : FabB-dAb constructs comprising FabB heavy or light chain variable domain fused to a domain antibody. -
FIG. 7 Fab′A heavy and light chain sequences and FabA heavy chain sequence. -
FIGS. 8a, 8b & 8c Murinised Fab-didAb amino acid sequences. -
FIG. 8a shows the amino acid sequence of CDRs in various murine dAbs. -
FIG. 8b shows the amino acid sequence of mFabD-mdidAb: -
- dAbL1(CK-G4S×2)
- dAbH1(CH1-G4S×2)
- dAbL2(CK-G4S×2) &
- dAbH2(CH1-G4S×2)
-
FIG. 8c shows the amino acid sequence of mFabD-mdidAb: -
- dAbL1(CK-G4S×2)
- dAbH1(CH1-G4S×2)mFabC-mdAbH1
- dAbL2(CK-G4S×2) &
- dAbH2(CH1-
G4S× 2
-
FIG. 9 shows SDS PAGE of FabB-didAbs -
-
Lanes 1 & 4 are Fab′B -
Lanes 2 & 5 are FabB-didAb, -dAbL1 (CK-G4S×2) & -dAbH1(CH1-G4S×2) -
Lanes 3 & 6 are FabB-didAb, -dAbL2(CK-G4S×2) & -dAbH2(CH1-G4S×2)
-
-
FIG. 10 shows a diagrammatic representation of a Thermofluor thermal stability assay. -
FIG. 11 shows a plot of HAS-FITC signal/HAS-FITC mixes bound to activated mouse T cells. -
FIG. 12 shows a plot of an aggregation stability assay. -
FIG. 13 shows in vivo concentration profiles over time after subcutaneous and intravenous dosing -
FIGS. 14A , B and C show certain CD4+ cell and CD8+ cell readouts -
FIG. 15 shows SDS-PAGE analysis of FabB-645Fv -
FIG. 16 shows size exclusion analysis of FabB-645Fv -
FIG. 17 shows thermograms of FabB-645Fv with various linker lengths. -
FIG. 18 shows SDS-PAGE analysis of certain FabB constructs -
FIG. 19 shows size exclusion analysis of various FabB-645Fv constructs -
FIGS. 20 to 24 show sequences for certain formats. -
- -645Fv equates to didAbL1 and H1 (the linker used for each dAB will be the same unless indicated otherwise).
- 648Fv equates to didAbL2 and H2 (the linker used for each dAB will be the same unless indicated otherwise).
- -645dsFv equates to didAbL1 and H1 (the linker used for each dAB will be the same unless indicated otherwise) wherein L1 and H1 are stabilised by a disulfide bond.
- -648dsFv equates to didAbL2 and H2 (the linker used for each dAB will be the same unless indicated otherwise) wherein L2 and H3 are stabilised by a disulfide bond.
- Fab are Fabs which lack the interchain cysteine bond (ie between CH and CL or CK)
- Abbreviations: unless the context indicates otherwise “m” as a pre-fix is intended to refer to murine.
- Unless the context indicates otherwise “h” as a pre-fix is intended to refer to human. Fab A, Fab B, Fab C and Fab D components may be provided below in different formats.
- An in-frame DNA encoded transcription unit encoding a dAb with specificity for human serum albumin was produced using recombinant DNA technology.
- Where desired an in-frame DNA encoded transcription unit encoding a dAb with specificity for a recruitment protein can be produced using recombinant DNA technology.
- For fusion of a dAb to the C-terminus of the light chain, DNA was synthesised encoding a human kappa light chain constant region (with the Km3 allotype of the kappa constant region), a peptide linker and a dAb and cloned as a SacI-PvuII restriction fragment into the UCB-Celltech in-house expression vector pTTOD(Fab) (a derivative of pTTO-1, described in Popplewell et al., Methods Mol. Biol. 2005; 308: 17-30) which contains DNA encoding the human gamma-1 CH1 constant region. This gave rise to a dicistronic gene arrangement consisting of the gene for the humanised light chain fused via a linker to a dAb followed by the gene for the humanised heavy chain Fab fragment, both under the control of the tac promoter. Also encoded is a unique BspE1 site upstream of the Gly4Ser linker, or an AscI site upstream of the Ala-Pro-rich linker.
- For fusion of a dAb the C-terminus of the heavy chain, DNA was synthesised encoding a human CH1 fragment (of the γ1 isotype) followed by a linker encoding sequence and a dAb. This was subcloned as an ApaI-EcoRI restriction fragment into the UCB-Celltech in-house expression vector pTTOD(Fab) (a derivative of pTTO-1, described in Popplewell et al., above) which contains DNA encoding the human gamma-1 CH1 constant region. This gave rise to a dicistronic gene arrangement consisting of the gene for the humanised light chain a non-coding intergenic sequence and followed by a heavy chain fused via a linker to a dAb, both under the control of the tac promoter. The recombinant expression plasmid was transformed into the E. coli strain W3110 in which expression is induced by addition of IPTG. Expression experiments were performed at small scale initially (5 ml culture volumes) with addition of 200 uM IPTG at OD (600 nm) of approx. 0.5, cells were harvested 2 hours post induction and extracted overnight at 30° C. in Tris/EDTA. Clarified extracts were used for affinity analysis by Biacore. Constructs giving promising expression yields and activities were selected for fermentation.
- In the following examples the antibody chain to which the dAb is fused is denoted either as CK or LC for the cKappa light chain and as CH1 or HC for the heavy chain constant domain, CH1.
- Construction of FabA-dAb Fusion Plasmids for Expression in E. coli
- Fab-dAb fusion proteins were constructed by fusing dAbL3 or dAbH4 to the C-terminus of the constant region of either the light or heavy chain of FabA. A flexible (SGGGGSE (SEQ ID NO:1)) or a rigid (G(APAPA)2 (SEQ ID NO: 34)) linker was used to link the dAb to the cKappa region (SEQ ID NO:75) whereas the linker DKTHTS (SEQ ID NO:2) was used to link the dAb to the CHI region (SEQ ID NO:76). The DNA sequence coding for the constant region-dAb fusion was manufactured synthetically as fragments to enable sub-cloning into the FabA sequence of the in-house pTTOD vector.
- Light chain-dAb fusions were constructed by sub-cloning the SacI-ApaI fragment of the synthesized genes, encoding a C-terminal cKappa fused to either dAbL3 or dAbH4 via either a (SGGGGSE (SEQ ID NO:1)) or a rigid (G(APAPA)2 (SEQ ID NO: 34)) linker, into the corresponding sites of a plasmid capable of expressing FabA. Heavy chain-dAb fusions were constructed by sub-cloning the ApaI-EcoRI fragment of the synthesised genes, encoding a C-terminal CHI fused to either dAbL3 or dAbH4 via a DKTHTS linker, into the corresponding sites of a plasmid capable of expressing FabA.
- Fab′ A is derived from an IL-1 beta binding antibody, the heavy and light chain sequences of which are provided in SEQ ID NOs: 74 and 75 respectively as shown in
FIG. 7 . In Fab′A where the light chain has a dAb attached, the hinge of the heavy chain was altered to DKTHTS even where no dAb is attached to the heavy chain (SEQ ID NO:76). - FabA comprises the same light chain sequence (SEQ ID NO:75) and a truncated heavy chain sequence which terminates at the interchain cysteine (SEQ ID NO:77). dAbL3 and dAbH4 are light and heavy chain domain antibodies respectively which bind human serum albumin.
- Construction of FabA-didAb Fusion Plasmids for Expression in E. coli
- FabA-didAb with dAbL3 or dAbH4 on both light and heavy chains were constructed by sub-cloning the ApaI-EcoRI fragment coding for CH1-dAb fusions into the existing Fab-dAb plasmids where the dAb is fused to the light chain via the flexible linker.
- The FabB-dAbs, FabB-dAbH1 (CH1-G4S×2), FabB-dAbH2 (CH1-G4S×2), FabB-dAbL1 (CH1-G4S×2), FabB-dAbL2 (CH1-G4S×2) were all assembled by PCR then cloned into a mammalian expression vector under the control of the HCMV-MIE promoter and SV40E polyA sequence. These were paired with a similar vector containing the FabB light chain for expression in mammalian cells (see below).
- FabB is derived from an antibody which bids a cell surface co-stimulatory molecule. dAbH1, dAbH2, dAbL1 and dAbL2 were obtained as described in Example 3.
- Mammalian Expression of FabB-dAbs and didAbs
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 2 μg heavy chain plasmid+2 μg light chain plasmid was incubated with 10 μl 293fectin+340 μl Optimem media for 20 mins at RT. The mixture was then added to 5×106 HEK293 cells in suspension and incubated for 4 days with shaking at 37° C.
- Binding affinities and kinetic parameters for the interactions of Fab-dAb constructs were determined by surface plasmon resonance (SPR) conducted on a Biacore T100 using CM5 sensor chips and HBS-EP (10 mM HEPES (pH7.4), 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20) running buffer. Fab-dAb samples were captured to the sensor chip surface using either a human F(ab′)2-specific goat Fab (Jackson ImmunoResearch, 109-006-097) or an in-house generated anti human CH1 monoclonal antibody. Covalent immobilisation of the capture antibody was achieved by standard amine coupling chemistry.
- Each assay cycle consisted of firstly capturing the Fab-dAb using a 1 min injection, before an association phase consisting of a 3 min injection of antigen, after which dissociation was monitored for 5 min. After each cycle, the capture surface was regenerated with 2×1 min injections of 40 mM HCl followed by 30 s of 5 mM NaOH. The flow rates used were 10 μl/min for capture, 30 μl/min for association and dissociation phases, and 10 μl/min for regeneration.
- For kinetic assays, a titration of antigen (for human serum albumin typically 62.5 nM-2 μM, for IL-1β 1.25-40 nM) was performed, a blank flow-cell was used for reference subtraction and buffer-blank injections were included to subtract instrument noise and drift.
- Kinetic parameters were determined by simultaneous global-fitting of the resulting sensorgrams to a standard 1:1 binding model using Biacore T100 Evaluation software.
- In order to test for simultaneous binding, 3 min injections of either separate 5 μM HSA or 100 nM IL-1β, or a mixed solution of 5 μM HSA and 100 nM IL-1β were injected over the captured Fab-dAb.
- Fab-dAb Purification from E. coli
- E. coli pellets containing the Fab-dAbs within the periplasm were re-suspended in original culture volume with 100 mM Tris/HCl, 10 mM EDTA pH 7.4. These suspensions were then incubated at 4° C. for 16 hours at 250 rpm. The re-suspended pellets were centrifuged at 10000×g for 1 hour at 4° C. The supernatants were removed and 0.45 μm filtered.
- The Fab-dAbs were captured from the filtered supernatant by Protein-G chromatography. Briefly the supernatants were applied, with a 20 minute residence time, to a Gammabind Plus Sepharose (GE Healthcare) column equilibrated in 20 mM phosphate, 150 mM NaCl pH7.1. The column was washed with 20 mM phosphate, 150 mM NaCl pH7.1 and the bound material eluted with 0.1M glycine/HCl pH2.8. The elution peak was collected and pH adjusted to ˜pH5 with 1M sodium acetate. The pH adjusted elutions were concentrated and diafiltered into 50 mM sodium acetate pH4.5 using a 10 k MWCO membrane.
- The Fab-dAbs were further purified by cation exchange chromatography at pH4.5 with a NaCl elution gradient. Briefly the diafiltered Protein-G eluates were applied to a Source15S (GE Healthcare) column equilibrated in 50 mM sodium acetate pH4.5. The column was washed with 50 mM sodium acetate pH4.5 and the bound material eluted with a 20 column volume linear gradient from 0 to 1M NaCl in 50 mM sodium acetate pH4.5. Third column volume fractions were collected through out the gradient. The fractions were analysed by A280 and SDS-PAGE and relevant fractions pooled.
- If required the Fab-dAbs were further purified by gel filtration. Briefly the FabA-dAbL3 (CK-SG4SE) pooled ion exchange elution fractions were applied to a Superdex200 (GE Healthcare) column equilibrated in 50 mM sodium acetate, 125 mM NaCl pH 5.0 and eluted with an isocratic gradient of 50 mM sodium acetate, 125 mM NaCl pH 5.0. 1/120 column volume fractions were collected through out the gradient. The fractions were analysed by A280 and SDS-PAGE and relevant fractions pooled. For Fab-dAbs that did not undergo gel filtration, the pooled ion exchange elution fractions were concentrated and diafiltered into 50 mM sodium acetate, 125 mM NaCl pH 5.0 using a 10 k MWCO membrane.
- Samples were diluted with water where required and then to 10 μl was added 10
μL 2× sample running buffer. For non-reduced samples, 2 μL of 100 mM NEM was added at this point, for reducedsamples 2 μL of 10× reducing agent was added. The sample were vortexed, incubated at 85° C. for 5 mins, cooled and centrifuged at 12500 rpm for 30 secs. The prepared samples were loaded on to a 4-20% acrylamine Tris/Glycine SDS gel and run for 100 mins at 125V. The gels were either transferred onto PVDF membranes for Western blotting or stained with Coomassie Blue protein stain. - Gels were transferred to PVDF membranes in 12 mM Tris, 96 mM glycine pH8.3 for 16 hours at 150 mA. The PVDF membrane was block for 1 hr with 2% Marvel™ in PBS+0.1% Tween20 (Blocking buffer)
- HRP-rabbit anti-human kappa light chains, 1/5000 dilution in blocking buffer for 1 hr.
- mouse anti-human heavy chain, 1/7000 dilution in blocking buffer for 1 hr. Followed by HRP-goat anti-mouse, 1/2000 dilution in blocking buffer for 1 hr.
- rabbit anti-His6, 1/1000 dilution in blocking buffer for 1 hr. Followed by HRP-goat anti-rabbit IgG, 1/1000 dilution in blocking buffer for 1 hr.
- All blots were washed 6 times with 100 ml PBS+0.1% Tween20 for 10 minutes per wash. The blots were developed with either ECL reagent for 1 min before being exposed to Amersham Hyperfilm, or metal enhanced DAB reagent for 20-30 minutes followed by water.
- Samples (2 μg) were analysed on a 2.1 mm C8 Poroshell column at 80° C., with a flow rate of 2 ml/min and a gradient of 18-38% B over 4 mins. A=0.1% TFA in H2O B=0.065% TFA in 80:20 IPA:MeOH. Detection is by absorption at 214 nm.
- The yields of Fab-dAb were measured using a sandwich ELISA. Briefly, the Fab-dAb was captured with an anti-CH1 antibody then revealed with an anti-kappa-HRP.
- Samples (mFabD-didAb's) were incubated with 5 μg/ml FITC (fluorescein isothiocyanate) labelled HSA for 45 min. The sample/HSA-FITC incubations were then added to activated mouse CD4+ T-cells and incubated for a further 45 min. The cells were washed with PBS and the cell associated fluorescence measured by FACS (fluorescence activated cell sorting).
- ½ lop rabbits were immunised with recombinant chromapure human serum albumin (purchased from Jackson). Rabbits received 3 immunisations of 100 ug HSA protein subcutaneously, the first immunisation in complete Freunds adjuvant and subsequent immunisations in incomplete Freunds.
Antibodies antibodies - The light chain grafted sequences were sub-cloned into the rabbit light chain expression vector pVRbcK which contains the DNA encoding the rabbit C-Kappa constant region. The heavy chain grafted sequences were sub-cloned into the rabbit heavy chain expression vector pVRbHFab, which contains the DNA encoding the rabbit Fab′ heavy chain constant region. Plasmids were co-transfected into CHO cells and the antibodies produced screened for albumin binding and affinity (Table 1). Transfections of CHO cells were performed using the Lipofectamine™ 2000 procedure according to manufacturer's instructions (InVitrogen, catalogue No. 11668).
- Generating Humanised Domain Antibodies dAbL1, dAbH1, dAbL2 and dAbH2
- Humanised VL and VH regions were designed using human V-region acceptor frameworks and donor residues in the framework regions. One grafted VL region (L1 (SEQ ID NO:53) and L2 (SEQ ID NO:55)) and one VH region (H1 (SEQ ID NO:52) and H2 (SEQ ID NO:54)) were designed for each of
antibodies FIG. 5 . -
TABLE 1 Affinities of anti-albumin antibodies as rabbit Fab as humanised IgG HSA MurineSA HumanSA MurineSA RatSA nM nM nM nM nM Antibody 1 0.31 2.6 0.82 2.9 7.9 (Antibody 645) Antibody 20.33 12 0.13 23 54 (Antibody 648) Antibody 646 0.14 1.6 0.57 1.7 4.5 Antibody 647 0.60 3.6 1.3 26 10 Antibody 649 0.54 13 0.32 17 44 - FabB-dAb constructs were produced as described in the methods and the supernatants from the transfected HEK293 cells containing the FabB-dAbs were tested directly in BIAcore.
- Kinetic analysis was conducted to assess the interaction of HSA with FabB-dAb constructs. These consisted of either dAbL1, dAbH2 or dAbL3 fused to the C-terminus of CH1 of FabB (See
FIG. 6 ). The FabB-dAbL1 has a higher affinity for HSA, KD=170 nM, than FabB-dAbL3, KD=392 nM. The FabB-dAbH2 was shown to possess the poorest affinity towards HSA, KD=1074 nM, see Table 2. -
TABLE 2 Construct ka (×104M−1s−1) kd (×10−3s−1) KD (×10−9M) FabB-dAbL1 (CH1- 1.91 ± 0.74 2.18 ± 1.21 170 ± 78 G4Sx2) FabB-dAbH2 (CH1- 2.66 ± 0.39 29 ± 4.76 1074 ± 42 G4Sx2) FabB-dAbL3 (CH1- 2.63 ± 0.39 9.87 ± 1.63 392 ± 119 G4Sx2) - Affinity and kinetic parameters determined for the binding of HSA to FabBs fused to dAbL1, dAbH2 or dAbL3. The data shown are mean values±SEM. (For FabB-dAbL1 and FabB-dAbH2 n=4. For FabB-dAbL3 n=2).
- SDS-PAGE and western blotting of the FabB-dAb proteins confirmed that the FabB-dAbs produced were of the expected size.
- FabB-didAb constructs were produced as described in the methods and the supernatants from the transfected HEK293 cells containing the didAbs tested directly in BIAcore.
- Further analysis was performed using didAb constructs in which single dAbs were fused to both heavy and light C-termini of Fab. Constructs in which the didAb was derived from a natural heavy and light variable domain pairing showed a marked improvement in affinity compared to the single dAb alone (table 2 and 3). The didAb fusion consisting of two identical dAbL1s showed no improvement in affinity over that seen for the single dAbL1 (data not shown).
-
TABLE 3 Construct ka (×104M−1s−1) kd (×10−3s−1) KD (×10−9M) FabB-didAb, - 1.78 0.16 9 dAbL1 (CK-G4Sx2) & dAbH1 (CH1-G4Sx2) FabB-didAb, - 0.54 0.21 39 dAbL2 (CK-G4Sx2) & dAbH2 (CH1-G4Sx2) - Affinity and kinetic parameters determined for the binding of HSA to FabBs fused to both dAbL1 & dAbH1 or dAbL2 & dAbH2.
- SDS-PAGE of the FabB-didAb proteins confirmed that the FabB-didAbs expressed well and were of the expected size (See
FIG. 4a ). Note this SDS PAGE gel is total protein expressed by the cell. - Plasmids for expression of the Fab-dAbs, Fab′A-dAbL3 (CK-SG4SE) Fab′A-dAbL3 (CK-G[APAPA]2) in E. coli were constructed as described in the methods. The Fab-dAbs were expressed into the periplasm of the E. coli and purified to homogeneity as described in the methods. The purity of the Fab-dAbs were assessed by high temperature reverse phase HPLC, SDS-PAGE and Western blotting. The Fab-dAbs were also assessed for antigen binding by Biacore.
- High temperature reverse phase HPLC as performed as described in the methods gave quantitative analysis of all species contained in FabA-dAbL3 (CK-SG4SE) and FabA-dAbL3 (CK-G[APAPA]2). The percentage of each species present is shown in table 4.
-
TABLE 4 Quantification of species present in Fab-dAb batches Fab'A-dAbL3 Species (CK-SG4SE) Fab'A-dAbL3 (CK-G[APAPA]2) Peak 10.6% 1.8 % Peak 2 0.6% 0.0 % Peak 3 1.0% 0.3 % Peak 4 0.9% 0.8% Fab-dAb peak 85.5% 92.9% Di Fab-dAb peak 11.5% 4.2% - Fab-dAb samples were prepared under non-reduced and reduced conditions and run on a gel as described in the methods. The gel was Coomassie stained. The banding profile of both Fab-dAb samples, Fab′A-dAbL3 (CK-SG4SE) and Fab′A-dAbL3 (CK-G[APAPA]2), corresponds well to the profile observed by high temperature reverse phase HPLC (
FIG. 3 ). - Fab-dAb samples were subjected to non-reduced SDS-PAGE followed by western blot analysis with anti-light chain and anti-heavy chain antibodies as described in the methods. This confirmed that the dAb was on the light chain of the Fab and that the heavy chain was unmodified in both samples (
FIG. 4 ). It also demonstrates that all bands detected by coomassie stained, non-reduced SDS PAGE are Fab-dAb related products. - Kinetic analysis by SPR as described in the methods was used to assess the binding of human serum albumin to Fab′A-dAbL3 (CK-SG4SE) and Fab′A-dAbL3 (CK-G[APAPA]2). The results in table 5 demonstrate that both constructs are able to bind human serum albumin with a similar affinity (KD) of approximately 1 μM.
-
TABLE 5 ka Construct (×104M−1s−1) kd (×10−2s−1) KD (×10−9M) Fab'A-dAbL3 (CK-SG4SE) 3.44 1.42 411 Fab'A-dAbL3 9.61 2.85 296 (CK-G[APAPA]2) - Further kinetic analysis demonstrated that all the fusion constructs retained the interaction characteristics of the original FabA towards IL-1β, table 6, with only minor differences seen in the kinetic and affinity parameters.
-
TABLE 6 Construct ka (×105M−1s−1) kd (×10−5s−1) KD (×10−12M) Fab'A-dAbL3 1.90 4.21 221 (CK-SG4SE) Fab'A-dAbL3 2.17 3.99 184 (CK-G[APAPA]2) Fab'A 2.02 6.46 320 - The potential for each construct to bind simultaneously to both human serum albumin and the IL-1β antigen was assessed by capturing each construct to the sensor chip surface, before performing either separate 3 min injections of 5 μM human serum albumin or 100 nM IL-1β, or a mixed solution of both 5 μM human serum albumin and 100 nM IL-1β. For each Fab-dAb construct the response seen for the combined HSA/IL-1β solution was almost identical to the sum of the responses of the independent injections, see table 7. This shows that the Fab-dAbs are capable of simultaneous binding to both IL-1β and human serum albumin, and that binding of either IL-1β or human serum albumin does not inhibit the interaction of the other. The original FabA bound only to IL-1β, with negligible binding to human serum albumin.
-
TABLE 7 Construct Analyte Binding (RU) Fab'A-dAbL3 (CK-SG4SE) HSA + IL-1β 37.6 HSA 13.2 (37.9) IL-1β 24.7 Fab'A-dAbL3 (CK-G[APAPA]2) HSA + IL-1β 61.9 HSA 30.7 (63.6) IL-1β 32.9 Fab'A HSA + IL-1β 30.3 HSA 1.3 (30.0) IL-1β 28.7 - The table above shows the binding response (RU) seen for each construct after separate injections of HSA or IL-1β, or injection of premixed HSA and IL-1β. In each case the final concentration was 5 μM for HSA and 100 nM for IL-1β. The sum of the individual HSA and IL-1β responses is shown in parentheses.
- Expression of FabA-didAbs in E. coli
- FabA-dAbs and FabA-didAb fusions terminating with a C-terminal histidine tag (HIS6 tag) were expressed in Escherichia coli. After periplasmic extraction, dAb fusion proteins were purified via the C-terminal His6 tag. Fab expression was analysed by Western blotting of a non-reduced gel with anti-CH1 and anti-cKappa antibodies. FabA-dAb and FabA-didAb were expressed as full-length proteins and were shown to react to both antibody detection reagents.
- Analysis of FabA-didAbs Expressed in E. coli
- Further analysis was conducted to characterise the binding of HSA to FabA constructs to which one or more dAbs were fused. Binding assays were performed on a variety of constructs in which dAbL3 or dAbH4 fused to either the light or heavy chain of the FabA (see Table 8 for details of the constructs and summary of the binding data). Although constructs carrying only dAbH4, on either the light or heavy chain, were seen to bind HSA with comparatively poor affinity (≈9 μM and 3 μM respectively), higher affinity binding was observed for constructs carrying dAbL3, either as a single fusion (on either light or heavy chain) or partnered with a second dAb (dAbL3 or dAbH4) on the opposing chain.
-
TABLE 8 ka kd Construct (×104M−1s−1) (×10−3s−1) KD (×10−9M) FabA — — nb FabA-dAbL3 (LC-SG4SE) 4.46 16.2 363 FabA-dAbH4 (LC SG4SE) — — 9142 FabA-dAbL3 (HC-DKTHTS) 8.24 15.4 187 FabA-dAbH4 (HC-DKTHTS) — — 2866 FabA-didAb, - 3.00 15.1 502 dAbL3 (LC-SG4SE) & - dAbL3 (HC-DKTHTS) FabA-didAb, - 4.36 16.3 373 dAbL3 (LC-SG4SE) & - dAbH4 (HC-DKTHTS) - Affinity and kinetic parameters determined for the binding of HSA to FabAs carrying dAbL3 or dAbH4 on either light chain (LC) or heavy chain (HC) or both as indicated. No binding (nb) of HSA to the original FabA was detected. The interaction kinetics for the binding of HSA to the FabA with (dAbH4 on HC) or (dAbH4 on LC), were too rapid to determine, therefore affinity (KD) was determined from steady-state binding.
- Prior to transfection CHO-XE cells were washed in Earls Balanced Salts Solution (EBSS), pelleted and resuspended in EBSS at 2×108 cells/ml. Heavy and light chain plasmids were added to the cells at a total concentration of 400 ug. Optimised electrical parameters for 800 μl cells/DNA mix on the in-house electroporator were used for transfection. Transfected cells were directly transferred to 1 L CD-CHO media supplied with glutamax, HT and antimycotic antibiotic solution. Cells were incubated, shaking at 37° C. for 24 hours and then shifted to 32°
C. Sodium Butyrate 3 mM was added onday 4. Supernatants were harvested onday 14 by centrifugation at 1500×g to remove cells. Expression levels were determined by ELISA. - The mammalian supernatants containing ˜55 μg/ml of FabB-didAb as assessed by ELISA were concentrated from 1.8 L to 200 ml using a Minisette concentrator fitted with a 10 kDa molecular weight cut off polyethersulphone (PES) membrane.
- The concentrated supernatants were applied to a Gammabind Plus Sepharose (GE Healthcare) column equilibrated in 20 mM phosphate, 150 mM NaCl pH7.1. The column was washed with 20 mM phosphate, 150 mM NaCl pH7.1 and the bound material eluted with 0.1M glycine/HCl pH2.7. The elution peak was collected and pH adjusted to ˜pH7 with 2M Tris/HCl pH8.8. The pH adjusted elutions were concentrated to 1 mg/ml and diafiltered into 20 mM phosphate, 150 mM NaCl pH7.1 using a 10 kD molecular weight cut off PES membrane.
- Samples were diluted with water where required and then to 26 μl was added 10
μL 4×LDS sample running buffer. For non-reduced samples, 4 μL of 100 mM NEM was added and for reducedsamples 4 μL of 10× reducing agent was added. The samples were vortexed, incubated at 85° C. for 5 mins, cooled and centrifuged at 12500 rpm for 30 secs. The prepared samples were loaded on to a 4-20% acrylamine Tris/Glycine SDS gel and run for 110 mins at 125V. The gels were stained with Coomassie Blue protein stain. - The yields of Fab-didAb were measured using a sandwich ELISA. Briefly, the Fab-didAb was captured with an anti-CH1 antibody then revealed with an anti-kappa-HRP.
- FabB and FabB-didAb samples were prepared under non-reduced and reduced conditions and separated on a gel and stained as described in the methods. See
FIG. 9 . - Samples (1 μl of sample at ˜1 mg/ml, 8 μl of PBS and 1 μl of 30× stock of Sypro orange fluorescent dye) were run in quadruplicate in 384 well plates. The plate is heated from 20-99° C. using a 7900HT fast real-time PCR system and the fluorescence (excitation at 490 nm, emission at 530 nm) measured. The results are shown in Table D and
FIG. 10 . -
TABLE 9 Tm ° C. (Fab) Tm ° C. (Fv) FabB-didAb, - 81.9 ± 0.6 68.5 ± 0.5 dAbL1(CK-G4Sx2) & - dAbL1(CH1-G4Sx2) FabB-didAb, - 82.4 ± 0.2 70.6 ± 0.8 dAbL2(CK-G4Sx2) & - dAbL2(CH1-G4Sx2) - Samples at 1 mg/ml in PBS were incubated at 25° C. with vortexing at 1400 rpm. The absorbance is measured at 595 nm. This absorbance is due to light scattered by particles and can be correlated with sample aggregation. Both FabB-645Fv (G4S×2) and FabB-648Fv (G4S×2) are as resistant to aggregation as FabB alone. They are all more resistant to aggregation than the IgG control. (
FIG. 12 ) - Binding affinities for the interactions of Fab-Fv constructs with HSA were determined as described in the methods except that the running buffers at pH5.0, 5.5, 6.0 and 7.0 were created by mixing 40 mM citric acid, 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20 and 80 mM disodium hydrogen phosphate, 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20 to give the desired pH.
- The affinity of FabB-645Fv (G4S×2) for HSA is unaffected by pH from 7.4 (standard assay pH) to 5.0. The affinity of FabB-648Fv (G4S×2) for HSA is affected by pH and there is approximately a 10 fold loss in affinity between pH7.4 and pH5.0.
-
TABLE 10 KD (×10−9M) pH 7.0 pH 6.0 pH 5.5 pH 5.0 FabB-645Fv (G4Sx2) 13.3 12.5 10.7 7.1 FabB-648Fv (G4Sx2) 3.3 11.1 24.1 47.8 - The pharmacokinetics of FabB-645Fv (G4S×2) and FabB-648Fv (G4S×2) in male BALB/c mouse were determined following a single administration at 10 mg/kg either subcutaneously (sc) or intravenously (iv). Six mice were dosed for each construct and route of administration. Serial blood samples (30 μL) were collected from the tail vein at the following time points: 1, 4, 8, 24, 48, 72, 102 and 168 hours following subcutaneous administration and 30 minutes, 1, 8, 24, 48, 72, 96 and 168 hours following intravenous administration. The collected blood was dispensed into a Sarstedt microvette CB300Z with clot activator for serum separation, and left at room temperature for at least 20 minutes. The microvette was then centrifuged at 20° C. at 10,000 rpm for 5 minutes. Serum was removed and stored frozen prior to analysis. The concentration of FabB-645Fv (G4S×2) or FabB-648Fv (G4S×2) in serum samples was assessed by ELISA. Briefly Nunc Maxisorb Immunomodule Plates were coated with hOX40-Fc in PBS and blocked with 1% BSA in PBS. Serum samples and standards were diluted in 1% BSA in PBS and applied to the plate for 1 hour. The plate was washed with PBS and the revealing antibody of goat anti-human kappa HRP conjugate applied in 1% BSA in PBS for 1 hour. The plate was washed and then developed with TMB substrate followed by stopping with 2.5M sulphuric acid. The absorbance at 630 nm wash measured and the concentrations determined from the standard curve.
- Both FabB-645Fv (G4S×2) and FabB-648Fv (G4S×2) have extended half-life in plasma,
FIG. 13 . The half-lives for FabB-645Fv (G4S×2) are 71 h sc and 62 h iv and for FabB-648Fv (G4S×2) are 25 h sc and 30 h iv. - A study to investigate if FabB-645Fv and FabB-648Fv are efficacious in vivo was undertaken. Briefly this involved steady state dosing in HuSCID mice and the read out was the prevention of T cell engraftment.
- CB17 SCID mice were dosed with a loading dose subcutaneously on day −2 of 2.475 mg/kg FabB-645Fv or FabB-648Fv or FabB-PEG40 k or PBS. On every subsequent day up to and including
day 10 they were dosed with a maintenance dose subcutaneously of 0.75 mg/kg FabB-645Fv or FabB-648Fv or FabB-PEG40 k or PBS. Each dosing group consisted of 9-10 mice. On day −1 all the mice were treated with 0.87 mg/mouse of rat anti-murine TM-β1 antibody to abrogate natural killer cell activity. Onday 0 all the mice received an inter peritoneal injection of 8×106 human peripheral blood mononuclear cells. Onday 14 the mice are sacrificed and the blood, spleen and a peritoneal lavage were taken. The samples were analysed by FACS for CD4+ and CD8+ T cells. The data sets were analysed by one way Anova with Dunnett's post test comparison. All the test constructs FabB-645Fv, FabB-648Fv and FabB-PEG40 k were equally efficacious in all the compartments tested, i.e. blood peritoneum and spleen.FIGS. 14A , B and C. - Point mutations were introduced into selected residues in the CDRs of the heavy chain of the 645Fv portion of FabB-645dsFv (S3×G4S) by mutagenic PCR. For example I50A is a replacement of
Ile 50 with Ala. The various mutations are given in Table 11 below. The affinity of the Fab-645Fv mutants for human albumin was assessed by BIAcore as described in the methods. All the mutations had either unchanged or reduced affinity for human albumin. -
TABLE 11 Fv heavy mutation Albumin ka (1/Ms) kd (1/s) KD (nM) I50A HSA 3.12E+04 1.90E−03 60.9 T56A HSA 4.65E+04 3.78E−04 8.12 T95A FBA 2.81E+04 2.64E−03 94.0 V96A HSA 2.81E+04 6.42E−04 22.9 P97A HSA 4.60E+04 1.26E−02 275 G98A HSA 4.73E+04 2.71E−04 5.73 Y99A HSA 4.71E+04 4.79E−04 10.2 S100A HSA 3.94E+04 1.44E−03 36.6 T100aA HSA 3.60E+05 1.86E−02 51.6 Y100cA HSA 1.23E+04 1.07E−03 87.0 I50A and T95A HSA 2.12E+04 9.94E−03 468 I50A and G98A HSA 1.79E+04 6.96E−03 389 I50A and Y99A HSA >3500 T56A and T95A HSA 2.84E+04 8.57E−04 30.1 T56A and G98A HSA 2.40E+04 3.68E−03 153 T56A and Y99A HSA 2.24E+04 1.49E−02 664 - The FabB-645Fv's with either a SGGGGS, SGGGGSGGGGS, SGGGGSGGGGSGGGGS, SGGGGSGGGGSGGGGSGGGGS or SGGGGSGGGGSGGGGSGGGGSGGGGS linker between the C-termini of the Fab and the N-termini of the Fv were assembled by PCR then cloned into a mammalian expression vectors under the control of the HCMV-MIE promoter and SV40E polyA sequence. The relevant heavy and light chain plasmids were paired for expression in mammalian cells.
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 24 μg heavy chain plasmid+24 μg light chain plasmid was incubated with 120 μl 293fectin+4080 μl Optimem media for 20 mins at RT. The mixture was then added to 60×106 HEK293 cells in 60 mL suspension and incubated for 4 days with shaking at 37° C. All the constructs were equally well expressed.
- The mammalian expression suspensions were clarified by centrifugation and the supernatants were concentrated to ˜1.8 mL using 10 kDa molecular weight cut off centrifugation concentrators. The concentrated supernatants were centrifuged at 16000×g for 10 min to remove any precipitate and then 1.5 mL was loaded onto 1 ml HiTrap Protein-G columns (GE Healthcare) at 1 ml/min. The columns were washed with 20 mM phosphate, 40 mM NaCl pH7.4 and bound material eluted with 0.1M glycine/HCl pH2.7. The elution peak (2 mL) was collected and pH adjusted to ˜pH5 with 250 μL of 1M sodium acetate. The pH adjusted elutions were diafiltered into 20 mM phosphate, 150 mM NaCl pH7.1 using 10 kDa molecular weight cut off centrifugation concentrators and concentrated to ˜250 μL. All the constructs had similar purification profiles and the final concentrations were 0.5-1.1 mg/ml.
- The affinities of the purified FabB-645Fv (1-5×G4S) constructs for human and mouse albumin were determined as described in the Methods. The different linker lengths of the Fv of 1 to 5×Gly4Ser between the C-termini of the Fab and the N-termini of the Fv had no affect on the affinity of the 645Fv for either human or mouse albumin.
-
TABLE 12 Albumin KD (nM) Albumin KD (nM) FabB-645Fv (1xG4S) Human 8.77 Mouse 2.18 FabB-645Fv (2xG4S) Human 6.72 Mouse 8.01 FabB-645Fv (3xG4S) Human 9.87 Mouse 8.92 FabB-645Fv (4xG4S) Human 7.90 Mouse 7.24 FabB-645Fv (5xG4S) Human 3.90 Mouse 6.09 - FabB-645Fv (1-5×G4S) samples were prepared under non-reduced and reduced conditions and separated on a gel and stained as described in the methods. See
FIG. 15 . - FabB-645Fv (1-5×G4S) samples were analysed for size on a Superdex200 10/300GL Tricorn column (GE Healthcare) developed with an isocratic gradient of 20 mM phosphate 150 mM NaCl pH7.4 at 1 ml/min.
- A linker length between the C-termini of the Fab and the N-termini of the Fv of either 1×G4S or 2×G4S reduces the amount of monomer FabB-645Fv whilst increasing the amount of dimer and higher multimers. The amount of monomer is least for the 1×G4S linker length. A linker length between the C-termini of the Fab and the N-termini of the Fv of either 3×G4S, 4×G4S or 5×G4S increased the amount of monomer FabB-645Fv whilst decreasing the amount of dimer and higher multimers with the levels being similar for all three linker lengths.
FIG. 16 . -
TABLE 13 Monomer Dimer High Multimers FabB-645Fv (1xG4S) 5% 47% 48% FabB-645Fv (2xG4S) 27% 38% 36% FabB-645Fv (3xG4S) 51% 32% 17% FabB-645Fv (4xG4S) 55% 30% 15% FabB-645Fv (5xG4S) 51% 31% 18% - Samples (1 μl of sample at ˜1 mg/ml, 8 μl of PBS and 1 μl of 30× stock of Sypro orange fluorescent dye) were run in quadruplicate in 384 well plates. The plate is heated from 20-99° C. using a 7900HT fast real-time PCR system and the fluorescence (excitation at 490 nm, emission at 530 nm) measured. The results are shown in Table 14 and
FIG. 17 . -
TABLE 14 Tm ° C. (Fab) Tm ° C. (Fv) FabB-645Fv (1xG4S) 82.8 ± 0.6 67.4 ± 0.4 FabB-645Fv (2xG4S) 83.4 ± 0.3 68.7 ± 0.3 FabB-645Fv (3xG4S) 83.4 ± 0.3 69.5 ± 0.6 FabB-645Fv (4xG4S) 83.8 ± 0.3 71.3 ± 1.0 FabB-645Fv (5xG4S) 83.8 ± 0.4 72.0 ± 0.7 - FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S), FabΔB-645dsFv (2×G4S) and FabΔB-648dsFv (2×G4S) Fusion Plasmids for Expression in Mammalian Cells
- Point mutations were introduced into the FabB-645Fv (2×G4S) and FabB-648Fv (2×G4S) DNA sequences at selected residues in the framework region of both the heavy chain and the light chain of the Fv by mutagenic PCR. The mutations introduced to create an interchain disulphide bond between the heavy and light chains of the Fv were heavy chain G44C and light chain G100C. As well as adding the cysteins to create the interchain disulphide bond in the Fv, the natural interchain disulphide between the heavy chain and light chain of the Fab was removed by mutagenic PCR by changing the cysteines to serines. Fvs that contain an interchain disulphide bond were termed dsFv, Fabs that lack an interchain disulphide bond were termed FabA. The DNA for all these constructs was then cloned into a mammalian expression vectors under the control of the HCMV-MIE promoter and SV40E polyA sequence. The relevant heavy and light chain plasmids were paired for expression in mammalian cells.
- Mammalian Expression of FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S), FabΔB-645dsFv (2×G4S) and FabΔB-648dsFv (2×G4S)
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 24 μg heavy chain plasmid+24 μg light chain plasmid was incubated with 120 μl 293fectin+4080 μl Optimem media for 20 mins at RT. The mixture was then added to 60×106 HEK293 cells in 60 mL suspension and incubated for 4 days with shaking at 37° C. All the constructs were equally well expressed.
- Protein-G Purification of FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S), FabΔB-645dsFv (2×G4S) and FabΔB-648dsFv (2×G4S)
- The mammalian expression suspensions were clarified by centrifugation and the supernatants were concentrated to ˜1.8 mL using 10 kDa molecular weight cut off centrifugation concentrators. The concentrated supernatants were centrifuged at 16000×g for 10 min to remove any precipitate and then 1.5 mL was loaded onto 1 ml HiTrap Protein-G columns (GE Healthcare) at 1 ml/min. The columns were washed with 20 mM phosphate, 40 mM NaCl pH7.4 and bound material eluted with 0.1M glycine/HCl pH2.7. The elution peak (2 mL) was collected and pH adjusted to ˜pH5 with 250 μL of 1M sodium acetate. The pH adjusted elutions were diafiltered into 20 mM phosphate, 150 mM NaCl pH7.1 using 10 kDa molecular weight cut off centrifugation concentrators and concentrated to ˜250 μL. All the constructs had similar purification profiles and the final concentrations were 0.5-0.8 mg/ml.
- Affinity of FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S), FabΔB-645dsFv (2×G4S) and FabΔB-648dsFv (2×G4S) for Albumin
- The affinities of the purified FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S) FabΔB-645dsFv (2×G4S), FabΔB-648dsFv (2×G4S) constructs for human and mouse albumin were determined as described in the Methods. The disulphide stabilisation of the Fv had no affect or slightly increased the affinity of the Fv for both human or mouse albumin.
-
TABLE 15 Albumin KD (nM) Albumin KD (nM) FabB-645Fv (2xG4S) Human 17.5 Mouse 24.7 FabB-645dsFv (2xG4S) Human 12.6 Mouse 14.0 FabΔB-645dsFv (2xG4S) Human 8.3 Mouse 12.2 FabB-648Fv (2xG4S) Human 9.4 Mouse 42.4 FabB-648dsFv (2xG4S) Human 3.1 Mouse 59.6 FabΔB-648dsFv (2xG4S) Human 8.3 Mouse 59.8
SDS-PAGE Analysis of Purified FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S), FabΔB-645dsFv (2×G4S) and FabΔB-648dsFv (2×G4S) - Purified FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S) FabΔB-645dsFv (2×G4S), FabΔB-648dsFv (2×G4S) samples were prepared under non-reduced and reduced conditions and separated on a gel and stained as described in the methods. See
FIG. 18 . - Size Exclusion Analysis of Purified FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S), FabΔB-645dsFv (2×G4S) and FabΔB-648dsFv (2×G4S)
- Purified FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S) FabΔB-645dsFv (2×G4S), FabΔB-648dsFv (2×G4S) samples were analysed for size on a Superdex200 10/300GL Tricorn column (GE Healthcare) developed with an isocratic gradient of 20 mM phosphate 150 mM NaCl pH7.4 at 1 ml/min.
- The introduction of an interchain disulphide bond into the Fv of either a 645Fv or 648Fv increased the amount of monomer Fab-Fv species compared with the Fab-Fv in which the Fv did not have an inter chain disulphide. The removal of the natural interchain disulphide bond from the Fab part of a Fab-Fv had only a small effect on the amount of monomer species present.
FIG. 19 . -
TABLE 16 Monomer Dimer High Multimers FabB-645Fv (2xG4S) 26% 38% 35% FabB-645dsFv (2xG4S) 43% 21% 37% FabΔB-645dsFv (2xG4S) 40% 25% 34% FabB-648dsFv (2xG4S) 50% 26% 24% FabΔB-648dsFv (2xG4S) 55% 24% 20%
Thermofluor Thermal Stability Analysis of Purified FabB-645dsFv (2×G4S), FabB-648dsFv (2×G4S), FabΔB-645dsFv (2×G4S) and FabΔB-648dsFv (2×G4S) - Samples (1 μl of sample at ˜1 mg/ml, 8 μl of PBS and 1 μl of 30× stock of Sypro orange fluorescent dye) were run in quadruplicate in 384 well plates. The plate is heated from 20-99° C. using a 7900HT fast real-time PCR system and the fluorescence (excitation at 490 nm, emission at 530 nm) measured.
- The introduction of an interchain disulphide bond into the Fv part of a Fab-Fv of either a 645Fv or 648Fv increased the thermal stability of the Fv compared with the Fab-Fv in which the Fv did not have an inter chain disulphide. The removal of the natural interchain disulphide bond from the Fab part of a Fab-Fv decreased the thermal stability of the Fab part of the Fab-Fv
-
TABLE 17 Tm ° C. (Fab) Tm ° C. (Fv) FabB-645Fv (2xG4S) 81.9 ± 0.6 68.5 ± 0.5 FabB-645dsFv (2xG4S) 83.6 ± 0.3 71.6 ± 0.3 FabΔB-645dsFv (2xG4S) 79.5 ± 0.1 70.8 ± 0.6 FabB-648Fv (2xG4S) 82.4 ± 0.2 70.6 ± 0.8 FabB-648dsFv (2xG4S) 82.8 ± 0.3 75.0 ± 0.6 FabΔB-648dsFv (2xG4S) n.d. 73.6 ± 0.8 n.d. = not determined. The analysis software was unable to resolve this inflection point. - Binding affinities and kinetic parameters for the interactions of Fab-dAb and Fab-didAb constructs were determined by surface plasmon resonance (SPR) conducted on a Biacore T100 using CM5 sensor chips and HBS-EP (10 mM HEPES (pH7.4), 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20) running buffer. Human Fab samples were captured to the sensor chip surface using either a human F(ab′)2-specific goat Fab (Jackson ImmunoResearch, 109-006-097) or an in-house generated anti human CH1 monoclonal antibody. Murine Fab samples were captured using a murine F(ab′)2-specific goat Fab (Jackson ImmunoResearch, 115-006-072). Covalent immobilisation of the capture antibody was achieved by standard amine coupling chemistry.
- Each assay cycle consisted of firstly capturing the Fab-dAb or Fab-didAb construct using a 1 min injection, before an association phase consisting of a 3 min injection of antigen, after which dissociation was monitored for 5 min. After each cycle, the capture surface was regenerated with 2×1 min injections of 40 mM HCl followed by 30 s of 5 mM NaOH. The flow rates used were 10 μl/min for capture, 30 μl/min for association and dissociation phases, and 10 μl/min for regeneration.
- For kinetic assays, a titration of antigen (for human or mouse serum albumin typically 62.5 nM-2 μM, for IL-1β 1.25-40 nM, for cell surface receptor D 20-1.25 nM) was performed, a blank flow-cell was used for reference subtraction and buffer-blank injections were included to subtract instrument noise and drift.
- Kinetic parameters were determined by simultaneous global-fitting of the resulting sensorgrams to a standard 1:1 binding model using Biacore T100 Evaluation software.
- In order to test for simultaneous binding, 3 min injections of either separate 5 μM HSA or 100 nM IL-1β, or a mixed solution of 5 μM HSA and 100 nM IL-1β were injected over the captured Fab-dAb. Simultaneous binding of albumin and cell surface receptor D was assessed in the same manner using final concentrations of 2 μM HSA or MSA and 20 nM murine cell surface receptor D.
- Mammalian Expression of mFabC-mdidAbs and mFabD-mdidAbs
- HEK293 cells were transfected with the heavy and light chain plasmids using Invitrogen's 293fectin transfection reagent according to the manufacturer's instructions. Briefly, 2 μg heavy chain plasmid+2 μg light chain plasmid was incubated with 10 μl 293 fectin+340 μl Optimem media for 20 mins at RT. The mixture was then added to 5×106 HEK293 cells in suspension and incubated for 6 days with shaking at 37° C.
- The yields of mFab-mdidAb were measured using a sandwich ELISA. Briefly, the mFab-mdidAb was captured with an anti-CH1 antibody then revealed with an anti-kappa-HRP.
-
TABLE 18 ELISA expression (ug/mL) mFabD-mdidAb, -dAbL1(CK-G4Sx2) & 44 -dAbH1(CH1-G4Sx2) mFabD-mdidAb, -dAbL2(CK-G4Sx2) & 35 -dAbH2(CH1-G4Sx2) mFabC-mdidAb, -dAbL1(CK-G4Sx2) & 11 -dAbH1(CH1-G4Sx2) mFabC-mdidAb, -dAbL2(CK-G4Sx2) & 14 -dAbH2(CH1-G4Sx2) - Further kinetic analysis was conducted to assess the interactions of serum albumin and human OX40 to the purified FabB-didAb, -dAbL1(CK-G4S×2) & -dAbH1(CH1-G4S×2) and FabB-didAb, -dAbL2(CK-G4S×2) & -dAbH2(CH1-G4S×2) fusions (Table 19). Both FabB-didAb, -dAbL1(CK-G4S×2) & -dAbH1(CH1-G4S×2) and FabB-didAb, -dAbL2(CK-G4S×2) & -dAbH2(CH1-G4S×2) retained the affinity for human OX40 of the original FabB (Table 20).
- The potential for the FabB-didAb, -dAbL1(CK-G4S×2) & -dAbH1(CH1-G4S×2) and FabB-didAb, -dAbL2(CK-G4S×2) & -dAbH2(CH1-G4S×2) constructs to bind simultaneously to both human or mouse serum albumin and human OX40 was assessed by capturing each Fab-didAb construct to the sensor chip surface, before performing either separate 3 min injections of 2 μM albumin (human or mouse) or 50 nM human OX40, or a mixed solution of both 2 μM albumin and 50 nM OX40. HSA binding was seen for both Fab-didAb constructs. For each Fab-didAb construct the response seen for the combined albumin/OX40 solution was almost identical to the sum of the responses of the independent injections (summarised in table 21). This shows that the Fab-didAbs are capable of simultaneous binding to both OX40 and serum albumin. The original FabB bound only OX40, with no significant binding to either human or mouse albumin.
-
TABLE 19 Albu- ka kd KD Construct min (×104M−1s−1) (×10−5s−1) (×10−9M) FabB-didAb, HSA 1.65 2.06 12.5 -dAbL1(CK-G4Sx2) & -dAbH1(CH1-G4Sx2 FabB-didAb, HSA 1.80 1.24 6.92 -dAbL2(CK-G4Sx2) & -dAbH2(CH1-G4Sx2 FabB-didAb, MSA 1.83 1.82 9.94 -dAbL1(CK-G4Sx2) & -dAbH1(CH1-G4Sx2 FabB-didAb, MSA nd nd — -dAbL2(CK-G4Sx2) & -dAbH2(CH1-G4Sx2 - Affinity and kinetic parameters determined for HSA and MSA binding to Fab-didAb fusions.
-
TABLE 20 Construct ka (×105M−1s−1) kd (×10−5s−1) KD (×10−12M) FabB 2.92 22.6 775 FabB-didAb, 3.58 8.54 238 -dAbL1(CK-G4Sx2) & -dAbH1(CH1-G4Sx2 FabB-didAb, 3.27 13.6 415 -dAbL2(CK-G4Sx2) & -dAbH2(CH1-G4Sx2 - Affinity and kinetic parameters for hOX40-Fc binding to FabB and FabB-didAb fusions.
-
TABLE 21 Construct Analyte Binding (RU) FabB HSA 2.5 MSA −2.5 OX40 89.5 HSA + 90.1 (92) OX40 MSA + 86.5 (87) OX40 FabB-didAb, HSA 109.1 -dAbL1(CK-G4Sx2) & -dAbH1(CH1-G4Sx2 MSA 93.3 OX40 73.7 HSA + 186.1 (182.8) OX40 MSA + 170.3 (167) OX40 FabB-didAb, HSA 50.9 -dAbL2(CK-G4Sx2) & -dAbH2(CH1-G4Sx2 MSA 2.4 OX40 52.9 HSA + 104.2 (103.8) OX40 MSA + 54.9 (55.3) OX40 - The table above shows the binding response (RU) seen for each construct after separate injections of HSA or MSA or hOX40-Fc, or injection of premixed albumin and hOX40-Fc. In each case the final concentration was 2 μM albumin HSA and 50 nM hOX40-Fc. The sum of the individual albumin and hOX40-Fc responses is shown in parentheses.
- Further kinetic analysis was conducted to assess the interactions of serum albumin and murine cell surface receptor D to mFabD-mdidAb, -mdAbL1(CK-G4S×2) & mdAbH1(CH1-G4S×2) and mFabD-mdidAb, -mdAbL2(CK-G4S×2) & mdAbH2(CH1-G4S×2) (Table 22). Both mFabD-mdidAbs showed relatively high affinity binding to HSA (KD=2.78 nM and 8.97 nM respectively). mFabD-mdidAb, -mdAbL2(CK-G4S×2) & mdAbH2(CH1-G4S×2) also bound MSA with a similar affinity (KD=22 nM), however no binding to MSA was seen for mFabD-mdidAb, -mdAbL1(CK-G4S×2) & mdAbH1(CH1-G4S×2). Both mFabD-mdidAbs retained the affinity for murine cell surface receptor Dof the original mFabD (Table 23).
- The potential for mFabD-mdidAb, -mdAbL1(CK-G4S×2) & mdAbH1(CH1-G4S×2) and mFabD-mdidAb, -mdAbL2(CK-G4S×2) & mdAbH2(CH1-G4S×2) to bind simultaneously to both human or mouse serum albumin and murine cell surface receptor D was assessed by capturing each mFab-mdidAb construct to the sensor chip surface, before performing either separate 3 min injections of 2 μM albumin (human or mouse) or 20 nM murine cell surface receptor D, or a mixed solution of both 2 μM albumin and 20 nM cell surface receptor D. Again HSA binding was seen for both mFab-mdidAb constructs whereas only mFabD-mdidAb, -mdAbL2(CK-G4S×2) & mdAbH2(CH1-G4S×2) bound MSA. For each mFab-mdidAb construct the response seen for the combined albumin/cell surface receptor D solution was almost identical to the sum of the responses of the independent injections (summarised in table 24). This shows that the mFab-mdidAbs are capable of simultaneous binding to both cell surface receptor D and serum albumin. The original mFabD bound only cell surface receptor D, with no significant binding to either human or mouse albumin.
-
TABLE 22 Albu- ka kd KD Construct min (×104M−1s−1) (×10−5s−1) (×10−9M) mFabD-mdidAb, HSA 1.01 2.82 2.78 -mdAbL1(CK-G4Sx2) & mdAbH1(CH1-G4Sx2) mFabD-mdidAb, HSA 1.19 10.69 8.97 -mdAbL2(CK-G4Sx2) & mdAbH2(CH1-G4Sx2) mFabD-mdidAb, MSA — — — -mdAbL1(CK-G4Sx2) & mdAbH1(CH1-G4Sx2) mFabD-mdidAb, MSA 1.03 22.73 22.06 -mdAbL2(CK-G4Sx2) & mdAbH2(CH1-G4Sx2) - Affinity and kinetic parameters determined for HSA and MSA binding to mFabD-mdidAb, -mdAbL1(CK-G4S×2) & mdAbH1(CH1-G4S×2) and mFabD-mdidAb, -mdAbL2(CK-G4S×2) & mdAbH2(CH1-G4S×2).
-
TABLE 23 ka Construct (×105M−1s−1) kd (×10−5s−1) KD (×10−12M) mFabD 1.98 2.50 126 mFabD-mdidAb, 2.01 4.67 233 -mdAbL1(CK-G4Sx2) & mdAbH1(CH1-G4Sx2) mFabD-mdidAb, 3.62 6.36 176 -mdAbL2(CK-G4Sx2) & mdAbH2(CH1-G4Sx2) - Affinity and kinetic parameters for murine cell surface receptor D-Fc binding to mFabD, mFabD-mdidAb, -mdAbL1 (CK-G4S×2) & mdAbH1 (CH1-G4S×2) and mFabD-mdidAb, -mdAbL2(CK-G4S×2) & mdAbH2(CH1-G4S×2).
-
TABLE 24 Construct Analyte Binding (RU) mFabD receptor D 61.3 HSA 0.9 MSA −1.1 receptor D + 62.9 (62.2) HSA receptor D + 59.2 (60.2) MSA mFabD-mdidAb, receptor D 39.8 -mdAbL1(CK-G4Sx2) & HSA 59.9 mdAbH1(CH1-G4Sx2) MSA −0.6 receptor D + 101.2 (99.7) HSA receptor D + 39.9 (39.2) MSA mFabD-mdidAb, receptor D 42.6 -mdAbL2(CK-G4Sx2) & HSA 61.9 mdAbH2(CH1-G4Sx2) MSA 43.5 receptor D + 105.3 (104.5) HSA receptor D + 86.3 (86.1) MSA - The table above shows the binding response (RU) seen for each construct after separate injections of HSA or MSA or murine cell surface receptor D-Fc, or injection of premixed albumin and murine cell surface receptor D-Fc. In each case the final concentration was 2 μM albumin HSA and 20 nM murine cell surface receptor D-Fc. The sum of the individual albumin and murine cell surface receptor D-Fc responses is shown in parentheses.
- Further analysis was conducted to assess the simultaneous interaction of mFabD-mdidAb, -mdAbL1(CK-G4S×2) & mdAbH1 (CH1-G4S×2) or mFabD-mdidAb, -mdAbL2(CK-G4S×2) & mdAbH2(CH1-G4S×2) with serum albumin and murine cell surface receptor D expressed on the cell surface. Both mFabD-mdidAbs were capable of binding FITC labelled HSA and cell surface receptor X expressed on the cell surface of activated murine T-cells simultaneously (
FIG. 11 ). mFabD was capable of binding cell surface receptor X expressed on the cell surface of activated murine T-cells, data not shown, but did not bind FITC labelled HSA.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/508,967 US20200048372A1 (en) | 2008-09-26 | 2019-07-11 | Biological Products |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0817704.0 | 2008-09-26 | ||
GB0817704A GB0817704D0 (en) | 2008-09-26 | 2008-09-26 | Biological products |
GB0905314A GB0905314D0 (en) | 2009-03-26 | 2009-03-26 | Biological products |
GB0905314.1 | 2009-03-26 | ||
PCT/GB2009/002310 WO2010035012A1 (en) | 2008-09-26 | 2009-09-25 | Biological products |
US201113121055A | 2011-03-25 | 2011-03-25 | |
US16/508,967 US20200048372A1 (en) | 2008-09-26 | 2019-07-11 | Biological Products |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2009/002310 Division WO2010035012A1 (en) | 2008-09-26 | 2009-09-25 | Biological products |
US13/121,055 Division US10407513B2 (en) | 2008-09-26 | 2009-09-25 | Biological products |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200048372A1 true US20200048372A1 (en) | 2020-02-13 |
Family
ID=41664777
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/121,055 Expired - Fee Related US10407513B2 (en) | 2008-09-26 | 2009-09-25 | Biological products |
US16/508,967 Abandoned US20200048372A1 (en) | 2008-09-26 | 2019-07-11 | Biological Products |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/121,055 Expired - Fee Related US10407513B2 (en) | 2008-09-26 | 2009-09-25 | Biological products |
Country Status (17)
Country | Link |
---|---|
US (2) | US10407513B2 (en) |
EP (1) | EP2334705B1 (en) |
JP (2) | JP6063122B2 (en) |
CN (2) | CN105601745B (en) |
BR (1) | BRPI0918947A2 (en) |
CA (1) | CA2737241C (en) |
CY (1) | CY1118713T1 (en) |
DK (1) | DK2334705T3 (en) |
EA (1) | EA201100527A1 (en) |
ES (1) | ES2620603T3 (en) |
HR (1) | HRP20170374T1 (en) |
HU (1) | HUE033438T2 (en) |
LT (1) | LT2334705T (en) |
PL (1) | PL2334705T3 (en) |
PT (1) | PT2334705T (en) |
SI (1) | SI2334705T1 (en) |
WO (1) | WO2010035012A1 (en) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011030107A1 (en) * | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
US8734798B2 (en) | 2009-10-27 | 2014-05-27 | Ucb Pharma S.A. | Function modifying NAv 1.7 antibodies |
GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) * | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
WO2012009544A2 (en) * | 2010-07-14 | 2012-01-19 | Amgen Inc. | Domain insertion immunoglobulin |
RU2013110876A (en) * | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | ACTIVATED SPECIFIC ANTIBODIES |
RU2013110875A (en) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | SPECIFIC ANTIBODIES CONTAINING DISSULPHIDE-STABILIZED Fv Fragment |
US9598499B2 (en) | 2010-12-30 | 2017-03-21 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
AU2012206431B2 (en) | 2011-01-14 | 2015-04-30 | UCB Biopharma SRL | Antibody molecules which bind IL-17A and IL-17F |
JP6093715B2 (en) * | 2011-01-28 | 2017-03-08 | ナショナル リサーチ カウンシル オブ カナダ | Engineering the production of immunoglobulin domains |
JP2014515598A (en) * | 2011-03-10 | 2014-07-03 | エイチシーオー アンティボディ, インク. | Bispecific three-chain antibody-like molecule |
JP5986207B2 (en) * | 2011-09-06 | 2016-09-06 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Method for analyzing biopolymer complexes and uses thereof |
CN103958544B (en) | 2011-09-16 | 2018-04-24 | Ucb医药有限公司 | For the neutralizing antibody of the main exotoxins TcdA and TcdB of clostridium difficile |
JP6411214B2 (en) * | 2011-11-11 | 2018-10-24 | ユーシービー バイオファルマ エスピーアールエル | Albumin binding antibody and binding fragment thereof |
UA112203C2 (en) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
MX354862B (en) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof. |
CN104411718B (en) | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | It is used to prepare method of antibody Fc district conjugate of at least one binding entity comprising specific binding target and application thereof |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
TW201525001A (en) * | 2013-03-15 | 2015-07-01 | Amgen Res Munich Gmbh | Single chain binding molecules comprising N-terminal ABP |
RU2661087C2 (en) * | 2013-08-30 | 2018-07-11 | Априлбио Ко., Лтд | Hybrid structure, including antigen-binding fragment specific to serum albumin and effector component and methods for preparation thereof |
GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
RS57043B1 (en) | 2013-10-25 | 2018-05-31 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
AU2014347565B2 (en) | 2013-11-11 | 2020-08-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
KR20220151005A (en) * | 2014-02-24 | 2022-11-11 | 다케다 게엠베하 | Uti fusion proteins |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
WO2016076345A1 (en) | 2014-11-11 | 2016-05-19 | 中外製薬株式会社 | Library of antigen-binding molecules including modified antibody variable region |
PL3227332T3 (en) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
SG11201708323SA (en) | 2015-04-30 | 2017-11-29 | Harvard College | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
CA2987146A1 (en) | 2015-05-27 | 2016-12-01 | Ucb Biopharma Sprl | Method for the treatment of neurological disease |
WO2016192613A1 (en) * | 2015-06-01 | 2016-12-08 | 中山大学 | Bivalent antibody having single-domain antigen-binding fragment fused to conventional fab fragment |
AU2016289753C1 (en) | 2015-07-06 | 2021-08-05 | UCB Biopharma SRL | Tau-binding antibodies |
EA037092B1 (en) | 2015-07-06 | 2021-02-04 | Юсб Биофарма Срл | Tau-binding antibodies |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
US11142794B2 (en) | 2015-10-05 | 2021-10-12 | UCB Biopharma SRL | Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases |
US11492396B2 (en) | 2015-10-27 | 2022-11-08 | UCB Biopharma SRL | Methods of treatment using anti-IL-17A/F antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
GB201602414D0 (en) | 2016-02-10 | 2016-03-23 | Nascient Ltd | Biological materials and uses thereof |
JP7133544B2 (en) * | 2016-05-01 | 2022-09-08 | ユーシービー バイオファルマ エスアールエル | Affinity-engineered serum protein carrier binding domains |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
BR112019003866A2 (en) | 2016-08-29 | 2019-07-16 | Psioxus Therapeutics Ltd | bispecific mab fragment-stimulated adenovirus with t-cell redirection (bite) |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
CA3045726A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN110191896B (en) * | 2017-01-17 | 2023-09-29 | 埃博灵克斯股份有限公司 | Improved serum albumin conjugates |
JP7300385B2 (en) * | 2017-01-17 | 2023-06-29 | アブリンクス エン.ヴェー. | improved serum albumin binder |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
JP2020520943A (en) | 2017-05-19 | 2020-07-16 | シンダックス ファーマシューティカルズ, インコーポレイテッド | Combination therapy |
PT3630143T (en) | 2017-06-01 | 2023-08-29 | Akamis Bio Ltd | Oncolytic virus and method |
WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
CN110709418B (en) * | 2017-06-05 | 2023-09-26 | 努玛治疗有限公司 | Novel anti-HSA antibodies |
US20200165347A1 (en) | 2017-06-30 | 2020-05-28 | Aslan Pharmaceuticals Pte Ltd | Method of treatment using il-13r antibody |
EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
KR20200063155A (en) | 2017-10-10 | 2020-06-04 | 누맙 세러퓨틱스 아게 | Multispecific antibodies |
JP7357616B2 (en) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Antigen-binding molecules comprising engineered antibody variable regions that bind to CD3 and CD137 |
GB201811368D0 (en) | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
SG11202101652PA (en) | 2018-08-21 | 2021-03-30 | Citryll B V | Antibodies binding to citrullinated histone 2a and/or 4 |
JP2022501325A (en) * | 2018-09-28 | 2022-01-06 | 中外製薬株式会社 | Antigen-binding molecule containing modified antibody variable region |
CA3116091A1 (en) | 2018-10-16 | 2020-04-23 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
GB201817309D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
GB201817311D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
JP2022506761A (en) * | 2018-10-29 | 2022-01-17 | ティガティーエックス,インコーポレーテッド | Compositions and Methods Containing IgA Antibody Constructs |
JP2022528324A (en) | 2019-03-26 | 2022-06-10 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | Treatment with anti-IL13R antibody or binding fragment thereof |
SG11202110626SA (en) | 2019-03-27 | 2021-10-28 | Umc Utrecht Holding Bv | Engineered iga antibodies and methods of use |
EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
KR20210095781A (en) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety |
GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
US20230151108A1 (en) | 2020-02-13 | 2023-05-18 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd137 |
EP4103610A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Anti cd44-ctla4 bispecific antibodies |
EP4103611B1 (en) | 2020-02-13 | 2024-03-27 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
WO2021160268A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
WO2021160267A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
US20230089620A1 (en) | 2020-02-21 | 2023-03-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-IL-2 Antibody, and Antigen-Binding Fragment Thereof and Medical Use Thereof |
EP4126936A1 (en) | 2020-03-27 | 2023-02-08 | UCB Biopharma SRL | Autonomous knob domain peptides |
PE20230077A1 (en) | 2020-03-31 | 2023-01-11 | Chugai Pharmaceutical Co Ltd | MULTISPECIFIC ANTIGEN-BINDING MOLECULES DIRECTED TO DELTA 3-LIKE LIGAND (DLL3) AND THEIR USES |
CN115397860A (en) | 2020-05-14 | 2022-11-25 | 江苏恒瑞医药股份有限公司 | anti-CD 25 antibody, antigen binding fragment thereof, and medical use thereof |
EP3915580A1 (en) | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Multispecific antibody |
US20230303698A1 (en) * | 2020-06-30 | 2023-09-28 | Harbour Biomed (Shanghai) Co., Ltd | Multispecific binding protein of immune cell engager, preparation therefor and application thereof |
MX2022015959A (en) | 2020-07-02 | 2023-01-24 | Beijing Tuo Jie Biopharmaceutical Co Ltd | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof. |
KR20230044275A (en) | 2020-07-27 | 2023-04-03 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | Anti-CD79B antibody-drug conjugates, and methods for their preparation and pharmaceutical uses thereof |
GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
AU2021359092A1 (en) | 2020-10-15 | 2023-06-01 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
CN116782929A (en) | 2020-11-02 | 2023-09-19 | Ucb生物制药有限责任公司 | Use of anti-TREM 1 neutralizing antibodies for the treatment of motor neuron degenerative disorders |
JP2023551983A (en) | 2020-12-07 | 2023-12-13 | ユーシービー バイオファルマ エスアールエル | Antibodies against interleukin-22 |
AU2021395729A1 (en) | 2020-12-07 | 2023-07-13 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
EP4267185A1 (en) * | 2020-12-23 | 2023-11-01 | Lumen Bioscience, Inc. | Constructs comprising single domain vhh antibodies against sars-cov-2 |
EP4288451A1 (en) | 2021-02-02 | 2023-12-13 | Numab Therapeutics AG | Multispecific antibodies having specificity for ror1 and cd3 |
GB202102227D0 (en) | 2021-02-17 | 2021-03-31 | UCB Biopharma SRL | Antibodies |
AU2022263683A1 (en) | 2021-04-25 | 2023-11-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof |
KR20240004694A (en) | 2021-05-03 | 2024-01-11 | 유씨비 바이오파마 에스알엘 | antibody |
AU2022270356A1 (en) | 2021-05-04 | 2023-09-14 | Citryll B.V. | Inhibition of eosinophilic traps |
EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
WO2023274201A1 (en) | 2021-06-28 | 2023-01-05 | 江苏恒瑞医药股份有限公司 | Anti-cd40 antibody, antigen-binding fragment and medical use thereof |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023025249A1 (en) | 2021-08-25 | 2023-03-02 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition containing fusion protein |
TW202328195A (en) | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Proteins that specifically bind to pd-1 and the pharmaceutical use thereof |
TW202333784A (en) | 2021-10-29 | 2023-09-01 | 新加坡商亞獅康私人有限公司 | Anti-il-13r antibody formulation |
EP4183800A1 (en) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
US20230220115A1 (en) * | 2022-01-12 | 2023-07-13 | Biomolecular Holdings Llc | Tetrahedral antibodies |
WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
WO2023163659A1 (en) | 2022-02-23 | 2023-08-31 | Aslan Pharmaceuticals Pte Ltd | Glycosylated form of anti-il13r antibody |
CN114657125B (en) * | 2022-04-29 | 2023-08-08 | 中国科学院海洋研究所 | Method for separating single nucleus cell of shark, dilution of shark and use thereof |
WO2024038095A1 (en) | 2022-08-16 | 2024-02-22 | Iome Bio | NOVEL ANTI-RGMb ANTIBODIES |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024050354A1 (en) | 2022-08-31 | 2024-03-07 | Washington University | Alphavirus antigen binding antibodies and uses thereof |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
SE509359C2 (en) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Use of stabilized protein or peptide conjugates for the preparation of a drug |
DE4118120A1 (en) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE |
JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
AU668423B2 (en) | 1992-08-17 | 1996-05-02 | Genentech Inc. | Bispecific immunoadhesins |
GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
DK0672142T3 (en) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalent and multi-specific binding proteins as well as their preparation and use |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP0894135B1 (en) | 1996-04-04 | 2004-08-11 | Unilever Plc | Multivalent and multispecific antigen-binding protein |
JP4219985B2 (en) | 1996-07-23 | 2009-02-04 | タノックス ファーマ ベスローテン フェンノートシャップ | Induction of T cell tolerance using soluble molecules capable of simultaneously blocking two costimulatory pathways |
EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
AU2719099A (en) | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
DE19819846B4 (en) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalent antibody constructs |
DE69942148D1 (en) | 1998-06-22 | 2010-04-29 | Immunomedics Inc | USE OF BISPECIFIC ANTIBODIES IN DIAGNOSIS AND THERAPY |
US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
ATE422369T1 (en) | 1999-12-24 | 2009-02-15 | Genentech Inc | METHODS AND COMPOSITIONS FOR EXTENSING THE DISPOSAL HALF-LIFE OF BIODACTIC COMPOUNDS |
JP2003531588A (en) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | Multivalent antibodies and their uses |
DE10021678A1 (en) * | 2000-05-05 | 2002-04-18 | Stefan Duebel | Recombinant polyspecific antibody constructs, useful for diagnosis and treatment of cancer, comprises three antibody fragments,where at least one comprises a disulfide bridge |
WO2001090192A2 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
KR100919593B1 (en) | 2000-06-29 | 2009-09-29 | 아보트 러보러터리즈 | Dual specificity antibodies and methods of making them and composition comprising them |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
US20020010334A1 (en) | 2000-06-30 | 2002-01-24 | Xun Li | Processes to prepare pyrimidinediones |
CN1461344A (en) | 2000-07-25 | 2003-12-10 | 免疫医疗公司 | Multivalent target binding protein |
WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
DK1399484T3 (en) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Double-specific ligand and its use |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
JP2006512050A (en) | 2002-06-21 | 2006-04-13 | ダイアックス、コープ | Serum protein binding target-specific ligand and identification method thereof |
PT1517921E (en) | 2002-06-28 | 2006-09-29 | Domantis Ltd | DIFFERENTLY SPECIFIED LIGANDS WITH SEMI-LIFE IN THE INCREASED SERUM |
AU2003295330A1 (en) | 2002-09-16 | 2004-05-04 | Elusys Therapeutics, Inc. | Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
JP2006520584A (en) | 2002-11-08 | 2006-09-14 | アブリンクス エン.ヴェー. | Stabilized single domain antibody |
JP2006523090A (en) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | Bispecific single domain antibody specific for ligand and for ligand receptor |
GB0230201D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
SI1639011T1 (en) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegylated single domain antibodies (dAb) |
CN101484182B (en) * | 2005-04-06 | 2014-06-11 | Ibc药品公司 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
JP5838021B2 (en) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | Covalently bonded diabody and its use |
KR101308771B1 (en) | 2005-05-18 | 2013-09-23 | 아블린쓰 엔.브이. | Improved nanobodies™ against tumor necrosis factor-alpha |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
BRPI0710572A2 (en) * | 2006-01-24 | 2013-01-08 | Domantis Ltd | binder, use of binder, methods for treating an allergic, asthma and cancer disease, inhibiting a th2-type immune response, and administering anti-il-4 and anti-il-13 treatment, Pharmaceutical, Drug Dispensing Device, Isolated or Recombinant Nucleic Acid, Vector, Host Cell, Methods for Producing a Binder and Inhibiting Cell Proliferation |
CA2638794A1 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
NZ591252A (en) | 2006-03-17 | 2012-06-29 | Biogen Idec Inc | Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids |
NZ612319A (en) | 2006-06-12 | 2015-04-24 | Emergent Product Dev Seattle | Single-chain multivalent binding proteins with effector function |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
CA2691819A1 (en) | 2007-07-06 | 2009-02-19 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
CN101952312A (en) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | Multispecific epitope binding proteins and uses thereof |
ES2628395T3 (en) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Protease Regulated Antibody |
CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
CN101932608A (en) | 2007-11-30 | 2010-12-29 | 葛兰素集团有限公司 | Antigen-binding constructs |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
EP2826791A3 (en) * | 2008-02-20 | 2015-07-29 | Novo Nordisk A/S | Humanized anti-C5aR antibodies |
WO2010065882A1 (en) | 2008-12-04 | 2010-06-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
-
2009
- 2009-09-25 EA EA201100527A patent/EA201100527A1/en unknown
- 2009-09-25 CN CN201610114944.0A patent/CN105601745B/en not_active Expired - Fee Related
- 2009-09-25 CA CA2737241A patent/CA2737241C/en not_active Expired - Fee Related
- 2009-09-25 ES ES09736624.9T patent/ES2620603T3/en active Active
- 2009-09-25 BR BRPI0918947A patent/BRPI0918947A2/en active Search and Examination
- 2009-09-25 PT PT97366249T patent/PT2334705T/en unknown
- 2009-09-25 LT LTEP09736624.9T patent/LT2334705T/en unknown
- 2009-09-25 EP EP09736624.9A patent/EP2334705B1/en active Active
- 2009-09-25 JP JP2011528417A patent/JP6063122B2/en not_active Expired - Fee Related
- 2009-09-25 CN CN200980137520.4A patent/CN102164965B/en not_active Expired - Fee Related
- 2009-09-25 HU HUE09736624A patent/HUE033438T2/en unknown
- 2009-09-25 SI SI200931626A patent/SI2334705T1/en unknown
- 2009-09-25 US US13/121,055 patent/US10407513B2/en not_active Expired - Fee Related
- 2009-09-25 WO PCT/GB2009/002310 patent/WO2010035012A1/en active Application Filing
- 2009-09-25 PL PL09736624T patent/PL2334705T3/en unknown
- 2009-09-25 DK DK09736624.9T patent/DK2334705T3/en active
-
2015
- 2015-07-03 JP JP2015134223A patent/JP2015178536A/en active Pending
-
2017
- 2017-03-06 HR HRP20170374TT patent/HRP20170374T1/en unknown
- 2017-03-14 CY CY20171100321T patent/CY1118713T1/en unknown
-
2019
- 2019-07-11 US US16/508,967 patent/US20200048372A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2334705A1 (en) | 2011-06-22 |
JP6063122B2 (en) | 2017-01-18 |
CY1118713T1 (en) | 2017-07-12 |
PT2334705T (en) | 2017-03-22 |
ES2620603T3 (en) | 2017-06-29 |
CA2737241C (en) | 2017-08-29 |
HUE033438T2 (en) | 2017-11-28 |
WO2010035012A1 (en) | 2010-04-01 |
EA201100527A1 (en) | 2011-10-31 |
LT2334705T (en) | 2017-03-27 |
SI2334705T1 (en) | 2017-05-31 |
JP2015178536A (en) | 2015-10-08 |
EP2334705B1 (en) | 2016-12-14 |
CN102164965B (en) | 2016-03-30 |
JP2012503638A (en) | 2012-02-09 |
HRP20170374T1 (en) | 2017-05-05 |
US20110184152A1 (en) | 2011-07-28 |
PL2334705T3 (en) | 2017-06-30 |
CN105601745A (en) | 2016-05-25 |
US10407513B2 (en) | 2019-09-10 |
CN105601745B (en) | 2020-09-08 |
WO2010035012A9 (en) | 2011-03-17 |
CA2737241A1 (en) | 2010-04-01 |
DK2334705T3 (en) | 2017-03-27 |
BRPI0918947A2 (en) | 2015-12-01 |
CN102164965A (en) | 2011-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200048372A1 (en) | Biological Products | |
US11427650B2 (en) | Dual specificity antibody fusions | |
EP2480577B1 (en) | Disulfide stabilised multivalent antibodies | |
EP2776466B1 (en) | Albumin binding antibodies and binding fragments thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UCB PHARMA S.A., BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ADAMS, RALPH;HANCOCK, LAURA;HEYWOOD, SAM PHILIP;REEL/FRAME:049783/0438 Effective date: 20110321 Owner name: UCB BIOPHARMA SPRL, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UCB PHARMA, S.A.;REEL/FRAME:049783/0447 Effective date: 20151208 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |